# ESC Guidelines: Heart Failure (2021)

**Source**: `2021_Heart_Failure.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 128

---

## Table of Contents

- [ehab368-1](#ehab368-1) *(p. 9)*
- [ehab368-2](#ehab368-2) *(p. 11)*
- [ehab368-2.1](#ehab368-21) *(p. 11)*
- [tblfn1](#tblfn1) *(p. 11)*
- [tblfn2](#tblfn2) *(p. 12)*
- [ehab368-3](#ehab368-3) *(p. 14)*
- [ehab368-3.1](#ehab368-31) *(p. 14)*
- [ehab368-3.2](#ehab368-32) *(p. 14)*
- [tblfn3](#tblfn3) *(p. 14)*
- [ehab368-3.3](#ehab368-33) *(p. 15)*
- [tblfn4](#tblfn4) *(p. 15)*
- [tblfn5](#tblfn5) *(p. 15)*
- [tblfn6](#tblfn6) *(p. 15)*
- [tblfn7](#tblfn7) *(p. 15)*
- [ehab368-4](#ehab368-4) *(p. 16)*
- [ehab368-4.1](#ehab368-41) *(p. 16)*
- [tblfn15](#tblfn15) *(p. 18)*
- [ehab368-4.2](#ehab368-42) *(p. 19)*
- [ehab368-4.3](#ehab368-43) *(p. 19)*
- [tblfn10](#tblfn10) *(p. 19)*
- [tblfn11](#tblfn11) *(p. 19)*
- [tblfn12](#tblfn12) *(p. 19)*
- [tblfn13](#tblfn13) *(p. 19)*
- [tblfn8](#tblfn8) *(p. 19)*
- [tblfn9](#tblfn9) *(p. 19)*
- [tblfn14](#tblfn14) *(p. 20)*
- [ehab368-5](#ehab368-5) *(p. 21)*
- [ehab368-5.1](#ehab368-51) *(p. 21)*
- [ehab368-5.2](#ehab368-52) *(p. 21)*
- [ehab368-5.2.1](#ehab368-521) *(p. 21)*
- [ehab368-5.2.2](#ehab368-522) *(p. 21)*
- [tblfn16](#tblfn16) *(p. 21)*
- [tblfn17](#tblfn17) *(p. 21)*
- [tblfn18](#tblfn18) *(p. 21)*
- [ehab368-5.3](#ehab368-53) *(p. 22)*
- [tblfn26](#tblfn26) *(p. 22)*
- [tblfn27](#tblfn27) *(p. 22)*
- [tblfn28](#tblfn28) *(p. 22)*
- [ehab368-5.3.1](#ehab368-531) *(p. 23)*
- [ehab368-5.3.2](#ehab368-532) *(p. 23)*
- [ehab368-5.3.3](#ehab368-533) *(p. 23)*
- [ehab368-5.3.4](#ehab368-534) *(p. 23)*
- [tblfn19](#tblfn19) *(p. 23)*
- [tblfn20](#tblfn20) *(p. 23)*
- [tblfn21](#tblfn21) *(p. 23)*
- [tblfn22](#tblfn22) *(p. 23)*
- [tblfn23](#tblfn23) *(p. 23)*
- [tblfn24](#tblfn24) *(p. 23)*
- [tblfn25](#tblfn25) *(p. 23)*
- [ehab368-5.3.5](#ehab368-535) *(p. 24)*
- [ehab368-5.4](#ehab368-54) *(p. 24)*
- [ehab368-5.4.1](#ehab368-541) *(p. 25)*
- [ehab368-5.4.2](#ehab368-542) *(p. 25)*
- [ehab368-5.4.3](#ehab368-543) *(p. 25)*
- [ehab368-5.4.4](#ehab368-544) *(p. 25)*
- [ehab368-5.4.5](#ehab368-545) *(p. 25)*
- [tblfn29](#tblfn29) *(p. 25)*
- [tblfn30](#tblfn30) *(p. 25)*
- [tblfn31](#tblfn31) *(p. 25)*
- [tblfn32](#tblfn32) *(p. 25)*
- [ehab368-5.4.6](#ehab368-546) *(p. 27)*
- [ehab368-5.5](#ehab368-55) *(p. 27)*
- [ehab368-6](#ehab368-6) *(p. 27)*
- [ehab368-6.1](#ehab368-61) *(p. 27)*
- [tblfn61](#tblfn61) *(p. 27)*
- [tblfn62](#tblfn62) *(p. 27)*
- [tblfn63](#tblfn63) *(p. 27)*
- [ehab368-6.1.1](#ehab368-611) *(p. 28)*
- [ehab368-6.1.2](#ehab368-612) *(p. 28)*
- [ehab368-6.1.3](#ehab368-613) *(p. 28)*
- [ehab368-6.1.4](#ehab368-614) *(p. 28)*
- [ehab368-6.1.5](#ehab368-615) *(p. 28)*
- [ehab368-6.2](#ehab368-62) *(p. 29)*
- [tblfn64](#tblfn64) *(p. 29)*
- [tblfn65](#tblfn65) *(p. 29)*
- [tblfn66](#tblfn66) *(p. 29)*
- [ehab368-6.3](#ehab368-63) *(p. 30)*
- [ehab368-7](#ehab368-7) *(p. 30)*
- [ehab368-7.1](#ehab368-71) *(p. 30)*
- [ehab368-7.2](#ehab368-72) *(p. 31)*
- [ehab368-7.3](#ehab368-73) *(p. 31)*
- [ehab368-7.3.1](#ehab368-731) *(p. 31)*
- [ehab368-7.3.2](#ehab368-732) *(p. 31)*
- [ehab368-7.3.3](#ehab368-733) *(p. 31)*
- [ehab368-7.3.4](#ehab368-734) *(p. 31)*
- [ehab368-7.3.5](#ehab368-735) *(p. 31)*
- [tblfn67](#tblfn67) *(p. 31)*
- [tblfn68](#tblfn68) *(p. 31)*
- [tblfn69](#tblfn69) *(p. 31)*
- [ehab368-7.3.6](#ehab368-736) *(p. 32)*
- [ehab368-7.3.7](#ehab368-737) *(p. 32)*
- [ehab368-8](#ehab368-8) *(p. 32)*
- [ehab368-8.1](#ehab368-81) *(p. 32)*
- [ehab368-8.2](#ehab368-82) *(p. 32)*
- [ehab368-8.3](#ehab368-83) *(p. 32)*
- [ehab368-8.4](#ehab368-84) *(p. 33)*
- [tblfn33](#tblfn33) *(p. 33)*
- [tblfn34](#tblfn34) *(p. 33)*
- [tblfn35](#tblfn35) *(p. 33)*
- [tblfn36](#tblfn36) *(p. 34)*
- [tblfn37](#tblfn37) *(p. 34)*
- [tblfn38](#tblfn38) *(p. 34)*
- [tblfn39](#tblfn39) *(p. 34)*
- [tblfn40](#tblfn40) *(p. 34)*
- [tblfn41](#tblfn41) *(p. 34)*
- [tblfn42](#tblfn42) *(p. 34)*
- [ehab368-9](#ehab368-9) *(p. 35)*
- [ehab368-9.1](#ehab368-91) *(p. 35)*
- [ehab368-9.2](#ehab368-92) *(p. 35)*
- [ehab368-9.3](#ehab368-93) *(p. 35)*
- [tblfn43](#tblfn43) *(p. 35)*
- [tblfn44](#tblfn44) *(p. 35)*
- [tblfn45](#tblfn45) *(p. 35)*
- [ehab368-9.4](#ehab368-94) *(p. 38)*
- [ehab368-9.5](#ehab368-95) *(p. 38)*
- [ehab368-9.6](#ehab368-96) *(p. 38)*
- [tblfn47](#tblfn47) *(p. 38)*
- [tblfn48](#tblfn48) *(p. 38)*
- [tblfn49](#tblfn49) *(p. 38)*
- [tblfn50](#tblfn50) *(p. 38)*
- [tblfn51](#tblfn51) *(p. 38)*
- [tblfn52](#tblfn52) *(p. 38)*
- [ehab368-10](#ehab368-10) *(p. 39)*
- [ehab368-10.1](#ehab368-101) *(p. 39)*
- [tblfn53](#tblfn53) *(p. 39)*
- [tblfn54](#tblfn54) *(p. 39)*
- [tblfn55](#tblfn55) *(p. 39)*
- [tblfn56](#tblfn56) *(p. 40)*
- [ehab368-10.2](#ehab368-102) *(p. 41)*
- [ehab368-10.2.1](#ehab368-1021) *(p. 41)*
- [ehab368-10.2.2](#ehab368-1022) *(p. 41)*
- [tblfn57](#tblfn57) *(p. 41)*
- [tblfn58](#tblfn58) *(p. 44)*
- [tblfn59](#tblfn59) *(p. 44)*
- [tblfn60](#tblfn60) *(p. 44)*
- [ehab368-10.2.3](#ehab368-1023) *(p. 45)*
- [tblfn70](#tblfn70) *(p. 45)*
- [tblfn71](#tblfn71) *(p. 45)*
- [tblfn71a](#tblfn71a) *(p. 45)*
- [tblfn106](#tblfn106) *(p. 45)*
- [tblfn107](#tblfn107) *(p. 45)*
- [tblfn108](#tblfn108) *(p. 45)*
- [ehab368-10.2.4](#ehab368-1024) *(p. 46)*
- [ehab368-11](#ehab368-11) *(p. 46)*
- [ehab368-11.1](#ehab368-111) *(p. 46)*
- [tblfn72](#tblfn72) *(p. 46)*
- [tblfn73](#tblfn73) *(p. 46)*
- [ehab368-11.2](#ehab368-112) *(p. 48)*
- [ehab368-11.2.1](#ehab368-1121) *(p. 48)*
- [tblfn74](#tblfn74) *(p. 48)*
- [tblfn75](#tblfn75) *(p. 48)*
- [tblfn76](#tblfn76) *(p. 48)*
- [ehab368-11.2.2](#ehab368-1122) *(p. 49)*
- [ehab368-11.2.3](#ehab368-1123) *(p. 49)*
- [ehab368-11.2.4](#ehab368-1124) *(p. 49)*
- [tblfn77](#tblfn77) *(p. 49)*
- [tblfn78](#tblfn78) *(p. 49)*
- [tblfn78a](#tblfn78a) *(p. 49)*
- [ehab368-11.3](#ehab368-113) *(p. 51)*
- [ehab368-11.3.1](#ehab368-1131) *(p. 51)*
- [ehab368-11.3.2](#ehab368-1132) *(p. 53)*
- [ehab368-11.3.3](#ehab368-1133) *(p. 54)*
- [ehab368-11.3.4](#ehab368-1134) *(p. 56)*
- [ehab368-11.3.5](#ehab368-1135) *(p. 57)*
- [ehab368-11.3.6](#ehab368-1136) *(p. 57)*
- [ehab368-11.3.7](#ehab368-1137) *(p. 57)*
- [ehab368-11.3.8](#ehab368-1138) *(p. 58)*
- [ehab368-11.3.9](#ehab368-1139) *(p. 58)*
- [ehab368-11.3.10](#ehab368-11310) *(p. 58)*
- [tblfn79](#tblfn79) *(p. 58)*
- [tblfn80](#tblfn80) *(p. 58)*
- [tblfn81](#tblfn81) *(p. 58)*
- [tblfn82](#tblfn82) *(p. 58)*
- [tblfn83](#tblfn83) *(p. 58)*
- [tblfn84](#tblfn84) *(p. 58)*
- [ehab368-12](#ehab368-12) *(p. 59)*
- [ehab368-12.1](#ehab368-121) *(p. 59)*
- [ehab368-12.1.1](#ehab368-1211) *(p. 59)*
- [tblfn85](#tblfn85) *(p. 59)*
- [tblfn86](#tblfn86) *(p. 59)*
- [tblfn87](#tblfn87) *(p. 59)*
- [ehab368-12.1.2](#ehab368-1212) *(p. 62)*
- [ehab368-12.1.3](#ehab368-1213) *(p. 62)*
- [ehab368-12.2](#ehab368-122) *(p. 62)*
- [tblfn124](#tblfn124) *(p. 62)*
- [tblfn125](#tblfn125) *(p. 62)*
- [tblfn126](#tblfn126) *(p. 62)*
- [ehab368-12.3](#ehab368-123) *(p. 64)*
- [ehab368-12.3.1](#ehab368-1231) *(p. 64)*
- [tblfn127](#tblfn127) *(p. 64)*
- [tblfn128](#tblfn128) *(p. 64)*
- [tblfn129](#tblfn129) *(p. 64)*
- [ehab368-12.3.2](#ehab368-1232) *(p. 66)*
- [ehab368-12.3.3](#ehab368-1233) *(p. 66)*
- [tblfn130](#tblfn130) *(p. 67)*
- [tblfn131](#tblfn131) *(p. 67)*
- [tblfn132](#tblfn132) *(p. 67)*
- [tblfn133](#tblfn133) *(p. 67)*
- [tblfn134](#tblfn134) *(p. 67)*
- [ehab368-12.3.4](#ehab368-1234) *(p. 68)*
- [ehab368-12.4](#ehab368-124) *(p. 68)*
- [ehab368-12.5](#ehab368-125) *(p. 68)*
- [ehab368-13](#ehab368-13) *(p. 68)*
- [ehab368-13.1](#ehab368-131) *(p. 68)*
- [ehab368-13.2](#ehab368-132) *(p. 69)*
- [tblfn135](#tblfn135) *(p. 69)*
- [tblfn136](#tblfn136) *(p. 69)*
- [tblfn137](#tblfn137) *(p. 69)*
- [ehab368-13.3](#ehab368-133) *(p. 70)*
- [ehab368-13.4](#ehab368-134) *(p. 70)*
- [ehab368-13.5](#ehab368-135) *(p. 70)*
- [ehab368-13.6](#ehab368-136) *(p. 71)*
- [tblfn138](#tblfn138) *(p. 71)*
- [tblfn139](#tblfn139) *(p. 71)*
- [tblfn140](#tblfn140) *(p. 71)*
- [ehab368-13.7](#ehab368-137) *(p. 72)*
- [ehab368-13.8](#ehab368-138) *(p. 73)*
- [ehab368-13.9](#ehab368-139) *(p. 73)*
- [ehab368-13.10](#ehab368-1310) *(p. 74)*
- [ehab368-13.11](#ehab368-1311) *(p. 74)*
- [ehab368-13.12](#ehab368-1312) *(p. 74)*
- [ehab368-13.13](#ehab368-1313) *(p. 74)*
- [tblfn88](#tblfn88) *(p. 75)*
- [ehab368-13.14](#ehab368-1314) *(p. 77)*
- [ehab368-14](#ehab368-14) *(p. 77)*
- [ehab368-14.1](#ehab368-141) *(p. 77)*
- [ehab368-14.1.1](#ehab368-1411) *(p. 77)*
- [ehab368-14.1.2](#ehab368-1412) *(p. 77)*
- [tblfn89](#tblfn89) *(p. 77)*
- [tblfn90](#tblfn90) *(p. 77)*
- [tblfn91](#tblfn91) *(p. 77)*
- [tblfn92](#tblfn92) *(p. 77)*
- [ehab368-14.2](#ehab368-142) *(p. 79)*
- [ehab368-14.2.1](#ehab368-1421) *(p. 79)*
- [ehab368-14.2.2](#ehab368-1422) *(p. 79)*
- [tblfn93](#tblfn93) *(p. 80)*
- [tblfn94](#tblfn94) *(p. 80)*
- [tblfn95](#tblfn95) *(p. 81)*
- [tblfn96](#tblfn96) *(p. 81)*
- [tblfn97](#tblfn97) *(p. 81)*
- [tblfn98](#tblfn98) *(p. 82)*
- [tblfn99](#tblfn99) *(p. 82)*
- [ehab368-14.3](#ehab368-143) *(p. 83)*
- [tblfn100](#tblfn100) *(p. 83)*
- [ehab368-14.4](#ehab368-144) *(p. 84)*
- [ehab368-14.4.1](#ehab368-1441) *(p. 84)*
- [ehab368-14.4.2](#ehab368-1442) *(p. 84)*
- [ehab368-14.4.3](#ehab368-1443) *(p. 84)*
- [ehab368-14.5](#ehab368-145) *(p. 84)*
- [ehab368-14.5.1](#ehab368-1451) *(p. 84)*
- [ehab368-14.5.2](#ehab368-1452) *(p. 84)*
- [ehab368-14.6](#ehab368-146) *(p. 84)*
- [ehab368-14.6.1](#ehab368-1461) *(p. 84)*
- [tblfn101](#tblfn101) *(p. 84)*
- [tblfn102](#tblfn102) *(p. 85)*
- [tblfn103](#tblfn103) *(p. 86)*
- [ehab368-14.6.2](#ehab368-1462) *(p. 87)*
- [ehab368-14.7](#ehab368-147) *(p. 87)*
- [tblfn104](#tblfn104) *(p. 87)*
- [tblfn105](#tblfn105) *(p. 87)*
- [tblfn109](#tblfn109) *(p. 87)*
- [ehab368-14.8](#ehab368-148) *(p. 88)*
- [tblfn110](#tblfn110) *(p. 88)*
- [tblfn111](#tblfn111) *(p. 88)*
- [tblfn811](#tblfn811) *(p. 88)*
- [tblfn112](#tblfn112) *(p. 88)*
- [tblfn113](#tblfn113) *(p. 88)*
- [tblfn114](#tblfn114) *(p. 88)*
- [ehab368-15](#ehab368-15) *(p. 90)*
- [tblfn115](#tblfn115) *(p. 90)*
- [ehab368-16](#ehab368-16) *(p. 91)*
- [ehab368-17](#ehab368-17) *(p. 92)*
- [tblfn116](#tblfn116) *(p. 94)*
- [tblfn117](#tblfn117) *(p. 94)*
- [tblfn118](#tblfn118) *(p. 94)*
- [tblfn119](#tblfn119) *(p. 94)*
- [tblfn120](#tblfn120) *(p. 94)*
- [ehab368-18](#ehab368-18) *(p. 95)*
- [tblfn121](#tblfn121) *(p. 95)*
- [tblfn122](#tblfn122) *(p. 95)*
- [tblfn123](#tblfn123) *(p. 95)*
- [ehab368-19](#ehab368-19) *(p. 96)*
- [ehab368-20](#ehab368-20) *(p. 96)*
- [app1](#app1) *(p. 96)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
With the special contribution of the Heart Failure Association
(HFA) of the ESC
Authors/Task Force Members: Theresa A. McDonagh* (Chairperson) (United
Kingdom), Marco Metra
* (Chairperson) (Italy), Marianna Adamo (Task Force
Coordinator) (Italy), Roy S. Gardner (Task Force Coordinator) (United Kingdom),
Andreas Baumbach (United Kingdom), Michael Bo¨hm (Germany), Haran Burri
(Switzerland), Javed Butler (United States of America), Jelena Celutkien_e
(Lithuania), Ovidiu Chioncel (Romania), John G.F. Cleland (United Kingdom),
Andrew J.S. Coats (United Kingdom), Maria G. Crespo-Leiro (Spain),
Dimitrios Farmakis (Greece), Martine Gilard (France), Stephane Heymans
* Corresponding authors: The two chairpersons contributed equally to the document.
Theresa McDonagh, Cardiology Department, King’s College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom. Tel: þ44 203 299 325,
E-mail: theresa.mcdonagh@kcl.ac.uk;
Marco Metra, Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of
Brescia, Brescia, Italy. Tel: þ39 303 07221, E-mail: metramarco@libero.it
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council of Cardio-Oncology, Council on Basic Cardiovascular Science, Council on Valvular Heart Disease.
Working Groups: Adult Congenital Heart Disease, Cardiovascular Pharmacotherapy, Cardiovascular Regenerative and Reparative Medicine, Cardiovascular Surgery,
e-Cardiology, Myocardial and Pericardial Diseases, Myocardial Function.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and European Journal of Heart Failure. V
C the European Society of Cardiology 2021. All rights reserved.
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions,
please email journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehab368


<!-- PAGE 2 -->

### Page 2

..............................
(Netherlands), Arno W. Hoes (Netherlands), Tiny Jaarsma (Sweden),
Ewa A. Jankowska (Poland), Mitja Lainscak (Slovenia), Carolyn S.P. Lam (Singapore),
Alexander R. Lyon (United Kingdom), John J.V. McMurray (United Kingdom),
Alexandre Mebazaa (France), Richard Mindham (United Kingdom),
Claudio Muneretto (Italy), Massimo Francesco Piepoli (Italy), Susanna Price (United
Kingdom), Giuseppe M.C. Rosano (United Kingdom), Frank Ruschitzka (Switzerland),
Anne Kathrine Skibelund (Denmark), ESC Scientific Document Group
Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P. Christian Schulze
(CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France),
Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Elena Arbelo (Spain), Riccardo Asteggiano
(Italy), Johann Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A. Borger (Germany),
Werner Budts (Belgium), Maja Cikes (Croatia), Kevin Damman (Netherlands), Victoria Delgado
(Netherlands), Paul Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel (Austria),
Justin Ezekowitz (Canada), Volkmar Falk (Germany), Laurent Fauchier (France), Gerasimos Filippatos
(Greece), Alan Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale (United Kingdom),
Finn Gustafsson (Denmark), Julie Harris (United Kingdom), Bernard Iung (France), Stefan Janssens
(Belgium), Mariell Jessup (United States of America), Aleksandra Konradi (Russia), Dipak Kotecha (United
Kingdom), Ekaterini Lambrinou (Cyprus), Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany),
Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva (United Kingdom), Ales Linhart
(Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden), Donna Mancini (United States of
America), Josep Masip (Spain), Davor Milicic (Croatia), Christian Mueller (Switzerland), Holger Nef
(Germany), Jens-Cosedis Nielsen (Denmark), Lis Neubeck (United Kingdom), Michel Noutsias (Germany),
Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Piotr Ponikowski (Poland),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Dimitrios J. Richter (Greece), Evgeny Schlyakhto
(Russia), Petar Seferovic (Serbia), Michele Senni (Italy), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal),
Carlo G. Tocchetti (Italy), Rhian M. Touyz (United Kingdom), Carsten Tschoepe (Germany),
Johannes Waltenberger (Germany/Switzerland)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online
Online publish-ahead-of-print 27 August 2021
...................................................................................................................................................................................................
Keywords
Guidelines • heart failure • natriuretic peptides • ejection fraction • diagnosis • pharmacotherapy •
neuro-hormonal antagonists • cardiac resynchronization therapy • mechanical circulatory support •
transplantation • arrhythmias • comorbidities • hospitalization • multidisciplinary management •
advanced heart failure • acute heart failure
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3607
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3609
2.1 What is new . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3609
3 Definition, epidemiology and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.1 Definition of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2 Terminology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2.2 Right ventricular dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.2.3 Other common terminology used in heart failure . . . . . . . 3613
3.2.4 Terminology related to the symptomatic severity of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.3 Epidemiology and natural history of heart failure . . . . . . . . . . . . 3613
3.3.1 Incidence and prevalence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.3.2 Aetiology of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
3.3.3 Natural history and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
4 Chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
4.1 Key steps in the diagnosis of chronic heart failure . . . . . . . . . . . 3614


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
4.2 Natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616
4.2.1 Use in the non-acute setting . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
4.3 Investigations to determine the underlying aetiology of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
5 Heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3619
5.1 The diagnosis of heart failure with reduced ejection fraction . 3619
5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.2.1 Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.2.2 General principles of pharmacotherapy for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620
5.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3621
5.3.2 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621
5.3.3 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3621
5.3.4 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3621
5.3.5 Sodium-glucose co-transporter 2 inhibitors . . . . . . . . . . . . 3622
5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622
5.4.1 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.2 Angiotensin II type 1 receptor blockers . . . . . . . . . . . . . . . . . 3623
5.4.3 If-channel inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.4 Combination of hydralazine and isosorbide dinitrate . . . . 3623
5.4.5 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.6 Recently reported advances from trials in heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3624
5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3624
6 Cardiac rhythm management for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3624
6.1 Implantable cardioverter-defibrillator . . . . . . . . . . . . . . . . . . . . . . . 3625
6.1.1 Secondary prevention of sudden cardiac death . . . . . . . . . 3626
6.1.2 Primary prevention of sudden cardiac death . . . . . . . . . . . . 3626
6.1.3 Patient selection for implantable cardioverterdefibrillator therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626
6.1.4 Implantable cardioverter-defibrillator programming . . . . . 3626
6.1.5 Subcutaneous and wearable implantable cardioverter-defibrillators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626
6.2 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . 3627
6.3 Devices under evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
7 Heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . 3628
7.1 The diagnosis of heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
7.2 Clinical characteristics of patients with heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3 Treatments for patients with heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3629
7.3.2 Angiotensin receptor II type 1 receptor blockers . . . . . . . 3629
7.3.3 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3.4 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3629
7.3.5 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3629
7.3.6 Other drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
7.3.7 Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8 Heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . 3630
8.1 The background to heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.2 Clinical characteristics of patients with heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.3 The diagnosis of heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.4 Treatment of heart failure with preserved ejection fraction . . 3631
9 Multidisciplinary team management for the prevention and treatment of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.1 Prevention of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.2 Multidisciplinary management of chronic heart failure . . . . . . . 3633
9.2.1 Models of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.2.2 Characteristics and components of a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.3 Patient education, self-care and lifestyle advice . . . . . . . . . . . . . . 3633
9.4 Exercise rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5 Follow-up of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5.1 General follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5.2 Monitoring with biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.6 Telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
10 Advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637
10.1 Epidemiology, diagnosis, and prognosis . . . . . . . . . . . . . . . . . . . . 3637
10.2 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3639
10.2.1 Pharmacological therapy and renal replacement . . . . . . . 3639
10.2.2 Mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . 3639
10.2.3 Heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
10.2.4 Symptom control and end-of-life care . . . . . . . . . . . . . . . . . 3644
11 Acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
11.1 Epidemiology, diagnosis and prognosis . . . . . . . . . . . . . . . . . . . . 3644
11.2 Clinical presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3646
11.2.1 Acute decompensated heart failure . . . . . . . . . . . . . . . . . . . 3646
11.2.2 Acute pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647
11.2.3 Isolated right ventricular failure . . . . . . . . . . . . . . . . . . . . . . . 3647
11.2.4 Cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647
11.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
11.3.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
11.3.2 Oxygen therapy and/or ventilatory support . . . . . . . . . . . 3650
11.3.3 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652
11.3.4 Vasodilators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3654
11.3.5 Inotropes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.6 Vasopressors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.7 Opiates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.8 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3656
11.3.9 Thromboembolism prophylaxis . . . . . . . . . . . . . . . . . . . . . . 3656
11.3.10 Short-term mechanical circulatory support . . . . . . . . . . 3656
11.3.11 Pre-discharge assessment and post-discharge management planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12 Cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12.1 Arrhythmias and conduction disturbances . . . . . . . . . . . . . . . . . 3657
12.1.1 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12.1.2 Ventricular arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.1.3 Symptomatic bradycardia, pauses and atrio-ventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.2 Chronic coronary syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.2.1 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661
12.2.2 Myocardial revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
ESC Guidelines
3601


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
12.3 Valvular heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
12.3.1 Aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
12.3.2 Aortic regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664
12.3.3 Mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664
12.3.4 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
12.4 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
12.5 Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13 Non-cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13.1 Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13.2 Thyroid disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3667
13.3 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.4 Frailty, cachexia, sarcopenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.5 Iron deficiency and anaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.6 Kidney dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3669
13.7 Electrolyte disorders: hypokalaemia, hyperkalaemia,
hyponatraemia, hypochloraemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3670
13.8 Lung disease, sleep-disordered breathing . . . . . . . . . . . . . . . . . . 3671
13.9 Hyperlipidaemia and lipid-modifying therapy . . . . . . . . . . . . . . . 3671
13.10 Gout and arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.11 Erectile dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.12 Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.13 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.14 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14 Special conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14.1 Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14.1.1 Pregnancy in pre-existing heart failure . . . . . . . . . . . . . . . . . 3675
14.1.2 New heart failure presenting during pregnancy . . . . . . . . 3675
14.2 Cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.2.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.2.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.3 Left ventricular non-compaction . . . . . . . . . . . . . . . . . . . . . . . . . . 3681
14.4 Atrial disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5 Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6 Amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6.2 Therapy of amyloidosis and heart failure . . . . . . . . . . . . . . 3685
14.7 Iron overload cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685
14.8 Adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
15 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688
16 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3689
17 ‘What to do’ and ‘what not to do’ messages from the guidelines . 3690
18 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3693
19 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
20 Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
21 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
List of recommendations
Recommended diagnostic tests in all patients with suspected chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
Recommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618
Pharmacological treatments indicated in patients with
(NYHA class IIIV) heart failure with reduced ejection fraction
(LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620
Other pharmacological treatments indicated in selected patients with NYHA class IIIV heart failure with reduced ejection fraction (LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622
Recommendations for an implantable cardioverter-defibrillator in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3625
Recommendations for cardiac resynchronization therapy implantation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . 3627
Pharmacological treatments to be considered in patients with
(NYHA class IIIV) heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
Recommendations for the treatment of patients with heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632
Recommendations for the primary prevention of heart failure in patients with risk factors for its development . . . . . . . . . . . . . . . . . . . . . 3632
Multidisciplinary interventions recommended for the management of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
Recommendations for exercise rehabilitation in patients with chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
Recommendations for telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637
Recommendations for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
Recommendations for the initial treatment of acute heart failure . . . 3655
Recommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . 3656
Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure . . . . . . . . . . . 3657
Recommendations for the treatment of atrial fibrillation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
Recommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3662
Recommendations for the management of valvular heart disease in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3665
Recommendations for the treatment of diabetes in heart failure . . . 3667
Recommendations for the management of anaemia and iron deficiency in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3669
Recommendations for the management of patients with cancer and heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
Recommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608
Table 3 Definition of heart failure with reduced ejection fraction,
mildly reduced ejection fraction and preserved ejection fraction . . . 3613
Table 4 New York Heart Association functional classification based on severity of symptoms and physical activity . . . . . . . . . . . . . . . 3614
Table 5 Causes of heart failure, common modes of presentation and specific investigations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616
Table 6 Symptoms and signs typical of heart failure . . . . . . . . . . . . . . . . 3617


<!-- PAGE 5 -->

### Page 5

.............................................................................................................................................................................
Table 7 Causes of elevated concentrations of natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618
Table 8 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621
Table 9 Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular filling pressures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3631
Table 10 Risk factors for the development of heart failure and potential corrective actions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632
Table 11 Important characteristics and components in a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3634
Table 12 Patient education and self-care . . . . . . . . . . . . . . . . . . . . . . . . . . 3634
Table 13 Criteria for definition of advanced heart failure . . . . . . . . . . . 3638
Table 14 Interagency Registry for Mechanically Assisted
Circulatory Support profile descriptions of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3638
Table 15 Terms describing various indications for mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642
Table 16 Patients potentially eligible for implantation of a left ventricular assist device . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642
Table 17 Heart transplantation: indications and contraindications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
Table 18 Patients with heart failure in whom end-of-life care should be considered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
Table 19 Key components of palliative care service in patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
Table 20 Diagnostic tests in patients with acute heart failure . . . . . . . 3646
Table 21 Clinical presentations of acute heart failure . . . . . . . . . . . . . . 3647
Table 22 Inotropes and/or vasopressors used to treat acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
Table 23 Cancer drugs causing heart failure . . . . . . . . . . . . . . . . . . . . . . . 3673
Table 24 Infections in patients with heart failure . . . . . . . . . . . . . . . . . . . 3675
Table 25 Possible causes and disease modifiers of most frequent cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678
Table 26 Initial diagnostic assessment in patients with suspected cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678
Table 27 Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . 3679
Table 28 Hypertrophic cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3680
Table 29 Arrhythmogenic cardiomyopathy: specific aspects of diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3681
Table 30 Aetiologies to be considered triggering acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
Table 31 Diagnostic workup in suspected acute myocarditis . . . . . . . 3683
Table 32 Endomyocardial biopsy in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684
Table 33 Cardiac magnetic resonance in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685
Table 34 Treatment and follow-up of acute myocarditis . . . . . . . . . . . 3685
Table 35 “Red flags” for most common forms of cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
Table 36 Treatment of adult congenital heart disease and heart failure in specialized centres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688
Table 37 Main European Society of Cardiology Quality Indicators for the evaluation of care and outcomes for patients with heart failure . 3693
List of figures
Figure 1 The diagnostic algorithm for heart failure . . . . . . . . . . . . . . . . . 3615
Figure 2 Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction . . . . . . . . . . . 3620
Figure 3 Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . 3624
Figure 4 Algorithm for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3640
Figure 5 Triage of patients with advanced heart failure and appropriate timing of referral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641
Figure 6 Diagnostic workup of new onset acute heart failure . . . . . . . 3645
Figure 7 Management of acute decompensated heart failure . . . . . . . 3648
Figure 8 Management of pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . 3649
Figure 9 Management of right ventricular failure . . . . . . . . . . . . . . . . . . . 3650
Figure 10 Management of cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . 3651
Figure 11 Stages of management of patients with acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652
Figure 12 Initial management of acute heart failure . . . . . . . . . . . . . . . . 3653
Figure 13 Diuretic therapy (furosemide) in acute heart failure . . . . . . 3654
Figure 14 Management of atrial fibrillation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3658
Figure 15 Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661
Figure 16 Management of patients with severe low-flow low-gradient aortic stenosis and heart failure . . . . . . . . . . . . . . . . . . . . . 3663
Figure 17 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3664
Figure 18 Management of patients with cancer and heart failure . . . . 3674
Figure 19 Management of patients with heart failure before and during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3676
Figure 20 Management of patients with heart failure and acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684
Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart failure patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3687
Abbreviations and acronyms
6MWT
6-minute walk test
99mTc-PYP
Technetium-labelled pyrophosphate
AATAC
Ablation vs. Amiodarone for Treatment of
Atrial Fibrillation in Patients With
Congestive Heart Failure and an Implanted
ICD/CRTD (trial)
AC
Arrhythmogenic cardiomyopathy
ACE
Angiotensin-converting enzyme
ACE-I
Angiotensin-converting enzyme inhibitor
ACHD
Adult congenital heart disease
ACS
Acute coronary syndrome
ADHF
Acutely decompensated heart failure
AF
Atrial ﬁbrillation
AF-CHF
Atrial ﬁbrillation  Congestive Heart
Failure (trial)
ESC Guidelines
3603


<!-- PAGE 6 -->

### Page 6

............................................................................................................................................................................
AFFIRM
Atrial Fibrillation Follow-up Investigation of
Rhythm Management (trial)
AFFIRM-AHF
A Randomized, Double-blind Placebocontrolled Trial Comparing the Effect of
Intravenous Ferric Carboxymaltose on
Hospitalizations and Mortality in Irondeﬁcient Subjects Admitted for Acute Heart
Failure (trial)
AHF
Acute heart failure
AL
Light chain immunoglobulin
AL-CA
Light chain immunoglobulin cardiac amyloidosis
AMICA
Atrial Fibrillation Management in Congestive
Heart Failure With Ablation (trial)
ANCA
Antineutrophil cytoplasmic antibody
ARB
Angiotensin-receptor blocker
ARNI
Angiotensin receptor-neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ATTR
Transthyretin amyloidosis
AV
Atrio-ventricular b.i.d.
Bis in die (twice daily)
BAG3
Bcl2-associated athanogene 3
BiVAD
Biventricular assist device
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure b.p.m.
Beats per minute
BTB
Bridge to bridge
BTC
Bridge to candidacy
BTD
Bridge to decision
BTR
Bridge to recovery
BTT
Bridge to transplantation
CA
Cardiac amyloidosis (or amyloid cardiomyopathy)
CABANA
Catheter ABlation vs. ANti-arrhythmic drug therapy for Atrial ﬁbrillation (trial)
CABG
Coronary artery bypass graft
CAD
Coronary artery disease
CANVAS-R
CANagliﬂozin cardioVascular Assessment
Study - Renal
CARE-HF
CArdiac REsynchronization in Heart Failure
CASTLE-AF
Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular and Atrial Fibrillation (trial)
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CHA2DS2-VASc
Congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75
(doubled), Diabetes, Stroke (doubled)-
Vascular disease, Age 6574, Sex category
(female) (score)
CHAMPIT
Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/
Tamponade
CHARM
Candesartan in Heart Failure - Assessment of moRtality and Morbidity (trial)
CHF
Chronic heart failure
CI
Conﬁdence interval
CKD
Chronic kidney disease
CMP
Cardiomyopathy
CMR
Cardiac magnetic resonance
CMV
Cytomegalovirus
COAPT
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF
patients with functional mitral regurgitation
(trial)
COC
Cardio-Oncology Council (part of the
European Society of Cardiology)
COMMANDER-HF
A Study to Assess the Effectiveness and
Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in
Participants With Heart Failure and
Coronary Artery Disease Following an
Episode of Decompensated Heart Failure
(trial)
COMPASS
Rivaroxaban for the Prevention of Major
Cardiovascular Events in Coronary or
Peripheral Artery Disease (trial)
COPD
Chronic obstructive pulmonary disease
CORONA
COntrolled ROsuvastatin multiNAtional
(trial)
COVID-19
Coronavirus disease 2019
CR
Controlled release
CREDENCE
Canagliﬂozin and Renal Endpoints in
Diabetes with Established Nephropathy
Clinical Evaluation (trial)
CRT
Cardiac resynchronization therapy
CRT-D
Cardiac resynchronization therapy with deﬁbrillator
CRT-P
Cardiac resynchronization therapy pacemaker
CSA
Central sleep apnoea
CT
Computed tomography
CTCA
Computed tomography coronary angiography
CV
Cardiovascular
DAPA-HF
Dapagliﬂozin And Prevention of Adverseoutcomes in Heart Failure (trial)
DCM
Dilated cardiomyopathy
DECLARETIMI 58
Dapagliﬂozin Effect on CardiovascuLAR
Events (Thrombolysis in Myocardial
Infarction) (trial)
DIAMOND
Patiromer for the Management of
Hyperkalemia in Subjects Receiving RAASi
Medications for the Treatment of Heart
Failure (trial)
DIG
Digitalis Investigation Group (trial)
DNA
Deoxyribonucleic acid
DOAC
Direct-acting oral anticoagulant
DPD
3,3-diphosphono-1,2-propanodicarboxylic acid


<!-- PAGE 7 -->

### Page 7

............................................................................................................................................................................
DPP-4
Dipeptidyl peptidase-4
DSC2
Desmocollin 2
DSG2
Desmoglein 2
DSP
Desmoplakin
DT
Destination therapy
E/e0 (ratio)
E/e0 (ratio) = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler
EACVI
European Association of Cardiovascular
Imaging (part of the European Society of
Cardiology)
EAST-AFNET 4
Early Treatment of Atrial Fibrillation for
Stroke Prevention Trial 4 (trial)
ECG
Electrocardiogram
EchoCRT
Echocardiography Guided Cardiac
Resynchronization Therapy (trial)
ECLS
Extracorporeal life support
ECMO
Extracorporeal membrane oxygenation
EF
Ejection fraction eGFR
Estimated glomerular ﬁltration rate
EHRA
European Heart Rhythm Association
EMA
European Medicines Agency
EMB
Endomyocardial biopsy
EMPA-REG
OUTCOME
Empagliﬂozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus
Patients (trial)
EMPERORReduced
EMPagliﬂozin outcomE tRial in Patients
With chrOnic heaRt Failure With Reduced
Ejection Fraction (trial)
EROA
Effective regurgitant oriﬁce area
ESC
European Society of Cardiology
EU
European Union
EuroSCORE II
European System for Cardiac Operative
Risk Evaluation II (score)
FDA
Food and Drug Administration
FDG
Fluorodeoxyglucose
FiO2
Fraction of inspired oxygen
FLN
Filamin
FLNC
Filamin C
GGT
Gamma-glutamyl transferase
GISSI-HF
Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico 
Heart Failure (trial)
GLP-1
Glucagon-like peptide-1
GUIDE-HF
Hemodynamic-GUIDEd Management of
Heart Failure (trial)
h
Hour/hours
H2FPEF
Heavy (BMI >30 kg/m2), Hypertensive (use of
>_2 antihypertensive medications), atrial
Fibrillation (paroxysmal or persistent),
Pulmonary hypertension (Doppler
Echocardiographic estimated Pulmonary
Artery Systolic Pressure >35 mmHg), Elderly
(age >60 years), Filling pressure (Doppler
Echocardiographic E/e0 >9) (score)
HbA1c
Glycated haemoglobin
HCM
Hypertrophic cardiomyopathy
HEART
Heart Failure Revascularisation Trial
HER2
Human epidermal growth factor receptor 2
HF
Heart failure
HFA
Heart Failure Association
HFA-PEFF
Heart Failure Association of ESC diagnostic algorithm, P  Initial Workup (Step 1:
Pretest Assessment), E - Diagnostic
Workup (Step 2: Echocardiographic and
Natriuretic Peptide score), F1  Advanced
Workup (Step 3: Functional testing in Case of Uncertainty), F2  Aetiological Workup
(Step 4: Final Aetiology)
HF-MP
Heart failure management programme
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HHV
Human herpes virus
HIV
Human immunodeﬁciency virus
HLA-DR
Human leukocyte antigen-DR isotype
HMDP
Hydroxyl-methylene-diphosphonate
HR
Hazard ratio
HT
Heart transplantation
HTM
Home telemonitoring i.v.
Intravenous
IABP
Intra-aortic balloon pump
ICCU
Intensive coronary care unit
ICD
Implantable cardioverter-deﬁbrillator
ICU
Intensive care unit
IHD
Ischaemic heart disease
INR
International normalized ratio
INTERMACS
Interagency Registry for Mechanically
Assisted Circulatory Support
INTrEPID
Investigation of Nontransplant-Eligible
Patients Who Are Inotrope Dependent
(trial)
IOCM
Iron overload cardiomyopathy
IPD
Individual patient data
I-PRESERVE
Irbesartan in Patients with Heart Failure and
PRESERVEd Ejection Fraction (trial)
KCNH2
Potassium voltage-gated channel subfamily
H member 2
KCNQ1
Potassium voltage-gated channel subfamily
Q member 1
LA
Left atrium/atrial
LAE
Left atrial enlargement
LBBB
Left bundle branch block
LDB3
LIM domain binding 3
LFT
Liver function test
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LMWH
Low-molecular-weight heparin
LUS
Lung ultrasound
LV
Left ventricular/ventricle
LVAD
Left ventricular assist device
ESC Guidelines
3605


<!-- PAGE 8 -->

### Page 8

............................................................................................................................................................................
LVEDP
Left ventricular end-diastolic pressure
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end-systolic diameter
LVH
Left ventricular hypertrophy
LVNC
Left ventricular non-compaction
LVOT
Left ventricular outﬂow tract
LVOTO
Left ventricular outﬂow tract obstruction
MADIT-CRT
Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac
Resynchronization Therapy (trial)
MADIT-II
Multicenter Automatic Deﬁbrillator
Implantation Trial II (trial)
MADIT-RIT
Multicenter Automatic Deﬁbrillator
Implantation Trial  Reduce Inappropriate
Therapy (trial)
MAGGIC
Meta-Analysis Global Group in Chronic
Heart Failure
MCS
Mechanical circulatory support
MEK
Mitogen-activated protein kinase
MI
Myocardial infarction
MITRA-FR
Percutaneous Repair with the MitraClip
Device for Severe Functional/Secondary
Mitral Regurgitation (trial)
MMR
Mismatch repair
MR
Mitral regurgitation
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging mRNA
Messenger ribonucleic acid
MR-proANP
Mid-regional pro-atrial natriuretic peptide
MT
Medical therapy
MV
Mitral valve mWHO
Modiﬁed World Health Organization
MYPC
Myosin-binding protein C
NICM
Non-ischaemic cardiomyopathy
NKX2-5
NK2 transcription factor related, locus 5
NP
Natriuretic peptide
NSAID
Non-steroidal anti-inﬂammatory drug
NSVT
Non-sustained ventricular tachycardia
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association o.d
Omne in die (once daily)
OMT
Optimal medical therapy
OSA
Obstructive sleep apnoea
PA
Pulmonary artery
PaO2
Partial pressure of oxygen
PARADIGM-HF
Prospective comparison of ARNI with ACEI
to Determine Impact on Global Mortality and morbidity in Heart Failure (trial)
pCO2
Partial pressure of carbon dioxide
PCI
Percutaneous coronary intervention
PCR
Polymerase chain reaction
PCWP
Pulmonary capillary wedge pressure
PEP-CHF
Perindopril in Elderly People with Chronic
Heart Failure (trial)
PET
Positron emission tomography
PKP2
Plakophilin 2
PLN
Phospholamban
PPCM
Peripartum cardiomyopathy
PREVEND
Prevention of REnal and Vascular ENd-stage
Disease (trial)
PV
Pulmonary vein
PVC
Premature ventricular contraction
PVI
Pulmonary vein isolation pVO2
Peak exercise oxygen consumption
QI
Quality indicator
QOL
Quality of life
QRS
Q, R, and S waves of an ECG
RAAS
Renin-angiotensin-aldosterone system
RACE II
Rate Control Efﬁcacy in Permanent Atrial
Fibrillation: a Comparison between Lenient versus Strict Rate Control II (trial)
RAFT
Resynchronization/Deﬁbrillation for
Ambulatory Heart Failure Trial (trial)
RASi
Renin-angiotensin system inhibitor
RATE-AF
Rate Control Therapy Evaluation in
Permanent Atrial Fibrillation (trial)
RBM20
Ribonucleic acid binding motif 20
RCT
Randomized controlled trial
REMATCH
Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive
Heart Failure (trial)
REVERSE
REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction
(trial)
REVIVED
REVascularization for Ischaemic VEntricular
Dysfunction (trial)
RNA
Ribonucleic acid
RRT
Renal replacement therapy
RV
Right ventricular/ventricle
RVAD
Right ventricular assist device
RVEDP
Right ventricular end-diastolic pressure
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SAVR
Surgical aortic valve replacement
SBP
Systolic blood pressure
SCN5a
Sodium channel alpha subunit 5
SCORED
Effect of Sotagliﬂozin on Cardiovascular and
Renal Events in Patients with Type 2
Diabetes and Moderate Renal Impairment
Who Are at Cardiovascular Risk (trial)
SENIORS
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalizations in
Seniors with Heart Failure (trial)
SERVE-HF
Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by
Adaptive Servo Ventilation in Patients with
Heart Failure (trial)
SGLT2
Sodium-glucose co-transporter 2
S-ICD
Subcutaneous implantable cardioverterdeﬁbrillator
SMR
Secondary mitral regurgitation
SPECT
Single-photon emission computed tomography


<!-- PAGE 9 -->

### Page 9

.............................................................................................................................................................................
SpO2
Transcutaneous oxygen saturation
SR
Sinus rhythm
STEMI
ST-elevation myocardial infarction
STICH
Surgical Treatment for Ischemic Heart
Failure (trial)
STICHES
Extended follow-up of patients from the
STICH trial
STS-PROM
Society of Thoracic Surgeons Predicted Risk of Mortality
SZC
Sodium zirconium cyclosilicate
T2DM
Type 2 diabetes mellitus
TAVI
Transcatheter aortic valve implantation
TFT
Thyroid function test t.i.d.
Ter in die (three times a day)
TKI
Tyrosine kinase inhibitor
TMEM43
Transmembrane protein 43
TNNT
Troponin-T
TR
Tricuspid regurgitation
TRPM4
Transient receptor potential cation channel subfamily M member 4
TSAT
Transferrin saturation
TSH
Thyroid-stimulating hormone
TTN
Titin
TTR
Transthyretin
UK
United Kingdom
US
United States
VAD
Ventricular assist device
Val-HeFT
Valsartan Heart Failure Trial (trial)
VEGF
Vascular endothelial growth factor
VERTIS-CV
Cardiovascular Outcomes Following
Ertugliﬂozin Treatment in Type 2 Diabetes
Mellitus Participants With Vascular Disease
(trial)
VEST
Vest Prevention of Early Sudden Death Trial
(trial)
VKA
Vitamin K antagonist
VO2
Oxygen consumption
VPB
Ventricular premature beat vs.
Versus
VV interval
Interventricular delay interval
WARCEF
Warfarin and Aspirin in Reduced Cardiac
Ejection Fraction (trial)
wtTTR-CA
Wild-type transthyretin cardiac amyloidosis
XL
Extended release
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user.
The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/
Guidelines). The ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice guidelines, the ESC
carries out the EURObservational Research Programme of international registries of cardiovascular (CV) diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals,
healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines
(CPG) Committee policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC
and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task
Force. The finalized document is signed-off by the CPG for publication in the European Heart Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides,
summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus,
ESC Guidelines
3607


<!-- PAGE 10 -->

### Page 10

..............................
for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the European Heart Journal website. The National
Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the
ESC
Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies.
However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
Table 2
Levels of evidence
©ESC 2021
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
Table 1
Classes of recommendations
©ESC 2021
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. 
Conflicting evidence and/or a divergence of opinion about the usefulness/ 
efficacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Definition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/efficacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/efficacy. 
Should be considered
Class II


<!-- PAGE 11 -->

### Page 11

2 Introduction
The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence. Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations.
We have revised the format of the previous 2016 ESC HF
Guidelines1 to make each phenotype of HF stand-alone in terms of its diagnosis and management. The therapy recommendations mention the treatment effect supported by the class and level of evidence and are presented in tables. For HF with reduced ejection fraction
(HFrEF), the tabular recommendations focus on mortality and morbidity outcomes. Where there are symptomatic benefits, these are highlighted in the text and/or in the web appendices. Detailed summaries of the trials underpinning the recommendations are available in the web appendices. For diagnostic indications, we have suggested investigations that all patients with HF should receive, and investigations that can be targeted to specific circumstances. As diagnostic tests have rarely been subject to randomized controlled trials
(RCTs), most of the evidence would be regarded as level C.
However, that does not mean that there has not been appropriate rigorous evaluation of diagnostic tests.
In this guideline, we have decided to focus on the diagnosis and treatment of HF, not on its prevention. Management of CV risk and many CV diseases [especially systemic hypertension, diabetes mellitus, coronary artery disease, myocardial infarction (MI), atrial fibrillation (AF), and asymptomatic left ventricular (LV) systolic dysfunction]
will reduce the risk of developing HF, which is addressed by many other ESC Guidelines and in section 9.1 of the current guideline.27
This guideline is the result of a collaboration between the Task
Force (including two patient representatives), the reviewers, and the
ESC CPG Committee. As such, it is a consensus/majority opinion of the experts consulted in its development.
2.1 What is new
In addition to the recommendations listed below, the following table lists some new concepts compared with the 2016 version.
New concepts
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF).
A new simpliﬁed treatment algorithm for HFrEF.
The addition of a treatment algorithm for HFrEF according to phenotypes.
Modiﬁed classiﬁcation for acute HF.
Updated treatments for most non-cardiovascular comorbidities including diabetes, hyperkalaemia, iron deﬁciency, and cancer.
Updates on cardiomyopathies including the role of genetic testing and new treatments.
The addition of key quality indicators.
HF = heart failure.
New recommendations
Recommendations
Class
Recommendations for the diagnosis of HF
Right heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis,
restrictive cardiomyopathy, congenital heart disease, and high output states.
IIa
Right heart catheterization may be considered in selected patients with HFpEF to conﬁrm the diagnosis.
IIb
Recommendations for treatment of chronic HF
HFrEF
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
Vericiguat may be considered in patients in NYHA class IIIV
who have had worsening HF despite treatment with an ACE-I
(or ARNI), a beta-blocker and an MRA to reduce the risk of
CV mortality or HF hospitalization.
IIb
HFmrEF
An ACE-I may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
An ARB may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
A beta-blocker may be considered for patients with HFmrEF
to reduce the risk of HF hospitalization and death.
IIb
An MRA may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
Sacubitril/valsartan may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.
IIb
HFpEF
Screening for, and treatment of, aetiologies, and CV and nonCV comorbidities are recommended in patients with HFpEF
(see relevant sections of this document).
I
Prevention and monitoring
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.
I
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF
hospitalization and mortality.
I
Inﬂuenza and pneumococcal vaccinations should be considered in order to prevent HF hospitalizations.
IIa
A supervised, exercise-based, cardiac rehabilitation programme should be considered in patients with more severe disease, frailty, or with comorbidities.
IIa
Non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV death.
IIb
Recommendations for management of patients with advanced
HF
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.
I
Continued
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3609


<!-- PAGE 12 -->

### Page 12

Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.
IIb
Recommendations for management of patients after HF
hospitalization
It is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.
I
It is recommended that evidence-based oral medical treatment be administered before discharge.
I
An early follow-up visit is recommended at 12 weeks after discharge to assess signs of congestion, drug tolerance, and start and/or uptitrate evidence-based therapy.
I
Recommendations for management of patients with HF and atrial ﬁbrillation
Long-term treatment with an oral anticoagulant should be considered for stroke prevention in AF patients with a
CHA2DS2-VASc score of 1 in men or 2 in women.
IIa
Recommendations for management of patients with HF and
CCS
CABG should be considered as the ﬁrst-choice revascularization strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease.
IIa
In LVAD candidates needing coronary revascularization,
CABG should be avoided, if possible.
IIa
Coronary revascularization may be considered to improve outcomes in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal
LAD), comorbidities, life expectancy, and patient’s perspectives.
IIb
PCI may be considered as alternative to CABG, based on
Heart Team evaluation, considering coronary anatomy,
comorbidities, and surgical risk.
IIb
Recommendations for management of patients with HF and valvular heart disease
Aortic valve intervention, TAVI or SAVR is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.
I
It is recommended that the choice between TAVI and SAVR
be made by the Heart Team, according to individual patient preference and features including age, surgical risk, clinical,
anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.
I
Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite OMT and who fulﬁl criteria to achieve a reduction in HF hospitalizations.
IIa
Percutaneous edge-to-edge mitral valve repair may be considered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.
IIb
Continued
Recommendations for management of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin,
ertugliﬂozin, sotagliﬂozin) are recommended in patients with
T2DM at risk of CV events to reduce hospitalizations for HF,
major CV events, end-stage renal dysfunction, and CV death.
I
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.
I
The DPP-4 inhibitor saxagliptin is not recommended in patients with HF.
III
Recommendations for management of patients with HF and iron deﬁciency
It is recommended that all patients with HF are periodically screened for anaemia and iron deﬁciency with a full blood count, serum ferritin concentration, and TSAT.
I
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic HF patients recently hospitalized for HF and with LVEF <_50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL
with TSAT <20%, to reduce the risk of HF hospitalization.
IIa
Treatment of anaemia in HF with erythropoietin stimulating agents is not recommended in the absence of other indications for this therapy.
III
Recommendations for management of patients with HF and cancer
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease, previous cardiotoxicity or exposure to cardiotoxic agents, undergo
CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in Cardio-Oncology.
I
Treatment with an ACE-I and a beta-blocker (preferably carvedilol) should be considered in cancer patients developing LV systolic dysfunction, deﬁned as a 10% or more decrease in LVEF and to a value lower than 50%, during anthracycline chemotherapy.
IIa
A baseline CV risk assessment should be considered in all cancer patients scheduled to receive a cancer treatment with the potential to cause HF.
IIa
Recommendations for treatment of patients with HF and amyloidosis
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
Tafamidis is recommended in patients with wtTTR-CA and
NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CABG = coronary artery bypass graft; CCS = chronic coronary syndrome; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75
(doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CMP = cardiomyopathy; CV = cardiovascular; DPP-4 =
dipeptidyl peptidase-4; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction;
HFrEF = heart failure with reduced ejection fraction; HTM = home telemonitoring; hTTR = hereditary transthyretin; LAD = left anterior descending artery; LV =
left ventricular; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; T2DM =
type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT =
transferrin saturation; wtTTR-CA = wild-type transthyretin cardiac amyloidosis.
ESC 2021
..................................................................................................................................................................................


<!-- PAGE 13 -->

### Page 13

Changes in recommendations
2021
Class
2016
Class
Recommendations for diagnosis of HF
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in noninvasive stress tests.
IIb
Invasive coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.
IIa
CTCA should be considered in patients with a low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIa
Cardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIb
Recommendations for device therapy in HFrEF
An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of a non-ischaemic aetiology, and an LVEF <_35% despite >_3 months of OMT,
provided they are expected to survive substantially longer than 1 year with good functional status.
IIa
Primary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic
HF (NYHA class IIIII), and an LVEF <_35% despite >_3
months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status, and they have DCM.
I
CRT should be considered for symptomatic patients with
HF in sinus rhythm with a QRS duration of 130149 ms and LBBB QRS morphology and with LVEF <_35% despite
OMT in order to improve symptoms and reduce morbidity and mortality.
IIa
CRT is recommended for symptomatic patients with HF
in sinus rhythm with a QRS duration of 130149 ms and
LBBB QRS morphology and with LVEF <_35% despite
OMT in order to improve symptoms and reduce morbidity and mortality.
I
Patients with an LVEF <_35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing should be considered for
‘upgrade’ to CRT.
IIa
Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a high proportion of RV pacing may be considered for upgrade to CRT. This does not apply to patients with stable HF.
IIb
Recommendations for management of patients with acute HF
Combination of a loop diuretic with thiazide-type diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.
IIa
Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with resistant oedema or insufﬁcient symptomatic response.
IIb
In patients with AHF and SBP >110 mmHg, i.v. vasodilators may be considered as initial therapy to improve symptoms and reduce congestion.
IIb
In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce congestion.
IIa
Routine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety.
III
Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea and hypopnea may occur.
IIb
Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of the cause of cardiogenic shock or long-term MCS or transplantation.
IIa
Short-term MCS may be considered in refractory cardiogenic shock depending on patient age, comorbidities, and neurological function.
IIb
Continued
ESC Guidelines
3611


<!-- PAGE 14 -->

### Page 14

.........................................................
3 Definition, epidemiology and prognosis
3.1 Definition of heart failure
Heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure,
pulmonary crackles, and peripheral oedema). It is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.
Identification of the aetiology of the underlying cardiac dysfunction is mandatory in the diagnosis of HF as the specific pathology can determine subsequent treatment. Most commonly, HF is due to myocardial dysfunction: either systolic, diastolic, or both. However,
pathology of the valves, pericardium, and endocardium, and abnormalities of heart rhythm and conduction can also cause or contribute to HF.
3.2 Terminology
3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction
Traditionally, HF has been divided into distinct phenotypes based on the measurement of left ventricular ejection fraction (LVEF)
(Table 3). The rationale behind this relates to the original treatment trials in HF that demonstrated substantially improved outcomes in patients with LVEF <_40%. However, HF spans the entire range of
LVEF (a normally distributed variable), and measurement by echocardiography is subject to substantial variability. We have decided on the following classification of HF (Table 3):
• Reduced LVEF is defined as <_40%, i.e. those with a significant reduction in LV systolic function. This is designated as HFrEF.
• Patients with a LVEF between 41% and 49% have mildly reduced
LV systolic function, i.e. HFmrEF. Retrospective analyses from
RCTs in HFrEF or HF with preserved ejection fraction (HFpEF)
that have included patients with ejection fractions in the
4050% range suggest that they may benefit from similar
Recommendations for management of patients with HF and AF
DOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.
I
For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke,
intracranial haemorrhage, and mortality, which outweigh the increased risk of gastrointestinal haemorrhage.
IIa
Beta-blockers should be considered for short- and longterm rate control in patients with HF and AF.
IIa
For patients in NYHA class IIII, a beta-blocker, usually given orally, is safe and therefore is recommended as ﬁrstline treatment to control ventricular rate, provided the patient is euvolaemic.
I
In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite medical therapy, catheter ablation should be considered for the prevention or treatment of AF.
IIa
AV node catheter ablation may be considered to control heart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm control therapy, accepting that these patients will become pacemaker-dependent.
IIb
Recommendations for management of patients with HF and CCS
Coronary revascularization should be considered to relieve persistent symptoms of angina (or an anginaequivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, despite OMT
including anti-anginal drugs.
IIa
Myocardial revascularization is recommended when angina persists despite treatment with anti-anginal drugs.
I
Recommendations for management of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.
I
Empagliﬂozin should be considered in patients with T2DM
in order to prevent or delay the onset of HF and prolong life.
IIa
AF = atrial ﬁbrillation; AHF = acute heart failure; AV = atrio-ventricular; BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to cardiac recovery; CAD = coronary artery disease; CCS = chronic coronary syndrome; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CRT = cardiac resynchronization therapy; CT = computed tomography; CTCA = computed tomography coronary angiography; CV = cardiovascular; DCM = dilated cardiomyopathy; DOAC = direct oral anticoagulant; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; NOAC = non-vitamin K antagonist oral anticoagulant; NYHA = New York Heart Association; OMT = optimal medical therapy; QRS = Q, R, and S waves of an ECG;
RV = right ventricular/ventricle; SBP = systolic blood pressure; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus; VKA = vitamin K antagonist.
ESC 2021


<!-- PAGE 15 -->

### Page 15

..................................................................................................................
therapies to those with LVEF <_40%.813 This supports the renaming of HFmrEF from ‘heart failure with mid-range ejection fraction’ to ‘heart failure with mildly reduced ejection fraction’.14
• Those with symptoms and signs of HF, with evidence of structural and/or functional cardiac abnormalities and/or raised natriuretic peptides (NPs), and with an LVEF >_50%, have HFpEF.
The diagnosis of HFrEF, HFmrEF, and HFpEF is covered in more detail in their respective sections (sections 5, 7, and 8, respectively).
These definitions are consistent with a recent report on the
Universal Definition of Heart Failure.15
Patients with non-CV disease, e.g. anaemia, pulmonary, renal, thyroid, or hepatic disease may have symptoms and signs very similar to those of HF, but in the absence of cardiac dysfunction, they do not fulfil the criteria for HF. However, these pathologies can coexist with
HF and exacerbate the HF syndrome.
3.2.2 Right ventricular dysfunction
Heart failure can also be a result of right ventricular (RV) dysfunction. RV mechanics and function are altered in the setting of either pressure or volume overload.16 Although the main aetiology of chronic RV failure is LV dysfunction-induced pulmonary hypertension, there are a number of other causes of RV dysfunction [e.g.
MI, arrhythmogenic right ventricular cardiomyopathy (ARVC), or valve disease].17 The diagnosis is determined by a quantitative assessment of global RV function, most commonly by echocardiography, using at least one of the following measurements: fractional area change (FAC); tricuspid annular plane systolic excursion (TAPSE); and Doppler tissue imaging-derived systolic S0
velocity of the tricuspid annulus. The diagnosis and management of RV dysfunction is covered comprehensively in a recent Heart
Failure Association (HFA) position paper.18
3.2.3 Other common terminology used in heart failure
Heart failure is usually divided into two presentations: chronic heart failure (CHF) and acute heart failure (AHF). CHF describes those who have had an established diagnosis of HF or who have a more gradual onset of symptoms. If CHF deteriorates, either suddenly or slowly, the episode may be described as ‘decompensated’ HF. This can result in a hospital admission or treatment with intravenous (i.v.)
diuretic therapy in the outpatient setting. In addition, HF can present more acutely. Both of these are considered in the section on AHF
(section 11).
Some individuals with HF may recover completely [e.g. those due to alcohol-induced cardiomyopathy
(CMP),
viral myocarditis,
Takotsubo syndrome, peripartum cardiomyopathy (PPCM), or tachycardiomyopathy]. Other patients with LV systolic dysfunction may show a substantial or even complete recovery of LV systolic function after receiving drug and device therapy.
3.2.4 Terminology related to the symptomatic severity of heart failure
The simplest terminology used to describe the severity of HF is the
New York Heart Association (NYHA) functional classification
(Table 4). However, this relies solely on symptoms and there are many other better prognostic indicators in HF.19 Importantly,
patients with mild symptoms may still have a high risk of hospitalization and death.20 Predicting outcome is particularly important in advanced HF to guide selection of cardiac transplantation and device therapies. This will be covered in detail in the section on advanced
HF (section 10).
3.3 Epidemiology and natural history of heart failure
3.3.1 Incidence and prevalence
In developed countries, the age-adjusted incidence of HF may be falling, presumably reflecting better management of CV disease, but due to ageing, the overall incidence is increasing.2124 Currently, the incidence of HF in Europe is about 3/1000 person-years (all age-groups)
or about 5/1000 person-years in adults.25,26 The prevalence of HF
appears to be 12% of adults.21,2731 As studies only usually include recognized/diagnosed HF cases, the true prevalence is likely to be higher.32 The prevalence increases with age: from around 1% for those aged <55 years to >10% in those aged 70 years or over.3336 It
Table 3
Deﬁnition of heart failure with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction
Type of HF
HFrEF
HFmrEF
HFpEF
CRITERIA
1
Symptoms ± Signsa
Symptoms ± Signsa
Symptoms ± Signsa
2
LVEF <_40%
LVEF 4149%b
LVEF >_50%
3


Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV ﬁlling pressures, including raised natriuretic peptidesc
HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LV = left ventricle; LVEF = left ventricular ejection fraction.
aSigns may not be present in the early stages of HF (especially in HFpEF) and in optimally treated patients.
bFor the diagnosis of HFmrEF, the presence of other evidence of structural heart disease (e.g. increased left atrial size, LV hypertrophy or echocardiographic measures of impaired LV ﬁlling) makes the diagnosis more likely.
cFor the diagnosis of HFpEF, the greater the number of abnormalities present, the higher the likelihood of HFpEF.
ESC 2021
ESC Guidelines
3613


<!-- PAGE 16 -->

### Page 16

.................................................................................................................................................................
is generally believed that, of those with HF, about 50% have HFrEF
and 50% have HFpEF/HFmrEF, mainly based on studies in hospitalized patients.32,35,37,38 The ESC Long-Term Registry, in the outpatient setting, reports that 60% have HFrEF, 24% have HFmrEF, and 16% have
HFpEF.39 Somewhat more than 50% of HF patients are female.21,40,41
3.3.2 Aetiology of heart failure
The most common causes (as well as some key investigations)
of HF are shown in Table 5. The aetiology of HF varies according to geography.
In
Western-type and developed countries,
coronary artery disease (CAD) and hypertension are predominant factors.27
With regard to ischaemic aetiology, HFmrEF resembles HFrEF,
with a higher frequency of underlying CAD compared to those with
HFpEF.38,42,43
3.3.3 Natural history and prognosis
The prognosis of patients with HF has improved considerably since the publication of the first treatment trials a few decades ago.
However, it remains poor, and quality of life (QOL) is also markedly reduced. The improvement in prognosis has been confined to those with HFrEF.
Mortality rates are higher in observational studies than in clinical trials.44 In the Olmsted County cohort, 1-year and 5-year mortality rates after diagnosis, for all types of HF patients, were 20% and 53%,
respectively, between 2000 and 2010.45 A study combining the
Framingham Heart Study (FHS) and Cardiovascular Health Study
(CHS) cohorts reported a 67% mortality rate within 5 years following diagnosis.46 Despite receiving less evidence-based treatment, women have a better survival than men.47
Overall prognosis is better in HFmrEF compared to HFrEF.39 Of note, transition in ejection fraction over time is common, and patients who progress from HFmrEF to HFrEF have a worse prognosis than those who remain stable or transition to a higher ejection fraction category.4852
HFpEF is generally considered to confer a better survival than
HFrEF, but most observational studies show that this difference is negligible.45,46 In contrast, the large MAGGIC meta-analysis concluded that the adjusted mortality risk for patients with HFpEF was considerably lower than in patients with HFrEF.53
Studies from several countries have shown that between 1980 and
2000 survival in HF patients has improved markedly.41,5457
However, this positive trend may have levelled off since then.45
After the initial diagnosis, HF patients are hospitalized once every year on average.54 From 2000 to 2010, the mean rate of hospitalization in the Olmsted County cohort was 1.3 per person-year.
Interestingly, the majority (63%) of hospitalizations were related to non-CV causes.45 Studies from several European countries and the
United States (US) have shown that HF hospitalization rates peaked in the 1990s, and then declined.54,55*,5860 However, in a recent study of incident HF conducted between 1998 and 2017 in the
United Kingdom (UK), age-adjusted rates of first hospitalizations increased by 28% for both all-cause and HF admissions, and by 42%
for non-CV admissions.61 These increases were higher in women,
perhaps related to higher comorbidity rates. The risk of HF hospitalization is 1.5 times higher in patients with diabetes compared to controls. AF, a higher body mass index (BMI), and higher glycated haemoglobin (HbA1c), as well as a low estimated glomerular filtration rate (eGFR) are strong predictors of HF hospitalizations.29
Due to population growth, ageing, and the increasing prevalence of comorbidities, the absolute number of hospital admissions for HF
is expected to increase considerably in the future, perhaps by as much as 50% in the next 25 years.24,62
4 Chronic heart failure
4.1 Key steps in the diagnosis of chronic heart failure
The diagnosis of CHF requires the presence of symptoms and/or signs of HF and objective evidence of cardiac dysfunction (Figure 1).
Typical symptoms include breathlessness, fatigue, and ankle swelling
(Table 6). Symptoms and signs lack sufficient accuracy to be used alone to make the diagnosis of HF.6366
The diagnosis of CHF is made more likely in patients with a history of MI, arterial hypertension, CAD, diabetes mellitus, alcohol misuse,
chronic kidney disease (CKD), cardiotoxic chemotherapy, and in those with a family history of CMP or sudden death.
The following diagnostic tests are recommended for the assessment of patients with suspected chronic HF:
(1)
Electrocardiogram (ECG). A normal ECG makes the diagnosis of
HF unlikely.63 The ECG may reveal abnormalities such as AF, Q
waves, LV hypertrophy (LVH), and a widened QRS complex
(Table 7) that increase the likelihood of a diagnosis of HF and also may guide therapy.
Table 4
New York Heart Association functional classiﬁcation based on severity of symptoms and physical activity
Class I
No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Class II
Slight limitation of physical activity. Comfortable at rest,
but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Class III
Marked limitation of physical activity. Comfortable at rest,
but less than ordinary activity results undue breathlessness, fatigue, or palpitations.
Class IV
Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased.
ESC 2021


<!-- PAGE 17 -->

### Page 17

Y
Suspected heart failure
Echocardiography
NT-proBNP ≥ 125 pg/mL
or BNP ≥ 35 pg/mL
N
Y
Diagnostic algorithm for heart failure
Risk factors
Symptoms and/or signs
Abnormal ECG
or if HF strongly suspected or if NT-proBNP/BNP unavailable
Abnormal findings
Y
Heart failure confirmed
Define heart failure phenotype based on LVEF measurement
≤40%
(HFrEF)
41–49%
(HFmrEF)
≥50%
(HFpEF)
Determine aetiology and commence treatment
Heart failure unlikely
Consider other diagnoses
N
Figure 1 The diagnostic algorithm for heart failure. BNP= B-type natriuretic peptide; ECG= electrocardiogram; HFmrEF= heart failure with mildly reduced ejection fraction; HFpEF= heart failure with preserved ejection fraction; HFrEF= heart failure with reduced ejection fraction; LVEF= left ventricular ejection fraction; NT-proBNP= N-terminal pro-B type natriuretic peptide. The abnormal echocardiographic findings are described in more detail in the respective sections on HFrEF (section 5), HFmrEF (section 7), and HFpEF (section 8).
ESC Guidelines
3615


<!-- PAGE 18 -->

### Page 18

Table 5
Causes of heart failure, common modes of presentation and speciﬁc investigations
Cause
Examples of presentations
Specific investigations
CAD
Myocardial infarction
Angina or “angina-equivalent”
Arrhythmias
Invasive coronary angiography
CT coronary angiography
Imaging stress tests (echo, nuclear, CMR)
Hypertension
Heart failure with preserved systolic function
Malignant hypertension/acute pulmonary oedema
24 h ambulatory BP
Plasma metanephrines, renal artery imaging
Renin and aldosterone
Valve disease
Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation
Congenital valve disease
Echo  transoesophageal/stress
Arrhythmias
Atrial tachyarrhythmias
Ventricular arrhythmias
Ambulatory ECG recording
Electrophysiology study, if indicated
CMPs
All
Dilated
Hypertrophic
Restrictive
ARVC
Peripartum
Takotsubo syndrome
Toxins: alcohol, cocaine, iron, copper
CMR, genetic testing
Right and left heart catheterization
CMR, angiography
Trace elements, toxicology, LFTs, GGT
Congenital heart disease
Congenitally corrected/repaired transposition of great arteries
Shunt lesions
Repaired tetralogy of Fallot
Ebstein’s anomaly
CMR
Infective
Viral myocarditis
Chagas disease
HIV
Lyme disease
CMR, EMB
Serology
Drug-induced
Anthracyclines
Trastuzumab
VEGF inhibitors
Immune checkpoint inhibitors
Proteasome inhibitors
RAFþMEK inhibitors
Inﬁltrative
Amyloid
Sarcoidosis
Neoplastic
Serum electrophoresis and serum free light chains, Bence
Jones protein, bone scintigraphy, CMR, CT-PET, EMB
Serum ACE, CMR, FDG-PET, chest CT, EMB
CMR, EMB
Storage disorders
Haemochromatosis
Fabry disease
Glycogen storage diseases
Iron studies, genetics, CMR (T2* imaging), EMB
a-galactosidase A, genetics, CMR (T1 mapping)
Endomyocardial disease
Radiotherapy
Endomyocardial ﬁbrosis/eosinophilia
Carcinoid
CMR
EMB
24 h urine 5-HIAA
Pericardial disease
Calciﬁcation
Inﬁltrative
Chest CT, CMR, right and left heart catheterization
Metabolic
Endocrine disease
Nutritional disease (thiamine, vitamin B1 and selenium deﬁciencies)
Autoimmune disease
TFTs, plasma metanephrines, renin and aldosterone, cortisol
Speciﬁc plasma nutrients
ANA, ANCA, rheumatology review
Neuromuscular disease
Friedreich’s ataxia
Muscular dystrophy
Nerve conduction studies, electromyogram, genetics
CK, electromyogram, genetics
5-HIAA = 5-hydroxyindoleacetic acid; ACE = angiotensin-converting enzyme; ANA = anti-nuclear antibody; ANCA = anti-nuclear cytoplasmic antibody; ARVC = arrhythmogenic right ventricular cardiomyopathy; BP = blood pressure; CAD = coronary artery disease; CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CK = creatinine kinase; CT
= computed tomography; ECG = electrocardiogram; Echo = echocardiography; EMB = endomyocardial biopsy; FDG = ﬂuorodeoxyglucose; GGT = gamma-glutamyl transferase;
HIV = human immunodeﬁciency virus; h = hour; LFT = liver function test; LGE = late gadolinium enhancement; MEK = mitogen-activated protein kinase; PET = positron emission tomography; TFT = thyroid function test; VEGF = vascular endothelial growth factor.
ESC 2021


<!-- PAGE 19 -->

### Page 19

...........................................................
(2)
Measurement of NPs are recommended, if available. A plasma concentration of B-type natriuretic peptide (BNP) <35 pg/mL,
N-terminal pro-B-type natriuretic peptide (NT-proBNP) <125 pg/
mL, or mid-regional pro-atrial natriuretic peptide (MR-proANP)
<40 pmol/L68 make a diagnosis of HF unlikely. These will be discussed in more detail in section 4.2.69,70
(3)
Basic investigations such as serum urea and electrolytes, creatinine,
full blood count, liver and thyroid function tests are recommended to differentiate HF from other conditions, to provide prognostic information, and to guide potential therapy.
(4)
Echocardiography is recommended as the key investigation for the assessment of cardiac function. As well as the determination of the
LVEF, echocardiography also provides information on other parameters such as chamber size, eccentric or concentric LVH, regional wall motion abnormalities (that may suggest underlying CAD,
Takotsubo syndrome, or myocarditis), RV function, pulmonary hypertension,
valvular function,
and markers of diastolic function.16,71
(5)
A chest X-ray is recommended to investigate other potential causes of breathlessness (e.g. pulmonary disease). It may also provide supportive evidence of
HF
(e.g.
pulmonary congestion or cardiomegaly).
4.2 Natriuretic peptides
Plasma concentrations of NPs are recommended as initial diagnostic tests in patients with symptoms suggestive of HF to rule out the diagnosis. Elevated concentrations support a diagnosis of HF, are useful for prognostication,72 and may guide further cardiac investigation.73
However, it should be noted that there are many causes of an elevated NP—both CV and non-CV—that might reduce their diagnostic accuracy (Table 7). These causes include AF, increasing age, and acute or chronic kidney disease.74 Conversely, NP concentrations may be disproportionately low in obese patients.75
4.2.1 Use in the non-acute setting
The diagnostic value of NPs, in addition to signs and symptoms and other diagnostic tests, such as an ECG, has been assessed in several studies in the primary care setting.68,7680 The aim of these studies was to either exclude or establish a diagnosis of HF. The Task Force considered studies of adequate quality that included NP cut-off points in their diagnostic algorithms, below which the probability of having HF
was extremely low. The upper limits of normal in the non-acute setting are 35 pg/mL for BNP, and 125 pg/mL for NT-proBNP. In these studies, the negative predictive values of NP concentrations below these thresholds range from 0.94 to 0.98.7678 Fewer data are available for MR-proANP in CHF than in AHF. A concentration of <40 pmol/L
can be used to rule out HF.68
4.3 Investigations to determine the underlying aetiology of chronic heart failure
Recommended tests to determine the underlying aetiology of CHF
are summarized in Table 5.
Recommended diagnostic tests in all patients with suspected chronic heart failure
Recommendations
Classa
Levelb
BNP/NT-proBNPc
I
B
12-lead ECG
I
C
Transthoracic echocardiography
I
C
Chest radiography (X-ray)
I
C
Routine blood tests for comorbidities, including full blood count, urea and electrolytes, thyroid function, fasting glucose and HbA1c, lipids, iron status (TSAT and ferritin)
I
C
BNP = B-type natriuretic peptide; ECG = electrocardiogram; HbA1c = glycated haemoglobin; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSAT =
transferrin saturation.
aClass of recommendation.
bLevel of evidence.
cReferences are listed in section 4.2 for this item.
Table 6
Symptoms and signs typical of heart failure
Symptoms
Signs
Typical
More speciﬁc
Breathlessness
Orthopnoea
Paroxysmal nocturnal dyspnoea
Reduced exercise tolerance
Fatigue, tiredness, increased time to recover after exercise
Ankle swelling
Elevated jugular venous pressure
Hepatojugular reﬂux
Third heart sound (gallop rhythm)
Laterally displaced apical impulse
Less typical
Less speciﬁc
Nocturnal cough
Wheezing
Bloated feeling
Loss of appetite
Confusion (especially in the elderly)
Depression
Palpitation
Dizziness
Syncope
Bendopneaa
Weight gain (>2 kg/week)
Weight loss (in advanced HF)
Tissue wasting (cachexia)
Cardiac murmur
Peripheral oedema (ankle,
sacral, scrotal)
Pulmonary crepitations
Pleural effusion
Tachycardia
Irregular pulse
Tachypnoea
Cheyne-Stokes respiration
Hepatomegaly
Ascites
Cold extremities
Oliguria
Narrow pulse pressure
HF = heart failure.
aThis symptom of advanced HF corresponds to shortness of breath when leaning forward.67
ESC 2021
ESC 2021
..........................................................................................................
ESC Guidelines
3617


<!-- PAGE 20 -->

### Page 20

Exercise or pharmacological stress echocardiography may be used for the assessment of inducible ischaemia in those who are considered suitable for coronary revascularization.81 In patients with
HFpEF, valve disease, or unexplained dyspnoea, stress echocardiography might help clarify the diagnosis.82
Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE), T1 mapping and extracellular volume will identify myocardial fibrosis/scar, which are typically subendocardial for patients with ischaemic heart disease (IHD) in contrast to the mid-wall scar typical of dilated cardiomyopathy (DCM). In addition, CMR allows myocardial characterization in, e.g. myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease, LV
non-compaction CMP, haemochromatosis, and arrhythmogenic cardiomyopathy (AC).83,84
Computed tomography coronary angiography (CTCA) may be considered in patients with a low to intermediate pre-test probability of CAD, or those with equivocal non-invasive stress tests in order to exclude the diagnosis of CAD.5
Single-photon emission CT (SPECT) can also be used to assess myocardial ischaemia and viability, myocardial inflammation or infiltration. Scintigraphy with technetium (Tc)-labelled bisphosphonate has shown high sensitivity and specificity for imaging cardiac transthyretin amyloid.85
ESC 2021
Recommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure
Recommendations
Classa
Levelb
CMR
CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic windows.
I
C
CMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂammatory disease (myocarditis), LV non-compaction, amyloid,
sarcoidosis, iron overload/haemochromatosis.
I
C
CMR with LGE should be considered in DCM to distinguish between ischaemic and non-ischaemic myocardial damage.
IIa
C
Invasive coronary angiography (in those who are considered eligible for potential coronary revascularization)
Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.5
I
B
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests.89
IIb
B
Non-invasive testing
CTCA should be considered in patients with a low to intermediate pre-test probability of CAD
or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIa
C
Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischaemia and viability in patients with CAD who are considered suitable for coronary revascularization.9093
IIb
B
Exercise testing may be considered to detect reversible myocardial ischaemia and investigate the cause of dyspnoea.9496
IIb
C
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS.9496
I
C
Cardiopulmonary exercise testing should be considered to optimize prescription of exercise training.9496
IIa
C
Cardiopulmonary exercise testing should be considered to identify the cause of unexplained dyspnoea and/or exercise intolerance.9496
IIa
C
Right heart catheterization
Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS.
I
C
Continued
Table 7
Causes of elevated concentrations of natriuretic peptides86-88
Cardiac
Heart failure
ACS
Pulmonary embolism
Myocarditis
Left ventricular hypertrophy
Hypertrophic or restrictive cardiomyopathy
Valvular heart disease
Congenital heart disease
Atrial and ventricular tachyarrhythmias
Heart contusion
Cardioversion, ICD shock
Surgical procedures involving the heart
Pulmonary hypertension
Non-cardiac
Advanced age
Ischaemic stroke
Subarachnoid haemorrhage
Renal dysfunction
Liver dysfunction (mainly liver cirrhosis with ascites)
Paraneoplastic syndrome
COPD
Severe infections (including pneumonia and sepsis)
Severe burns
Anaemia
Severe metabolic and hormone abnormalities
(e.g. thyrotoxicosis, diabetic ketosis)
ACS = acute coronary syndrome; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-deﬁbrillator.
............................................................................................................................................................................


<!-- PAGE 21 -->

### Page 21

................................................................................................................................................................
Coronary angiography is recommended in patients with HF, who have angina pectoris or an ‘angina equivalent’ despite pharmacological therapy, in order to establish the diagnosis of CAD and its severity.
Coronary angiography may also be considered in patients with
HFrEF who have an intermediate to high pre-test probability of CAD
and who are considered potentially suitable for coronary revascularization.5
5 Heart failure with reduced ejection fraction
5.1 The diagnosis of heart failure with reduced ejection fraction
The diagnosis of HFrEF requires the presence of symptoms and/or signs of HF and a reduced ejection fraction (LVEF <_40%). This is most usually obtained by echocardiography. Details about the quality standards that should be adhered to when determining the presence of reduced LV systolic function by echocardiography can be found in the European Association of Cardiovascular
Imaging (EACVI) position paper.99 If assessment of EF is not possible by echocardiography, then CMR or rarely, nuclear techniques can be employed.
An algorithm for the diagnosis of HFrEF is depicted in Figure 1. For the investigation of the underlying aetiology, please refer to Table 5.
5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction
5.2.1
Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction
Pharmacotherapy is the cornerstone of treatment for HFrEF and should be implemented before considering device therapy, and alongside non-pharmacological interventions.
There are three major goals of treatment for patients with HFrEF:
(i) reduction in mortality, (ii) prevention of recurrent hospitalizations due to worsening HF, and (iii) improvement in clinical status, functional capacity, and QOL.100102
The key evidence supporting the recommendations in this section for patients with symptomatic HFrEF is given in Supplementary Table 1.
Figure 2 depicts the algorithm for the treatment strategy, including drugs and devices in patients with HFrEF, for Class I indications for the reduction of mortality (either all-cause or CV). The recommendations for each treatment are summarized below.
5.2.2
General principles of pharmacotherapy for heart failure with reduced ejection fraction
Modulation of the renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems with angiotensin-converting enzyme inhibitors (ACE-I) or an angiotensin receptor-neprilysin inhibitor (ARNI),
beta-blockers, and mineralocorticoid receptor antagonists (MRA)
has been shown to improve survival, reduce the risk of HF hospitalizations, and reduce symptoms in patients with HFrEF. These drugs serve as the foundations of pharmacotherapy for patients with
HFrEF. The triad of an ACE-I/ARNI, a beta-blocker, and an MRA is recommended as cornerstone therapies for these patients, unless the drugs are contraindicated or not tolerated.103105 They should be uptitrated to the doses used in the clinical trials (or to maximally tolerated doses if that is not possible). This guideline still recommends the use of ARNI as a replacement for ACE-I in suitable patients who remain symptomatic on ACE-I, beta-blocker, and MRA
therapies; however, an ARNI may be considered as a first-line therapy instead of an ACE-I.106,107 The recommended doses of these drugs are given in Table 8. Angiotensin-receptor blockers (ARBs) still have a role in those who are intolerant to ACE-I or ARNI.
The sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin added to therapy with ACE-I/ARNI/betablocker/MRA reduced the risk of CV death and worsening HF in patients with HFrEF.108,109 Unless contraindicated or not tolerated,
dapagliflozin or empagliflozin are recommended for all patients with
HFrEF already treated with an ACE-I/ARNI, a beta-blocker, and an
MRA, regardless of whether they have diabetes or not.
Other drugs may be used for selected patients with HFrEF. These are discussed in section 5.4.
Right heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis, restrictive cardiomyopathy, congenital heart disease, and high output states.
IIa
C
Right heart catheterization should be considered in patients with probable pulmonary hypertension, assessed by echo in order to conﬁrm the diagnosis and assess its reversibility before the correction of valve/structural heart disease.
IIa
C
Right heart catheterization may be considered in selected patients with HFpEF to conﬁrm the diagnosis.
IIb
C
EMB
EMB should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a speciﬁc diagnosis,
which can be conﬁrmed only in myocardial samples.97,98
IIa
C
CAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA =
computed tomography coronary angiography; DCM = dilated cardiomyopathy;
EMB = endomyocardial biopsy; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction;
LGE = late gadolinium enhancement; LV = left ventricular; MCS = mechanical circulatory support; PET = positron emission tomography; SPECT = single-photon emission computed tomography.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3619


<!-- PAGE 22 -->

### Page 22

Management of patients with HFrEF
LVEF ≤35% and
QRS <130 ms and where appropriate
(Class I)
SR and
LVEF ≤35% and
QRS ≥130 ms
If symptoms persist, consider therapies with Class II recommendations
LVEF >35% or device therapy not indicated or inappropriate
ACE-I/ARNIa
Beta-blocker
MRA
Dapagliflozin/Empagliflozin
Loop diuretic for fluid retention
Ischaemic
(Class I)
Non-ischaemic
(Class IIa)
ICD
QRS ≥150 ms
(Class I)
QRS 130–149 ms
(Class IIa)
CRT-Db/-P
Figure 2 Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction. ACE-I =angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D=cardiac resynchronization therapy with defibrillator; CRT-P= cardiac resynchronization therapy pacemaker; ICD= implantable cardioverter-defibrillator; HFrEF= heart failure with reduced ejection fraction; MRA= mineralocorticoid receptor antagonist; QRS= Q, R, and S waves of an ECG; SR = sinus rhythm. aAs a replacement for ACE-I. bWhere appropriate. Class I = green.
Class IIa= Yellow.
Pharmacological treatments indicated in patients with (NYHA class II–IV) heart failure with reduced ejection fraction
(LVEF <_40%)
Recommendations
Classa
Levelb
An ACE-I is recommended for patients with HFrEF to reduce the risk of HF
hospitalization and death.110113
I
A
A beta-blocker is recommended for patients with stable HFrEF to reduce the risk of
HF hospitalization and death.114120
I
A
An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.121,122
I
A
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.108,109
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF
hospitalization and death.105
I
B
ACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.
aClass of recommendation.
bLevel of evidence.
ESC 2021
5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction


<!-- PAGE 23 -->

### Page 23

.............................................................................................................................................................................
5.3.1
Angiotensin-converting enzyme inhibitors
ACE-Is were the first class of drugs shown to reduce mortality and morbidity in patients with HFrEF.110113 They have also been shown to improve symptoms.111 They are recommended in all patients unless contraindicated or not tolerated. They should be uptitrated to the maximum tolerated recommended doses.
Practical guidance on how to use ACE-Is is given in Supplementary
Table 2.
5.3.2
Beta-blockers
Beta-blockers have been shown to reduce mortality and morbidity in patients with HFrEF, in addition to treatment with an ACE-I and diuretic.114120 They also improve symptoms.123 There is consensus that ACE-I and beta-blockers can be commenced together as soon as the diagnosis of symptomatic HFrEF is established. There is no evidence favouring the initiation of a beta-blocker before an ACE-I and vice versa.124 Beta-blockers should be initiated in clinically stable,
euvolaemic, patients at a low dose and gradually uptitrated to the maximum tolerated dose. In patients admitted with AHF, betablockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized.
An individual patient data (IPD) meta-analysis of all major betablocker trials in HFrEF has shown no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF.125
However, since this is a retrospective subgroup analysis, and because beta-blockers did not increase risk, the guideline committee decided not to make a separate recommendation according to heart rhythm.
Practical guidance on how to use beta-blockers is given in
Supplementary Table 3.
5.3.3
Mineralocorticoid receptor antagonists
MRAs (spironolactone or eplerenone) are recommended, in addition to an ACE-I and a beta-blocker, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization.121,122 They also improve symptoms.121 MRAs block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormones (e.g. corticosteroid and androgen) receptors. Eplerenone is more specific for aldosterone blockade and, therefore, causes less gynaecomastia.
Caution should be exercised when MRAs are used in patients with impaired renal function and in those with serum potassium concentrations >5.0 mmol/L.
Practical guidance on how to use MRAs is given in Supplementary
Table 4.
5.3.4
Angiotensin receptor-neprilysin inhibitor
In the PARADIGM-HF trial, sacubitril/valsartan, an ARNI, was shown to be superior to enalapril in reducing hospitalizations for worsening
HF, CV mortality, and all-cause mortality in patients with ambulatory
HFrEF with LVEF <_40% (changed to <_35% during the study). Patients in the trial had elevated plasma NP concentrations, an eGFR >_30 mL/
min/1.73 m2 and were able to tolerate enalapril and then sacubitril/
valsartan during the run-in period.105 Additional benefits of sacubitril/
valsartan included an improvement in symptoms and QOL,105 a reduction in the incidence of diabetes requiring insulin treatment,126
and a reduction in the decline in eGFR,127 as well as a reduced rate of hyperkalaemia.128 Additionally, the use of sacubitril/valsartan may allow a reduction in loop diuretic requirement.129 Symptomatic hypotension was reported more commonly in patients treated with sacubitril/valsartan as compared to enalapril, but despite developing hypotension, these patients also gained clinical benefits from sacubitril/valsartan therapy.128,130
Table 8
Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction
Starting dose
Target dose
ACE-I
Captoprila
6.25 mg t.i.d.
50 mg t.i.d.
Enalapril
2.5 mg b.i.d.
1020 mg b.i.d.
Lisinoprilb
2.55 mg o.d.
2035 mg o.d.
Ramipril
2.5 mg b.i.d.
5 mg b.i.d.
Trandolaprila
0.5 mg o.d.
4 mg o.d.
ARNI
Sacubitril/valsartan
49/51 mg b.i.d.c
97/103 mg b.i.d.
Beta-blockers
Bisoprolol
1.25 mg o.d.
10 mg o.d.
Carvedilol
3.125 mg b.i.d.
25 mg b.i.d.e
Metoprolol succinate
(CR/XL)
12.525 mg o.d.
200 mg o.d.
Nebivolold
1.25 mg o.d.
10 mg o.d.
MRA
Eplerenone
25 mg o.d.
50 mg o.d.
Spironolactone
25 mg o.d.f
50 mg o.d.
SGLT2 inhibitor
Dapagliﬂozin
10 mg o.d.
10 mg o.d.
Empagliﬂozin
10 mg o.d.
10 mg o.d.
Other agents
Candesartan
4 mg o.d.
32 mg o.d.
Losartan
50 mg o.d.
150 mg o.d.
Valsartan
40 mg b.i.d.
160 mg b.i.d.
Ivabradine
5 mg b.i.d.
7.5 mg b.i.d.
Vericiguat
2.5 mg o.d.
10 mg o.d.
Digoxin
62.5 mg o.d.
250 mg o.d.
Hydralazine/
Isosorbide dinitrate
37.5 mg t.i.d./20 mg t.i.d.
75 mg t.i.d./40 mg t.i.d.
ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptorneprilysin inhibitor; b.i.d. = bis in die (twice daily); CR = controlled release; CV =
cardiovascular; MRA = mineralocorticoid receptor antagonist; o.d. = omne in die
(once daily); SGLT2 = sodium-glucose co-transporter 2; t.i.d. = ter in die (three times a day); XL = extended release.
aIndicates an ACE-I where the dosing target is derived from post-myocardial infarction trials.
bIndicates drugs where a higher dose has been shown to reduce morbidity/mortality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimum dose is uncertain.
cSacubitril/valsartan may have an optional lower starting dose of 24/26 mg b.i.d.
for those with a history of symptomatic hypotension.
dIndicates a treatment not shown to reduce CV or all-cause mortality in patients with heart failure (or shown to be non-inferior to a treatment that does).
eA maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg.
fSpironolactone has an optional starting dose of 12.5 mg in patients where renal status or hyperkalaemia warrant caution.
ESC 2021
ESC Guidelines
3621


<!-- PAGE 24 -->

### Page 24

.............................
Therefore, it is recommended that an ACE-I or ARB is replaced by sacubitril/valsartan in ambulatory patients with HFrEF, who remain symptomatic despite optimal treatment outlined above. Two studies have examined the use of ARNI in hospitalized patients, some of whom had not been previously treated with ACE-I. Initiation in this setting appears safe and reduces subsequent CV death or HF hospitalizations by 42% compared to enalapril.106,107,131 As such, initiation of sacubitril/valsartan in ACE-I naive (i.e. de novo) patients with HFrEF
may be considered (class of recommendation IIb, level of evidence
B). Patients being commenced on sacubitril/valsartan should have an adequate blood pressure (BP), and an eGFR >_30 mL/min/1.73 m2. A
washout period of at least 36 h after ACE-I therapy is required in order to minimize the risk of angioedema.
Practical guidance on how to use ARNI is given in Supplementary
Table 5.
5.3.5
Sodium-glucose co-transporter 2 inhibitors
The DAPA-HF trial investigated the long-term effects of dapagliflozin
(SGLT2 inhibitor) compared to placebo in addition to optimal medical therapy (OMT), on morbidity and mortality in patients with ambulatory HFrEF.108 Patients participated in the trial if they were in
NYHA class IIIV, and had an LVEF <_40% despite OMT. Patients were also required to have an elevated plasma NT-proBNP and an eGFR >_30 mL/min/1.73 m2.108
Therapy with dapagliflozin resulted in a 26% reduction in the primary endpoint: a composite of worsening HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or CV death. Both of these components were significantly reduced. Moreover, dapagliflozin reduced all-cause mortality,108 alleviated HF symptoms, improved physical function and QOL in patients with symptomatic HFrEF.132
Benefits were seen early after the initiation of dapagliflozin, and the absolute risk reduction was large. Survival benefits were seen to the same extent in patients with HFrEF with and without diabetes, and across the whole spectrum of HbA1c values.108
Subsequently, the EMPEROR-Reduced trial found that empagliflozin reduced the combined primary endpoint of CV death or HF hospitalization by 25% in patients with NYHA class IIIV symptoms, and an LVEF <_40% despite OMT.109 This trial included patients with an eGFR >20 mL/min/1.73 m2 and there was also a reduction in the decline in eGFR in individuals receiving empagliflozin. It was also associated with an improvement in QOL.133 Although there was not a significant reduction in CV mortality in the EMPEROR-Reduced trial,
a recent meta-analysis of the DAPA-HF and EMPEROR-Reduced trials found no heterogeneity in CV mortality.134
Therefore, dapagliflozin or empagliflozin are recommended, in addition to OMT with an ACE-I/ARNI, a beta-blocker and an MRA,
for patients with HFrEF regardless of diabetes status. The diuretic/
natriuretic properties of SGLT2 inhibitors may offer additional benefits in reducing congestion and may allow a reduction in loop diuretic requirement.135
The combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been studied in patients with diabetes who were hospitalized with HF. The drug reduced CV death and hospitalization for HF.136 It is discussed further in the AHF and comorbidity sections.
Therapy with SGLT2 inhibitors may increase the risk of recurrent genital fungal infections. A small reduction in eGFR following initiation is expected and is reversible and should not lead to premature discontinuation of the drug.
Practical guidance on how to use the SGLT2 inhibitors dapagliflozin and empagliflozin are given in Supplementary Table 6.
5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction
Other pharmacological treatments indicated in selected patients with NYHA class II–IV heart failure with reduced ejection fraction (LVEF 40%)
Recommendations
Classa
Levelb
Loop diuretics
Diuretics are recommended in patients with
HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce HF hospitalizations.137
I
C
ARB
An ARBc is recommended to reduce the risk of
HF hospitalization and CV death in symptomatic patients unable to tolerate an ACE-I or ARNI
(patients should also receive a beta-blocker and an MRA).138
I
B
If-channel inhibitor
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in SR and a resting heart rate >_70 b.p.m. despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE-I/(or
ARNI), and an MRA, to reduce the risk of HF
hospitalization and CV death.139
IIa
B
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in SR and a resting heart rate >_70 b.p.m. who are unable to tolerate or have contraindications for a beta-blocker to reduce the risk of HF hospitalization and CV
death. Patients should also receive an ACE-I (or
ARNI) and an MRA.140
IIa
C
Soluble guanylate cyclase stimulator
Vericiguat may be considered in patients in
NYHA class IIIV who have had worsening HF
despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of
CV mortality or HF hospitalization.141
IIb
B
Hydralazine and isosorbide dinitrate
Hydralazine and isosorbide dinitrate should be considered in self-identiﬁed black patients with
LVEF <_35% or with an LVEF <45% combined with a dilated left ventricle in NYHA class IIIIV
despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of
HF hospitalization and death.142
IIa
B
Continued
................................................................................................................................................


<!-- PAGE 25 -->

### Page 25

.............................................................................................................................................................................
5.4.1
Diuretics
Loop diuretics are recommended to reduce the signs and/or symptoms of congestion in patients with HFrEF. The quality of the evidence regarding diuretics is poor and their effects on morbidity and mortality have not been studied in RCTs. However, it should also be remembered that the major disease-modifying treatment trials for
HFrEF were conducted with a high background use of loop diuretic therapy. One meta-analysis has shown that in patients with HFrEF,
loop and thiazide diuretics appear to reduce the risk of death and worsening HF compared with a placebo, and compared with an active control, diuretics improve exercise capacity.137
Loop diuretics produce a more intense and shorter diuresis than thiazides, although they act synergistically (sequential nephron blockade) and the combination may be used to treat diuretic resistance.
However, adverse effects are more likely, and these combinations should only be used with care. Of note, ARNI, MRAs, and SGLT2
inhibitors may also possess diuretic properties.129,145
The aim of diuretic therapy is to achieve and maintain euvolaemia with the lowest diuretic dose. In some euvolaemic/hypovolaemic patients, the use of a diuretic drug might be reduced or discontinued.146 Patients should be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements.
Practical guidance on how to use diuretics is given in
Supplementary Table 7.
5.4.2
Angiotensin II type 1 receptor blockers
The place of ARBs in the management of HFrEF has changed over the last few years. They are now recommended for patients who cannot tolerate ACE-I or ARNI because of serious side effects.
Candesartan in the CHARM-Alternative study reduced CV deaths and HF hospitalizations in patients who were not receiving an ACE-I
due to previous intolerance.138 Valsartan, in addition to usual therapy,
including ACE-I, reduced HF hospitalizations in the Val-HeFT trial.147
However, no ARB has reduced all-cause mortality in any trial.
5.4.3
If -channel inhibitor
Ivabradine slows heart rate by inhibition of the If channel in the sinus node and is therefore only effective in patients in SR. Ivabradine reduced the combined endpoint of CV mortality and HF hospitalization in patients with symptomatic HFrEF with an LVEF <_35%, with HF
hospitalization in recent 12 months, in sinus rhythm (SR) and with a heart rate >_70 b.p.m. who were on evidence-based therapy including an ACE-I (or ARB), a beta-blocker, and an MRA.139,140 Our recommendation is based on the heart rate of >_70 b.p.m. used in the SHIFT
trial. However, the European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF <_35%
and in SR with a resting heart rate >_75 b.p.m., because in this group ivabradine conferred a survival benefit148 based on a retrospective subgroup analysis. Every effort should be made to commence and uptitrate beta-blocker therapy to guideline recommended/maximally tolerated doses prior to considering ivabradine.
Practical guidance on how to use ivabradine is given in
Supplementary Table 8.
5.4.4
Combination of hydralazine and isosorbide dinitrate
There is no clear evidence to suggest the use of this fixed-dose combination therapy in all patients with HFrEF. A small RCT conducted in self-identified black patients showed that an addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy
(an ACE-I, a beta-blocker, and an MRA) reduced mortality and HF
hospitalizations in patients with HFrEF and NYHA classes IIIIV.142
These results are difficult to translate to patients of other racial or ethnic origins.
Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, ARNI, or an ARB (or if they are contraindicated) to reduce mortality. However, this recommendation is based on the results of the relatively small Veterans Administration
Cooperative Study, which included only male patients with symptomatic HFrEF who were treated with digoxin and diuretics.143
5.4.5
Digoxin
Digoxin may be considered in patients with HFrEF in SR to reduce the risk of hospitalization,144 although its effect on those routinely treated with beta-blockers has not been tested. In the DIG trial, the overall effect on mortality with digoxin was neutral.
The effects of digoxin in patients with HFrEF and AF have not been studied in RCTs. Some studies have suggested a potentially higher risk of events in patients with AF receiving digoxin,149,150 whereas another meta-analysis concluded, on the basis of non-RCTs, that digoxin has no deleterious effect on mortality in patients with AF and
HF, most of whom had HFrEF.151 Therefore, in patients with symptomatic HF and AF, digoxin may be useful for the treatment of patients with HFrEF and AF with rapid ventricular rate, when other therapeutic options cannot be pursued.150,152155
Digoxin has a narrow therapeutic window and so levels should be checked aiming for a serum digoxin concentration <1.2 ng/mL.156,157
Caution should also be exercised when using it in females, the elderly,
frail, hypokalaemic, and malnourished subjects. In patients with reduced renal function, digitoxin could be considered. Digitoxin use in HF and SR is currently being investigated.158
Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF who cannot tolerate any of an ACE-I, an ARB, or
ARNI (or they are contraindicated) to reduce the risk of death.143
IIb
B
Digoxin
Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a betablocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF
hospitalizations).144
IIb
B
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; b.p.m. = beats per minute; CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SR =
sinus rhythm.
aClass of recommendation.
bLevel of evidence.
cThe ARBs with evidence in HFrEF are candesartan, losartan, and valsartan.
ESC 2021
ESC Guidelines
3623


<!-- PAGE 26 -->

### Page 26

Diuretics
SR with LBBB ≥ 150 ms
To reduce mortality - for all patients
To reduce HF hospitalization/mortality - for selected patients
Volume overload
ACE-I/ARNI
BB
MRA
SGLT2i
Exercise rehabilitation
To reduce HF hospitalization and improve QOL - for all patients
For selected advanced HF patients
CRT-P/D
Atrial fibrillation
Anticoagulation
MCS as BTT/BTC
Aortic stenosis
SAVR/TAVI
Mitral regurgitation
TEE MV Repair
Heart rate SR>70 bpm
Ivabradine
Black Race
Hydralazine/ISDN
ACE-I/ARNI intolerance
ARB
Atrial fibrillation
Digoxin
Coronary artery disease
CABG
Iron deficiency
Ferric carboxymaltose
ICD
Ischaemic aetiology
Heart transplantation
Long-term MCS as DT
Multi-professional disease management
Non-ischaemic aetiology
SR with LBBB 130–149 ms or non LBBB ≥ 150 ms
CRT-P/D
Management of HFrEF
ICD
PVI
Figure 3 Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction. ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor; BB=beta-blocker; b.p.m.=beats per minute; BTC
=bridge to candidacy; BTT=bridge to transplantation; CABG=coronary artery bypass graft; CRT-D= cardiac resynchronization therapy with defibrillator;
CRT-P=cardiac resynchronization therapy pacemaker; DT=destination therapy; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; ICD=
implantable cardioverter-defibrillator; ISDN=isosorbide dinitrate; LBBB=left bundle branch block; MCS=mechanical circulatory support; MRA=mineralocorticoid receptor antagonist; MV=mitral valve; PVI=pulmonary vein isolation; QOL=quality of life; SAVR=surgical aortic valve replacement; SGLT2i=sodiumglucose co-transporter 2 inhibitor; SR=sinus rhythm; TAVI=transcatheter aortic valve replacement; TEE=transcatheter edge to edge. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation). The Figure shows management options with Class I and IIa recommendations. See the specific Tables for those with Class IIb recommendations.


<!-- PAGE 27 -->

### Page 27

..........
5.4.6
Recently reported advances from trials in heart failure with reduced ejection fraction
Soluble guanylate cyclase stimulator
The VICTORIA study assessed the efficacy and safety of the oral soluble guanylate cyclase stimulator, vericiguat, in patients with a reduced EF and recently decompensated CHF. The incidence of the primary endpoint of death from CV causes or hospitalization for HF was lower among those who received vericiguat than among those who received placebo.141 There was no reduction in either all-cause or CV mortality. Thus, vericiguat may be considered, in addition to standard therapy for HFrEF, to reduce the risk of CV mortality and hospitalizations for HF.
Cardiac myosin activator
The GALACTIC-HF study assessed the efficacy and safety of the cardiac myosin activator, omecamtiv mecarbil, in HFrEF patients, enrolling patients in both the inpatient and outpatient settings. The primary endpoint of a first HF event or CV death was reduced by 8%. There was no significant reduction in CV mortality. Currently, this drug is not licensed for use in HF. However, in the future it may be able to be considered, in addition to standard therapy for HFrEF to reduce the risk of CV mortality and hospitalization for HF.159
5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction
In addition to the general therapies considered in section 5, other therapies are appropriate to consider in selected patients. These are covered in detail in later sections. Some of the main ones (i.e. those with Class I and IIa Mortality/Hospitalization indications) are depicted in Figure 3. The effect of some interventions on symptoms/QOL are outlined in Supplementary Table 9.
6 Cardiac rhythm management for heart failure with reduced ejection fraction
This section provides recommendations on the use of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT). Other implantable devices will be discussed at the end of this section.
6.1 Implantable cardioverterdefibrillator
A high proportion of deaths among patients with HF, especially in those with milder symptoms, occur suddenly and unexpectedly.
Many of these may be due to electrical disturbances, including ventricular arrhythmias, bradycardia, and asystole, although some are due to other acute vascular events. Treatments that improve or delay the progression of CV disease have been shown to reduce the annual rate of sudden death,105,160 but they do not treat arrhythmic events when they occur. ICDs are effective at correcting potentially lethal ventricular arrhythmias, and in the case of transvenous systems, also prevent bradycardia. Some antiarrhythmic drugs might reduce the rate of tachyarrhythmias and sudden death, but they do not reduce overall mortality,161 and may increase it.
Recommendations for an implantable cardioverterdeﬁbrillator in patients with heart failure
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.162164
I
A
Primary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of an ischaemic aetiology (unless they have had a MI in the prior 40 days—see below), and an LVEF
<_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.161,165
I
A
An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class
IIIII) of a non-ischaemic aetiology, and an LVEF
<_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.161,166,167
IIa
A
Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals, the patient’s needs and clinical status may have changed.168172
IIa
B
A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device.173176
IIb
B
ICD implantation is not recommended within 40
days of a MI as implantation at this time does not improve prognosis.177,178
III
A
ICD therapy is not recommended in patients in
NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation.179183
III
C
CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association; OMT = optimal medical therapy; VAD = ventricular assist device.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3625


<!-- PAGE 28 -->

### Page 28

.............................................................................................................................................................................
6.1.1
Secondary prevention of sudden cardiac death
Compared with amiodarone treatment, ICDs reduce mortality in survivors of cardiac arrest and in patients who have experienced sustained symptomatic ventricular arrhythmias. An ICD is recommended in such patients when the intent is to increase survival; the decision to implant should take into account the patient’s view and their QOL, the LVEF (survival benefit is uncertain when LVEF >35%)
and the absence of other diseases likely to cause death within the following year.162164,184
6.1.2
Primary prevention of sudden cardiac death
In an analysis of over 40 000 patients from 12 pivotal HF trials, rates of sudden cardiac death decreased by 44% over the 20-year period
(from the mid-1990s to 2015).160 This is almost certainly due to advances in HF treatment, as many key guideline-recommended therapies, including beta-blockers, MRAs, sacubitril/valsartan, and
CRT pacemakers (CRT-P), reduce the risk of sudden death. While the afore-mentioned HF therapies have been shown to reduce mortality in patients with HFrEF, amiodarone has not.161 However, if it is to be used, it should be with caution due to its significant side-effect profile. Conversely, dronedarone185 and the class I antiarrhythmic agents disopyramide, encainide, and flecainide186 should not be used for prevention of arrhythmias due to the increase in mortality seen in clinical studies.
Although an ICD reduces the rate of sudden arrhythmic death in patients with HFrEF,187 it would be expected that, in well-managed patients, the additional benefit afforded by an ICD would be lower. In the DANISH trial, rates of sudden death were low in patients with nonischaemic cardiomyopathy (NICM); only 70 patients out of 1116 followed up over 5 years had sudden death.166 Whilst there was a modest absolute reduction in sudden death with a defibrillator-containing device, this did not significantly improve the overall risk of mortality.
However, subgroup analysis suggested there was a benefit in those <_70
years.188 In a recent meta-analysis of studies that examined the effect of
ICDs in NICM a survival benefit was still seen, although the effect was significantly weakened by the inclusion of the DANISH trial.167
On average, patients with IHD are at greater risk of sudden death than patients with NICM and therefore, although the relative benefits are similar, the absolute benefit is greater in patients with IHD.187 Two
RCTs showed no benefit in patients who had an ICD implanted within
40 days after a MI.177,178 Although sudden arrhythmic deaths were reduced, this was balanced by an increase in non-arrhythmic deaths.
Accordingly, an ICD for primary prevention is contraindicated in this time period. Furthermore, ICD implantation is recommended only if a minimum of 3 months of OMT has failed to increase the LVEF to
>35%. OMT ideally includes the use of Class I recommended drugs for
HFrEF. However, the ICD trials we cite predate the use of ARNI and
SGLT2 inhibitors. Whether implantation of ICDs reduces mortality in those with an LVEF >35% is unknown. There is an ongoing trial of ICD
therapy in such patients with the presence of scar on CMR imaging.189
6.1.3
Patient selection for implantable cardioverterdefibrillator therapy
Patients with HFrEF and a QRS duration >_130 ms can be considered for CRT with a defibrillator (CRT-D) rather than ICD. See the section on CRT for further details (section 6.2).
In patients with moderate or severe HF, a reduction in sudden death may be partially or wholly offset by an increase in death due to worsening HF.161 As such, ICD therapy is not recommended in patients in NYHA class IV, with severe symptoms refractory to pharmacological therapy, who are not candidates for a ventricular assist device (VAD) or cardiac transplantation. Such patients have a very limited life expectancy and are likely to die from pump failure.
Similarly, patients with serious comorbidities who are unlikely to survive substantially more than 1 year with good QOL are unlikely to obtain substantial benefit from an ICD.179183
Although the DANISH trial did not show a significant benefit from
ICD therapy in patients with NICM, it should be remembered that
NICM is a heterogeneous condition, and certain subgroups (e.g. laminopathies, sarcoidosis) are at higher risk of sudden death and therefore merit careful consideration of ICD implantation. Tools to help risk stratification (e.g. scar burden on magnetic resonance imaging)
can be helpful in that regard.190192
Patients should be counselled as to the purpose of an ICD and involved in the decision-making process. They should also be aware of the potential complications related to implantation, any additional implications for driving, and the risk of inappropriate shocks. Furthermore,
patients should be informed about the circumstances where the defibrillator (or defibrillator component of a CRT-D) might be deactivated
(e.g. terminal disease) or explanted (e.g. infection or recovery of LV
function).193 Subsequent timely conversations regarding defibrillator deactivation should be held with the patient and caregiver(s).
When an ICD generator reaches its end of life or requires explantation, it should not be replaced automatically. Rather, shared decision making should be undertaken.168172 Patients should be carefully evaluated by an experienced cardiologist as treatment goals may have changed since implantation (the risk of fatal arrhythmia may be lower, or the risk of non-arrhythmic death may be higher).
It is a matter of some controversy whether patients whose
LVEF has greatly improved and who have not required device therapy during the lifetime of the ICD should have another device implanted.168172
6.1.4
Implantable cardioverter-defibrillator programming
Routine defibrillation threshold testing is no longer performed following implantation of an ICD or CRT-D as it does not improve shock efficacy or reduce arrhythmic death.194 Conservative programming with long delays195 between detection and the ICD delivering therapy dramatically reduces the risk of both inappropriate and appropriate but unnecessary shocks.194,196,197 Generally, for primary prevention, defibrillators are programmed to minimize pacing (e.g.
ventricular demand pacing VVI at 40/min), and with a tachycardia treatment zone >200/min.194,198 Ultimately—and particularly for secondary prevention—programming should be adapted according to the patient’s specific needs.
6.1.5
Subcutaneous and wearable implantable cardioverter-defibrillators
Subcutaneous ICDs (S-ICDs) appear to be as effective as conventional transvenous ICDs with a similar complication rate. Although the risk of inappropriate shocks appeared to be higher initially,


<!-- PAGE 29 -->

### Page 29

improved patient selection has shown S-ICDs are non-inferior to transvenous ICDs in this regard.199202 They may be the preferred option for patients with difficult venous access or those who require
ICD explantation due to infection. Patients must be carefully selected, as S-ICDs cannot treat bradyarrhythmia (except post-shock pacing) and cannot deliver either anti-tachycardia pacing or CRT.
Substantial RCTs with these devices and more long-term data on safety and efficacy are awaited.
A wearable cardioverter-defibrillator that is able to recognize and treat ventricular arrhythmias may be considered for a limited period of time in selected patients with HF who are at high risk for sudden death but otherwise are not suitable for ICD
implantation.162,175,176,203 However, the large VEST trial failed to show that the wearable cardioverter-defibrillator reduced arrhythmic death in patients with an LVEF <_35% following a recent acute
MI.204
For more detailed recommendations on the use/indications of
ICD we refer the reader to the ESC/European Heart Rhythm
Association (EHRA) Guidelines on ventricular tachyarrhythmias and sudden cardiac death.201
6.2 Cardiac resynchronization therapy
In appropriately selected individuals, CRT reduces morbidity and mortality.211 Furthermore, CRT improves cardiac function, and enhances QOL.209,225
Whilst the CARE-HF206,208 and COMPANION210 trials compared the effect of CRT with medical therapy (MT), the majority of CRT
studies have compared CRT-D with ICD, and a few have compared
CRT-P with backup pacing. The prevention of fatal bradycardia might be an important mechanism of benefit shared by all pacing devices. In
CARE-HF, at baseline, 25% of patients had a resting heart rate of <_60
b.p.m.206,208,209 If prevention of bradycardia is important, the effect of
CRT will appear greater in trials where there is no device in the control group. However, in MADIT-II, 35% of those who died with an
ICD did so suddenly even though they were protected from both brady- and tachyarrhythmia.226
Most studies of CRT have specified that the LVEF should be <_35%,
but RAFT212 and MADIT-CRT213,214 specified an LVEF <_30%, while
REVERSE207,215,227
specified
<_40%
and
BLOCK-HF216
<_50%.
Relatively few patients with an LVEF of 3540% have been randomized, but an IPD meta-analysis suggests no diminution of the effect of
CRT in this group.211
Assessing the ‘response’ to CRT is challenging. Indeed, many who do not appear to ‘respond’ favourably in terms of their symptoms or
LV function may well have experienced the mortality benefit. Several characteristics predict improvement in morbidity and mortality. The extent of reverse remodelling is one of the most important mechanisms of action of CRT. Patients with HFrEF of an ischaemic aetiology have less improvement in LV function due to myocardial scar tissue,
which is less likely to undergo favourable remodelling.228 Conversely,
women may be more likely to respond than men, possibly due to smaller body and heart size.220,224,229 QRS width predicts CRT
response and was the inclusion criterion in all randomized trials,211
but QRS morphology has also been related to a beneficial response to CRT. Several studies have shown that patients with left bundle branch block (LBBB) morphology are more likely to respond favourably to CRT, whereas there is less certainty about patients with nonLBBB morphology.230 This latter group is also underrepresented in the large CRT trials.206,210,213 However, patients with LBBB
Recommendations for cardiac resynchronization therapy implantation in patients with heart failure
Recommendations
Classa
Levelb
CRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and
LBBB QRS morphology and with LVEF <_35%
despite OMT in order to improve symptoms and reduce morbidity and mortality.205215
I
A
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or
QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with
AF.216219
I
A
CRT should be considered for symptomatic patients with HF in SR with a QRS duration
>_150 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.205215
IIa
B
CRT should be considered for symptomatic patients with HF in SR with a QRS duration of
130149 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.211,220
IIa
B
Patients with an LVEF <_35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing should be considered for ‘upgrade’ to CRT.221
IIa
B
Continued
CRT may be considered for symptomatic patients with HF in SR with a QRS duration of
130149 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.208,213
IIb
B
CRT is not recommended in patients with a
QRS duration <130 ms who do not have an indication for pacing due to high degree AV
block.222224
III
A
AF = atrial ﬁbrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction;
ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block;
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association;
OMT = optimal medical therapy (class I recommended medical therapies for at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right ventricular; SR =
sinus rhythm.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3627


<!-- PAGE 30 -->

### Page 30

.............................................................................................................................................................................
morphology often have wider QRS durations, and there is a current debate about whether QRS durations or QRS morphology is the main predictor of a beneficial response to CRT. Evidence from two
IPD meta-analyses indicates that after accounting for QRS duration,
there is little evidence to suggest that QRS morphology or aetiology of disease influence the effect of CRT on morbidity or mortality.211,220 In addition, none of the landmark trials selected patients for inclusion according to QRS morphology, sex, or ischaemic aetiology,
nor were they powered for subgroup analyses.
The Echo-CRT trial222,223 and an IPD meta-analysis213 suggest possible harm from CRT when QRS duration is <130 ms, thus implantation of CRT is not recommended if QRS duration is <130 ms.
If a patient is scheduled to receive an ICD and is in SR, with a
LBBB, CRT-D should be considered if the QRS is between 130
and 149 ms and is recommended if QRS is >_150 ms. However,
clinical practice varies widely among countries and if the primary reason for implanting CRT is for the relief of symptoms, then the clinician should choose CRT-P or CRT-D, whichever they consider appropriate. The only randomized trial to compare CRT-P
and CRT-D210 did not demonstrate a difference in morbidity or mortality between these technologies (although the trial was not powered to show such a difference). Furthermore, in the
DANISH study in patients with NICM where 58% of patients received CRT there was no suggestion from subgroup analysis that CRT-P was inferior to CRT-D.166,167
When LVEF is reduced, RV pacing may exacerbate cardiac dyssynchrony. This can be prevented by CRT, which might improve patient outcomes.216218,231 However, a difference in outcome was not observed between CRT and RV pacing in a subgroup analysis of
RAFT.212 On balance, CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed. Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, despite
OMT, should be considered for ‘upgrading’ to CRT.
Only two small trials have compared pharmacological therapy alone vs. CRT in patients with AF, with conflicting results. Several studies have indicated that CRT is superior to RV pacing in patients undergoing atrio-ventricular
(AV)
node ablation.217,218,231
However, AF is not an indication to carry out AV node ablation in patients with CRT except in a few cases when ventricular rate remains persistently high despite attempts at pharmacological rate control. A subgroup analysis of patients with AF from the RAFT
study found no benefit from CRT-D compared with ICD, although less than half of patients had >90% biventricular capture.219 In view of the paucity of evidence for the efficacy of CRT in patients with
AF, it may be an option in selected patients—particularly those with a QRS >_150 ms—ensuring a proportion of biventricular pacing as high as possible.
Observational studies report that when biventricular capture is
<98%, the prognosis of patients with CRT declines.218,232 Whether this association reflects a loss of resynchronization (which might be remedied by device programming), poor placement of the LV lead,
or greater difficulty in pacing severely diseased myocardium is uncertain. This observation has not been confirmed in any randomized trial.
Early studies suggested that imaging tests for dyssynchrony were not of value in selecting patients for CRT.233 However, a recent study has suggested that two novel markers of dyssynchrony (apical rocking and septal flash) are associated with a response to CRT, but these have not been tested as selection criteria or as prespecified subgroups in a randomized trial.234 Patients with extensive myocardial scar will have less improvement in LV function with CRT, but this is true of any treatment for HFrEF and does not reliably predict less clinical benefit. Pacing thresholds are higher in scarred myocardium and, if possible, lead placement should avoid such regions.235,236
Although patients with extensive scarring have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from CRT.211
The value of trying to optimize AV intervals or interventricular delay intervals (VV intervals) after implantation using echo- or electrocardiographic criteria or BP response is uncertain but may be considered for patients who have had a disappointing response to
CRT.237,238 Other options to consider to optimize response to CRT
are covered in a recently published practical article.239
Following CRT implantation, a review of diuretic therapy is advised as a reduction in dose or its discontinuation may be required. In addition, CRT implantation may afford an opportunity to further optimize
MT for HFrEF.240
The reader is directed to guidelines on pacing and CRT for recommendations on device implantation procedures.240a
6.3 Devices under evaluation
Cardiac contractility modulation (CCM) has been evaluated in patients with NYHA class IIIIV HF, with an LVEF >_25% to <_45%
and QRS duration <130 ms, and was associated with a small improvement in exercise tolerance and QOL.241,242
Technologies that involve modification of the activity of the autonomic nervous system, e.g. baroreflex activation therapy,243,244 have also been shown to offer a modest improvement in effort capacity and QOL. However, currently, the evidence is considered insufficient to support specific guideline recommendations for a reduction in mortality or hospitalization for these and a variety of other implantable electrical therapeutic technologies (see also Gaps in Evidence in section 16).
7 Heart failure with mildly reduced ejection fraction
7.1 The diagnosis of heart failure with mildly reduced ejection fraction
The diagnosis of HFmrEF requires the presence of symptoms and/or signs of HF, and a mildly reduced EF (4149%) The presence of elevated NPs (BNP >_35 pg/mL or NT-proBNP >_125 pg/mL) and other evidence of structural heart disease [e.g. increased left atrial (LA) size,
LVH or echocardiographic measures of LV filling] make the diagnosis more likely but are not mandatory for diagnosis if there is certainty regarding the measurement of LVEF.
An algorithm for the diagnosis of HFmrEF is depicted in Figure 1.
For the investigation of the underlying aetiology, please refer to
Table 5 (which refers to investigations regardless of LVEF).


<!-- PAGE 31 -->

### Page 31

............................................................................................................................................................................
7.2 Clinical characteristics of patients with heart failure with mildly reduced ejection fraction
There is a substantial overlap of clinical characteristics, risk factors,
patterns of cardiac remodelling, and outcomes among the LVEF categories in HF. Patients with HFmrEF have, on average, features that are more similar to HFrEF than HFpEF, in that they are more commonly men,
younger,
and are more likely to have
CAD
(5060%),38,42,43 and less likely to have AF and non-cardiac comorbidities (Supplementary Table 10). However, ambulatory patients with
HFmrEF have a lower mortality than those with HFrEF, more akin to those with HFpEF.
Patients with HFmrEF may include patients whose LVEF has improved from <_40% or declined from >_50%.50
7.3 Treatments for patients with heart failure with mildly reduced ejection fraction
As in other forms of HF, diuretics should be used to control congestion. No substantial prospective RCT has been performed exclusively in patients with HFmrEF (Supplementary Table 11). Some data can be gleaned from subgroup analysis of trials in HFpEF, none of which have met their primary endpoint. Although strong recommendations cannot be made about specific therapies at this point in time, we have included a Table of Recommendations to help guide the management of patients in this category.
7.3.1
Angiotensin-converting enzyme inhibitors
There are no specific trials of ACE-I in patients with HFmrEF.
Although, the PEP-CHF trial was conducted in patients with HFpEF
and included patients with an LVEF >40%, it did not report outcomes according to LVEF.11
However, in patients with HFmrEF, many will also have CAD,
hypertension, or post-MI LV systolic dysfunction and will, therefore,
already be treated with ACE-I.
Therefore, ACE-I use may be considered in patients with HFmrEF.
7.3.2
Angiotensin receptor II type 1 receptor blockers
There are no specific trials of ARBs in HFmrEF. The CHARMPreserved trial missed its primary endpoint of CV death or HF hospitalizations.245 However, a retrospective analysis showed that candesartan reduced the number of patients hospitalized for HF among those with HFmrEF (with similar trends for CV and all-cause mortality).8 Moreover, a recurrent-event analysis suggested a reduction in hospitalizations for HF among the entire CHARM-Preserved cohort,
including those with HFmrEF.248
As for ACE-I, many with HFmrEF will already be on an ARB for other CV indications. Therefore, treatment with ARBs may be considered in patients with HFmrEF.
7.3.3
Beta-blockers
There is no specific trial of beta-blockade in HFmrEF. An IPD metaanalysis of landmark trials of beta-blockers suggested similar reductions in CV and all-cause mortality (of 50%) for patients in SR with
HFrEF and HFmrEF.12 This IPD meta-analysis included the SENIORS
trial where nebivolol reduced the composite primary endpoint of allcause mortality or CV hospital admissions in the overall population.
No interaction between LVEF (35% of patients had an LVEF of
3550%) and the effect of nebivolol on the primary outcome was observed.119,249 Many patients with HFmrEF may have another CV
indication, such as AF or angina, for a beta-blocker. Therefore, treatment with beta-blockers may be considered in patients with HFmrEF.
7.3.4
Mineralocorticoid receptor antagonists
There is no specific trial of MRAs in HFmrEF. In a retrospective analysis of the TOPCAT trial in patients with an LVEF >_45%,9 spironolactone reduced hospitalizations for HF in those with an LVEF <55%.
There was a similar trend for CV but not all-cause mortality.
Treatment with an MRA may be considered in patients with
HFmrEF.
7.3.5
Angiotensin receptor-neprilysin inhibitor
There is no specific trial of ARNI in HFmrEF. In the PARAGON-HF
trial, which included patients with EF >_45%, although the trial missed its primary endpoint overall, a significant EF-by-treatment interaction was observed. Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalizations by 22% in those with an EF below or equal to the median of 57%.13 Further data are available from a combined analysis of the PARADIGM-HF and PARAGON-HF trials showing that sacubitril/valsartan, compared to other forms of RAAS blockade,
has a beneficial effect, especially on hospitalizations for HF in those with HFmrEF.247
Pharmacological treatments to be considered in patients with (NYHA class II–IV) heart failure with mildly reduced ejection fraction
Recommendations
Classa
Levelb
Diuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs.137
I
C
An ACE-I may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.11
IIb
C
An ARB may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.245
IIb
C
A beta-blocker may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.12,119
IIb
C
An MRA may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.246
IIb
C
Sacubitril/valsartan may be considered for patients with HFmrEF to reduce the risk of HF
hospitalization and death.13,247
IIb
C
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York
Heart Association.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3629


<!-- PAGE 32 -->

### Page 32

.............................................................................................................................................................................
Treatment with an ARNI may be considered in patients with
HFmrEF.
7.3.6
Other drugs
In the DIG trial,10 for those with HFmrEF in SR, there was a trend to fewer hospitalizations for HF in those assigned to digoxin, but no reduction in mortality and a trend to an excess of CV deaths.
Therefore, there are insufficient data to recommend its use.
There are also insufficient data on ivabradine in HFmrEF to draw any conclusions.
7.3.7
Devices
While post hoc analyses of landmark CRT trials suggest that CRT
may benefit patients with LVEF >35%, trials of CRT for HFmrEF were abandoned due to poor recruitment.250 There are no substantial trials of ICDs for primary prevention of ventricular arrhythmias for
HFmrEF; trials conducted more than 20 years ago suggested no benefit from ICD implantation for secondary prevention of ventricular arrhythmias for HFmrEF.
Therefore, there is insufficient evidence to advise CRT or ICD
therapy in patients with HFmrEF.
In HF patients with an LVEF >_40%, the implantation of an interatrial shunt device was found to be safe, and this device is subject to investigation in a larger study before any recommendation on their use in HFpEF or HFmrEF can be given.251
8 Heart failure with preserved ejection fraction
8.1 The background to heart failure with preserved ejection fraction
This guideline acknowledges the historical changes in nomenclature and the lack of consensus on the optimal LVEF cut-off to define the group of patients with HF without overtly reduced EF. The term ‘preserved’ was originally proposed in the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM)
Programme to refer to patients with an EF (>40%) that was not clearly ‘reduced’ or completely ‘normal’.252 While the current guidelines have designated patients with an LVEF 4149% as HFmrEF, we recognize that there will be debate about what constitutes ‘mildly reduced’ EF, what these EF cut-offs should be, and whether they should be different for men and women.14,253 The EACVI defines systolic dysfunction as being <52% for males and <54% for females.16
Whether patients with higher EFs and HF should be named HF
with ‘normal’ EF has also been considered.14,254 However, given the known variability of echocardiographic measurements of LVEF, the difficulties in interpreting LVEF measured using different imaging modalities, and remaining controversies regarding the precise LVEF
cut-off to define ‘normal’ , which may vary not only with sex but also with other factors such as age and ethnicity,255 this guideline has kept the nomenclature of HFpEF using an EF cut-off of 50%. Importantly,
clinicians should be aware that LVEF is a continuous variable with a normal distribution in the general population, and the EF cut-offs used in definitions are therefore arbitrary. Moreover, while the LVEF
cut-off to define ‘normal’ will likely be higher than 50%, the presence of a very high EF (e.g. above 6570%) should also prompt a search for pathology, such as cardiac amyloidosis (CA) or hypertrophic cardiomyopathy (HCM), where a ‘supra-normal’ EF may result from shrinkage of the LV end-diastolic volume (denominator of EF).256,257
8.2 Clinical characteristics of patients with heart failure with preserved ejection fraction
HFpEF differs from HFrEF and HFmrEF in that HFpEF patients are older and more often female. AF, CKD, and non-CV comorbidities are more common in patients with HFpEF than in those with
HFrEF.258
There are numerous potential causes of HFpEF (Table 5). The pathophysiology of various HFpEF syndromes differs, and thus they require distinct therapies. Red flags for the potential presence of CA
include low normal BP in patients with a history of hypertension,
intolerance to beta-blockers or ACE-I, history of bilateral carpal tunnel syndrome, low voltage on ECG and echocardiographic features such as thickening of the septum, posterior wall, or RV wall, enlarged atria, a small pericardial effusion, or valve thickening [for more details see the section on CMP (section 14.2)]. Furthermore, it is important to exclude other conditions that might mimic the HFpEF syndrome
(e.g. lung disease, anaemia, obesity, and deconditioning). For a more comprehensive overview on HFpEF, see the ESC/HFA position statement.259
8.3 The diagnosis of heart failure with preserved ejection fraction
The diagnosis of HFpEF remains challenging. Several diagnostic criteria have been proposed by societies and in clinical trials.260 These criteria vary widely in their sensitivities and specificities for diagnosing HFpEF.
More recently, two score-based algorithms (H2FPEF and HFA-PEFF)
have been proposed to aid the diagnosis.259,261 While the generalizability of the scores has been tested in various trial and observational cohorts, their diagnostic performance has varied.262269
Both scores assign a substantial proportion of suspected HFpEF
patients as intermediate likelihood, wherein additional diagnostics are proposed. Thus, depending on which score is used, different patients will be referred for additional testing or allocated as having HFpEF.
Furthermore, physicians may not have access to all the specialized tests recommended by the specific diagnostic algorithms. This limits the broad clinical applicability of the scores and demonstrates the ongoing diagnostic uncertainty in HFpEF.267
To facilitate broad clinical application, this guideline recommends a simplified pragmatic approach that distils the common major elements in prior diagnostic criteria and emphasizes the most frequently used variables widely available to clinicians. Some of these variables, in particular, LA size (LA volume index
>32 mL/m2), mitral E velocity >90 cm/s, septal e0 velocity <9 cm/s,
E/e0 ratio >9 have been shown to be pivot points beyond which the risk of CV mortality is increased, underscoring their value.270
This recommendation is therefore consistent with the consensus document of the HFA, and does not represent a new algorithm or diagnostic score but rather a simplified approach. Physicians with access to expertise may refer to the full diagnostic approach recommended by the HFA.259


<!-- PAGE 33 -->

### Page 33

.....................................................................................................
This simplified diagnostic approach starts with assessment of pretest probability (see clinical characteristics above). The diagnosis should include the following:
(1)
Symptoms and signs of HF.
(2)
An LVEF >_50%.*
(3)
Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/
raised LV filling pressures, including raised NPs (Table 9).
*Of note, patients with a history of overtly reduced LVEF (<_40%),
who later present with LVEF >_50%, should be considered to have recovered HFrEF or ‘HF with improved LVEF’ (rather than HFpEF).
Continued treatment for HFrEF is recommended in these patients.271
It is not known whether starting HF therapy in patients with recovered LVEF is beneficial. Patients with HFpEF tend to have stable trajectory of LVEF over time.272 However, in those who develop a clinical indication for a repeat echo during follow-up, around one third have a decline in LVEF.273
In the presence of AF, the threshold for LA volume index is >40
mL/m2. Exercise stress thresholds include E/e0 ratio at peak stress >_15
or tricuspid regurgitation (TR) velocity at peak stress >3.4 m/s.275 LV
global longitudinal strain <16% has a sensitivity of 62% and a specificity of 56% for the diagnosis of HFpEF by invasive testing.261
The approach to the diagnosis should involve additional confirmatory tests in cases of diagnostic uncertainty, such as cardiopulmonary exercise testing (to confirm a reduction in exercise capacity and to help differentiate the cause of dyspnoea), exercise stress testing, and invasive haemodynamic testing.259
If resting echocardiographic and laboratory markers are equivocal,
a diastolic stress test is recommended.259,274 The confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing.
An invasively measured pulmonary capillary wedge pressure
(PCWP) of >_15 mmHg (at rest) or >_25 mmHg (with exercise) or LV
end-diastolic pressure >_16 mmHg (at rest) is generally considered diagnostic.266 However, instead of an exercise PCWP cut-off, some have used an index of PCWP to cardiac output for the invasive diagnosis of HFpEF260,276. Recognizing that invasive haemodynamic exercise testing is not available in many centres worldwide, and is associated with risks, its main use is limited to the research setting. In the absence of any disease-modifying treatments, the current guidelines do not mandate gold standard testing in every patient to make the diagnosis, but emphasize that the greater the number of objective non-invasive markers of raised LV filling pressures (Table 9), the higher the probability of a diagnosis of HFpEF.
8.4 Treatment of heart failure with preserved ejection fraction
To date, no treatment has been shown to convincingly reduce mortality and morbidity in patients with HFpEF, although improvements have been seen for some specific phenotypes of patients within the overall HFpEF umbrella. However, none of the large
RCTs conducted in HFpEF have achieved their primary endpoints.
These include PEP-CHF (perindopril),277 CHARM-Preserved (candesartan),245 I-PRESERVE (irbesartan),278 TOPCAT (spironolactone),246
DIG-Preserved
(digoxin),279
and
PARAGON-HF
(sacubitril/valsartan)13 (see Supplementary Table 12 for the details about these and additional trials). Hospitalizations for HF were reduced by candesartan and spironolactone and there was a trend towards reduction with sacubitril/valsartan, although as these trials were neutral for their primary endpoints, these are hypothesisgenerating findings only. Although nebivolol significantly reduced the combined primary endpoint of all-cause mortality or CV hospital admission in the SENIORS trial, this trial included only 15% with an LVEF >50%.119,249 Trials targeting the nitric oxide-cyclic guanosine monophosphate pathway have also failed to improve exercise
Table 9
Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular ﬁlling pressures259,261
Parametera
Threshold
Comments
LV mass index
Relative wall thickness
>_95 g/m2 (Female), >_115 g/m2 (Male)
>0.42
Although the presence of concentric LV remodelling or hypertrophy is supportive, the absence of LV hypertrophy does not exclude the diagnosis of HFpEF
LA volume indexa
>34 mL/m2 (SR)
In the absence of AF or valve disease, LA enlargement reﬂects chronically elevated LV ﬁlling pressure (in the presence of AF, the threshold is
>40 mL/m2)
E/e’ ratio at resta
>9
Sensitivity 78%, speciﬁcity 59% for the presence of HFpEF by invasive exercise testing, although reported accuracy has varied. A higher cut-off of 13 had lower sensitivity (46%) but higher speciﬁcity (86%).71,259,274
NT-proBNP
BNP
>125 (SR) or
>365 (AF) pg/mL
>35 (SR) or
>105 (AF) pg/mL
Up to 20% of patients with invasively proven HFpEF have NPs below diagnostic thresholds, particularly in the presence of obesity
PA systolic pressure
TR velocity at resta
>35 mmHg
>2.8 m/s
Sensitivity 54%, speciﬁcity 85% for the presence of HFpEF by invasive exercise testing259,261
AF = atrial ﬁbrillation; BNP = B-type natriuretic peptide; E/e’ratio = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler; HFpEF = heart failure with preserved ejection fraction; LA = left atrial; LV = left ventricular; NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PA = pulmonary artery;
SR = sinus rhythm; TR = tricuspid regurgitation.
Note: The greater the number of abnormalities present, the higher the likelihood of HFpEF.
aOnly commonly used indices are listed in the table; for less commonly used indices refer to the consensus document of the ESC/HFA.259
ESC 2021
ESC Guidelines
3631


<!-- PAGE 34 -->

### Page 34

capacity or QOL in HFpEF, e.g. NEAT-HFpEF,280 INDIE-HFpEF,281
VITALITY-HFpEF,282 and CAPACITY-HFpEF (praliciguat).283
Despite the lack of evidence for specific disease-modifying therapies in HFpEF, as the vast majority of HFpEF patients have underlying hypertension and/or CAD, many are already treated with ACE-I/
ARB, beta-blockers, or MRAs. In the PARAGON-HF study at baseline, more than 86% of patients were on ACE-I/ARBs, 80% were on beta-blockers, and more than 24% were on MRAs.13
The Task Force acknowledge that the treatment options for
HFpEF are being revised as this guideline is being published. We note that the Food and Drug Administration (FDA) has endorsed the use of sacubitril/valsartan and spironolactone in those with an LVEF ‘less than normal’. These statements relate to patients within both the
HFmrEF and HFpEF categories. For sacubitril/valsartan, this decision was based on the subgroup analysis from the PARAGON-HF study,
which showed a reduction in HF hospitalizations in those with an
LVEF <57%, and a meta-analysis of the PARADIGM-HF and
PARAGON-HF studies, showing a reduction in CV death and HF
hospitalization in those with an LVEF below the normal range.247
Regarding spironolactone, the subgroup of individuals in the
TOPCAT study recruited in the Americas had a significant reduction in the primary endpoint of CV death and HF hospitalization,
and a subsequent post hoc analysis by EF showed a significant reduction in outcomes for those with an LVEF <55%.9,247 There are also ongoing trials with SGLT2 inhibitors. These developments may well accelerate a redefinition of HFpEF in the future and have therapeutic implications.
In the absence of recommendations regarding disease-modifying therapies, treatment should be aimed at reducing symptoms of congestion with diuretics. Loop diuretics are preferred, although thiazide diuretics may be useful for managing hypertension. Reducing body weight in obese patients and increasing exercise may further improve symptoms and exercise capacity and should therefore be considered in appropriate patients.284,285
It is important to identify and treat the underlying risk factors, aetiology, and coexisting comorbidities in HFpEF (e.g. hypertension in section 12.4, CAD in section 12.2, amyloidosis in section 14.6, AF in section 12.1.1,
and valvular heart disease in section 12.3).
Undoubtably, treatment of some of the underlying phenotypes of the the HFpEF syndrome leads to improved outcomes.
Recommendations for the treatment of patients with heart failure with preserved ejection fraction
Recommendations
Classa
Levelb
Screening for, and treatment of, aetiologies, and cardiovascular and non-cardiovascular comorbidities is recommended in patients with HFpEF
(see relevant sections of this document).
I
C
Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.137
I
C
HFpEF = heart failure with preserved ejection fraction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
Table 10
Risk factors for the development of heart failure and potential corrective actions
Risk factors for heart failure
Preventive strategies
Sedentary habit
Regular physical activity
Cigarette smoking
Cigarette smoking cessation
Obesity
Physical activity and healthy diet
Excessive alcohol intake286
General population: no/light alcohol intake is beneﬁcial
Patients with alcohol-induced CMP
should abstain from alcohol
Inﬂuenza
Inﬂuenza vaccination
Microbes (e.g. Trypanosoma cruzi, Streptococci)
Early diagnosis, speciﬁc antimicrobial therapy for either prevention and/or treatment
Cardiotoxic drugs (e.g.,
anthracyclines)
Cardiac function and side effect monitoring, dose adaptation, change of chemotherapy
Chest radiation
Cardiac function and side effect monitoring, dose adaptation
Hypertension
Lifestyle changes, antihypertensive therapy
Dyslipidaemia
Healthy diet, statins
Diabetes mellitus
Physical activity and healthy diet,
SGLT2 inhibitors
CAD
Lifestyle changes, statin therapy
CAD = coronary artery disease; CMP = cardiomyopathy; SGLT2 = sodium-glucose co-transporter 2.
ESC 2021
Recommendations for the primary prevention of heart failure in patients with risk factors for its development
Recommendations
Classa
Levelb
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent
HF hospitalizations.287290
I
A
Treatment with statins is recommended in patients at high risk of CV disease or with CV
disease in order to prevent or delay the onset of
HF, and to prevent HF hospitalizations.291,292
I
A
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,
empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.293297
I
A
Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of
HF.298302
I
C
CV=cardiovascular; HF= heart failure; SGLT2= sodium-glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.
............................................................................................................................................................................


<!-- PAGE 35 -->

### Page 35

.......................................................
9 Multidisciplinary team management for the prevention and treatment of chronic heart failure
9.1 Prevention of heart failure
General advice about risk factors for the development of HF (see
Supplementary Figure 1) and strategies to prevent HF early in the CV
continuum are summarized in Table 10.
It is widely recognized that, in addition to optimizing medical and device therapies for HF, attention should also be given to how HF
care is delivered. The HFA of the ESC has issued several position papers that cover non-pharmacological management, discharge planning, and standards for delivering HF care.303305 It has also underscored the need for specialist HF cardiologists and specialist HF
nurses to help provide care. Detailed curricula, to aid training of these, are available to be adapted for national implementation.306,307
This section focuses on areas where recommendations with an evidence level can be given: multidisciplinary team management, lifestyle advice, exercise training, follow-up, and monitoring.
9.2 Multidisciplinary management of chronic heart failure
9.2.1 Models of care
In order to reduce hospitalizations and mortality, earlier guidelines1
recommended the use of multidisciplinary
HF
management programmes (HF-MPs), which enable patients to have the correct investigations, an accurate diagnosis, appropriate evidence-based therapy, education, and suitable follow-up. The optimal implementation of a HF-MP requires a multidisciplinary team that is active along the whole HF trajectory; from onset, through critical events, periods of apparent stability, and its terminal stages.303 Since the 2016 guidelines, new studies have been published that underscore the need for
HF-MPs and reveal more insights into how care can be delivered.
A network meta-analysis including 53 randomized trials published in 2017, concluded that both disease-management clinics and home visits by nurses reduced all-cause mortality compared to usual care;
home visits being most effective.308 An IPD meta-analysis of 20 studies, including 5624 patients, concluded that self-management interventions in HF patients improve outcomes despite heterogeneity in the intensity, content, and the personnel who deliver the interventions.309
HF-MPs vary in their components and can apply different service models, such as clinic-based approaches (in primary, secondary, or tertiary care), home-based programmes, case management, or hybrids of these. Components used in the services vary, e.g. some
HF-MPs use telemonitoring that may be applied at a local, regional,
or national level. No service model has been shown to be consistently superior to others.310 While home visits and HF clinics do reduce all-cause admissions and mortality, educational programmes,
used alone, do not.308,309 HF-MPs should be patient-centred and take a holistic approach to the patient rather than focussing solely on HF;
management of comorbid conditions, such as arrhythmias, hypertension, diabetes, renal dysfunction, and depression, improve patient well-being and self-management, leading to better outcomes.309,311
The organization of a HF-MP should be adapted to the healthcare system, available resources (infrastructure, facilities, staff, and finances), administrative policies, and tailored to the patient’s needs.
Many patients with HF would derive benefit from the early integration of a palliative and supportive approach within the care provided by all members of the HF multidisciplinary team.312,313 Palliative and supportive care should be thought about for all patients with HF,
regardless of stage of their illness. Patients in the advanced stages and those considered for mechanical circulatory support (MCS) or heart transplantation should receive a palliative care consultation before such interventions as a matter of protocol (see section 10.2.4).
9.2.2 Characteristics and components of a heart failure management programme
Clinical trials have included complex, bundled interventions, making it difficult to determine the efficiency and effectiveness of each specific component. Table 11 presents an overview of characteristics and components that are important to consider in a HF-MP.
9.3 Patient education, self-care and lifestyle advice
Adequate patient self-care is essential in the effective management of
HF and allows patients to understand what is beneficial, and to agree to self-monitoring and management plans.319 HF patients who report more effective self-care have a better QOL, lower readmission rates,
and reduced mortality.309
Misunderstandings, misconceptions, and lack of knowledge all contribute to insufficient self-care and therefore patient education is vital.
Improving patients’ knowledge of their condition is fundamental for the development of self-care skills.304
Education to improve self-care should be tailored to the individual patient and based on, where available, scientific evidence or expert opinion. There is little evidence that specific lifestyle advice improves
Multidisciplinary interventions recommended for the management of chronic heart failure
Recommendations
Classa
Levelb
It is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalization and mortality.309,314,315,316
I
A
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.309
I
A
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospitalization and mortality.310,317
I
A
Inﬂuenza and pneumococcal vaccinations should be considered in order to prevent HF
hospitalizations.315,316
IIa
B
HF = heart failure.
aClass of recommendation.
bLevel of evidence.
ESC 2021
......................................................................................................................
ESC Guidelines
3633


<!-- PAGE 36 -->

### Page 36

Table 11
Important characteristics and components in a heart failure management programme
Characteristics
1.
Patient/person-centred318
2.
Multidisciplinary
3.
The focus of the programme should be ﬂexible and include:
• prevention of disease progression
• symptom control
• maintaining patients in their preferred place of care for end-stage heart failure
4.
Competent and professionally educated staff
5.
Encourage patient/carer engagement in the understanding and management of their condition
Components
1.
Optimized management; lifestyle choices, pharmacological, and devices
2.
Patient education, with special emphasis on self-care and symptom management
3.
Provision of psychosocial support to patients and family caregivers
4.
Follow-up after discharge (clinic; home visits; telephone support or telemonitoring)
5.
Easy access to healthcare, especially to prevent and manage decompensation
6.
Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional and functional status, quality of life, sleep problems, psychosocial problems or other ﬁndings (e.g., laboratory values)
7.
Access to advanced treatment options; supportive and palliative care
Table 12
Patient education and self-care
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
Explanation about HF
To understand the cause of their HF, symptoms and treatment choice.
Provide tailored information.
The HF trajectory
To understand prognosis and the different possible phases in the HF trajectory.
To make joint treatment decisions that recognise the patient’s position on the HF trajectory.
Sensitively communicate information on prognosis at time of diagnosis, during decision making about treatment options, when there is a change in the clinical condition and whenever the patient requests.
Medical treatment
Medication
To be able to make joint decisions about medication.
To understand the indications, beneﬁts, the need for longterm adherence to certain drugs, and the dosing and side effects of medication.
To be able to recognize the common side effects of medication and know what actions to take.
Provide written and oral information on indication, beneﬁts, dosing, effects and side effects.
Discuss practical issues such as optimal time-schedule, what to do in case of a missed dose etc.
Discuss possible barriers for medication taking.
Advise on support aids such as dosette box, electronic reminders etc. when appropriate.320
Implanted devices
To be able to make joint decisions on device implantation.
To understand the indications, importance, expectations and check-up routine for implanted devices, and any exception management.
To be able to recognize the common complications
(including the risk of inappropriate deﬁbrillator shocks),
and know what actions to take.
Provide written and oral information about the importance and expectations of implanted devices, and possible ways of followup (remote monitoring).
Discuss expectations and any possible impact on driving.
Clearly identify situations where the device might be deactivated or explanted.
Involve patient and caregiver in decision making.
Self-care aspects
Activity and exercise
To undertake regular exercise and be physically active.
To be able to adapt physical activity to symptom status and personal circumstances.
Advise on exercise that recognizes physical and functional limitations, such as frailty, comorbidities.
Refer to exercise programme or other activity modes.
Discuss possible barriers, side-effects and opportunities.
Sleep and breathing
To recognize the importance of sleep and rest for (CV)
health.
To be able to recognize problems with sleeping and how to optimize sleep.
Review sleep history.
Advise and discuss the importance of good sleep and provide advice on ‘sleep health’ (including timing of diuretics).
Continued
ESC 2021


<!-- PAGE 37 -->

### Page 37

Table 12
Continued
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
Consider and carefully discuss the beneﬁts and deleterious effects of sleep medication.
Fluids
To avoid large volumes of ﬂuid intake. A ﬂuid restriction of 1.52 L/day may be considered in patients with severe HF/hyponatraemia to relieve symptoms and congestion.
To avoid dehydration: where ﬂuids are restricted, increase intake during periods of high heat/humidity and/or nausea/vomiting.
Provide information and discuss the advantages and disadvantages of ﬂuid restriction.
Advise to adapt ﬂuid intake to weight, and in times of high heat and humidity, nausea/vomiting.
Adjust advice during periods of acute decompensation and consider altering this advice towards end-of-life.
Healthy diet
To be able to prevent malnutrition and know how to eat healthily, avoiding excessive salt intake (>5 g/day) and maintaining a healthy body weight.
Discuss current food intake, role of salt, role of micronutrients.
Discuss the need for supplementing in case of nutrient deﬁciencies but there is no clear role for routine micronutrient supplementation.321
Discuss maintaining a healthy body weight.
Alcohol
To be able to abstain from or avoid excessive alcohol intake, especially for alcohol-induced CMP.
To restrict alcohol according to CV prevention guidelines.
Tailor alcohol advice to aetiology of HF; e.g. abstinence in alcoholic CMP.
Inform and discuss alcohol intake according to CV prevention guidelines (2 units per day in men or 1 unit per day in women)a.
Immunization
To be aware of the need for immunization for inﬂuenza and pneumococcal disease.
Discuss beneﬁts and possible barriers.
Advise on local immunization practice.
Smoking and recreational drugs
To be aware of the consequences for health of smoking and use of recreational drugs.
Stop smoking (including e-cigarettes) and taking recreational drugs.
Inform, discuss and help in decision making.
Refer for specialist advice for smoking cessation and drug withdrawal and replacement therapy.
Consider referral for cognitive behavioural theory and psychological support if patient wishes to stop smoking or taking drugs.
Travel, leisure, driving
To be able to prepare travel and leisure activities according to physical capacity.
To be able to take an informed decision about driving.
Inform and discuss practical issues related to long haul travel, staying abroad, exposure to sun (amiodarone effects), high humidity or heat (dehydration), and high altitude (oxygenation).
Provide practical advice related to travel with medication/devices
(keep medicines in hand luggage, have a list with medication,
device name/card and treating centres).
Inform about local/national/international regulation related to driving.
Sexual activity
To be able to resume or adapt sexual activity according to physical capacity.
To recognize possible problems with sexual activity and their relationship with HF or its treatment.
Inform and discuss that sexual activity is safe for stable HF
patients.
Provide advice on eliminating factors predisposing to sexual problems.
Discuss and provide available pharmacological treatment for sexual problems.
Refer to specialist for sexual counselling when necessary.
Symptom monitoring and symptom selfmanagement
Monitor and recognize change in signs and symptoms.
Being able to react adequately to change in signs and symptoms.
Know how and when to contact a healthcare professional.
Provide individualized information to support self-management such as:
In the case of increasing dyspnoea or oedema or a sudden unexpected weight gain of >2 kg in 3 days, patients may increase their diuretic dose and/or alert their healthcare team.
Living with HF
Psychological issues
To be able to live a good life with HF.
To be able to seek help in case of psychological problems such as depressive symptoms, anxiety or low mood which may occur in the course of the HF trajectory.
Regularly communicate information on disease, treatment options and self-care.
Regularly discuss the need for support.
Treat or referral to specialist for psychological support when necessary.
Continued
ESC Guidelines
3635


<!-- PAGE 38 -->

### Page 38

..........................................................................................................................................
QOL or prognosis; however, providing this information has become a key component of education for self-care.
General educational approaches include:
• Providing information in a variety of formats that take into account educational grade and health literacy.
Consider approaches with active roles for patients and caregivers such as
‘ask-tell-ask’, ‘teach back’, or motivational interviewing. Reinforce messages at regular time intervals.
• Recognizing barriers to communication (language, social skills,
cognition, anxiety/depression, hearing or visual challenges).
• Recommending ‘HFmatters.org’. Offer help and guidance to use it and offer discussion of questions arising.
• Inviting patients to be accompanied by a family member or friend.
Key topics to include are recommended in Table 12.
9.4 Exercise rehabilitation
There is consistent evidence that physical conditioning by exercise training improves exercise tolerance, and health-related QOL in patients with HF. Clinical trials and meta-analyses in people with
HFrEF show that exercise rehabilitation improves exercise capacity and QOL. Several meta-analyses also show that it reduces all-cause and HF hospitalizations, although uncertainty persists about its effects on mortality.322328 The effect on hospitalization is seen in those who are highly adherent to the exercise programme.329 Highintensity interval training, in patients who are able and willing,
may improve peak oxygen consumption (VO2).330,331 Supervised exercise-based rehabilitation should be considered in those who are frail, who have more severe disease or comorbidities.95
Physical conditioning also improves exercise capacity and
QOL.332335 No data on HFmrEF are available, but benefits observed in the other groups of HF should also apply to this group.
9.5 Follow-up of chronic heart failure
9.5.1 General follow-up
This is a relatively understudied area. Patients with HF, even if symptoms are well controlled and stable, require follow-up to ensure continued optimization of therapy, to detect asymptomatic progression of
HF or its comorbidities and to discuss any new advances in care. These guidelines recommend follow-up at intervals no longer than 6 months to check symptoms, heart rate and rhythm, BP, full blood count, electrolytes, and renal function. For patients recently discharged from hospital, or in those undergoing uptitration of medication, follow-up intervals should be more frequent. Whether such stable patients need to be followed-up by cardiologists is uncertain. Some studies suggest that follow-up in primary care may be appropriate.303,339 However,
uptake of evidence-based interventions is poor in many settings340,104
and several studies suggest that care and follow-up provided by HF
specialists, and use of quality improvement registries can lead to higher rates of optimal therapy and improved outcomes.341343
An ECG should be done annually to detect QRS prolongation344
as such patients may become candidates for CRT. Furthermore, it may identify conduction disturbances and AF.
Serial echocardiography is generally not necessary, although an echocardiogram should be repeated if there has been a deterioration in clinical status. An echocardiogram is also advised 36 months after optimization of standard therapies for HFrEF to determine the need for addition of newer pharmacological agents and implanted devices.
9.5.2 Monitoring with biomarkers
Trials investigating the use of biomarkers (particularly BNP and/or
NT-proBNP) to guide pharmacotherapy for HFrEF have produced conflicting results.345352 They are undoubtedly good prognostic markers.72,353,354 Conceptually, it is not clear what a biomarkersupported strategy might offer in addition to assiduous application of guideline-recommended therapy. Current evidence, therefore, does not support the routine measurement of BNP or NT-proBNP to guide titration of therapy.
9.6 Telemonitoring
Telemonitoring enables patients to provide, remotely, digital health information to support and optimize their care. Data such as
Table 12
Continued
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
To recognise that the carer or family members may be greatly affected and need to seek help.
Family and informal caregivers
To be able to ask for support.
Discuss the preference of caregiver/family involvement.
Involve patients and caregivers in a respectful way.
CMP = cardiomyopathy; CV = cardiovascular; HF = heart failure.
a1 unit is 10 mL of pure alcohol (e.g., 1 glass of wine, 1=2 pint of beer, 1 measure of spirit).
Recommendations for exercise rehabilitation in patients with chronic heart failure
Recommendations
Classa
Levelb
Exercise is recommended for all patients who are able in order to improve exercise capacity, QOL,
and reduce HF hospitalization.c 324328,335337
I
A
A supervised, exercise-based, cardiac rehabilitation programme should be considered in patients with more severe disease, frailty, or with comorbidities.95,324327,338
IIa
C
HF = heart failure; QOL = quality of life.
aClass of recommendation.
bLevel of evidence.
cIn those who are able to adhere to the exercise programme.
ESC 2021
ESC 2021


<!-- PAGE 39 -->

### Page 39

.................
symptoms, weight, heart rate, and BP, can be collected frequently,
stored in an electronic health record and used to guide patients
(directly or through a healthcare professional), to adjust therapy or to seek further advice. Home telemonitoring (HTM) can help maintain quality of care, facilitate rapid access to care when needed,
reduce patient travel costs, and minimize the frequency of clinic visits.355 Enforced cessation of face-to-face consultations in many countries during the recent COVID-19 pandemic have highlighted some of the potential advantages of HTM.356
Trials of HTM are diverse. Patients are usually required to make measurements and, as for many other aspects of HF management,
adherence may be incomplete. HTM may be provided as a local,
regional, or national service. Systems that focus on optimizing management rather than detecting and managing medical emergencies need only to be staffed during standard working hours.
Some systems are designed also to offer support at any time requested by the patient. The comparative effectiveness and cost effectiveness of each strategy is uncertain. Systems that focus on continuous optimization of care (a health maintenance approach)
rather than trying to anticipate and manage episodes of worsening
(a strategy that is plagued by a large number of false-positive alerts), appear more successful.357 HTM is an efficient method for providing patient education and motivation and aiding delivery of care, but it should be adapted to work in synergy with existing healthcare provision.358
A Cochrane systematic review conducted in 2017 identified 39
relevant trials of HTM, largely based on assessments of symptoms,
weight, heart rate and rhythm, and BP and found that HTM was associated with a reduction in all-cause mortality of 20% and HF hospitalization of 37%.359 Since then, several neutral trials and at least one positive trial have been published.357,360364 These are unlikely to change the positive results of the systematic review. Importantly, if social distancing and the ‘green’ agenda are important, HTM only needs to show that it is not inferior to contemporary methods of delivering care to be an appropriate means of supporting care.356
Whether wearable technologies for monitoring heart rate and rhythm or lung congestion (bio-impedance or lung radar) offer additional benefits to conventional
HTM
described above is uncertain.365367
Many implanted therapeutic devices can provide, wirelessly and remotely, information either on the device itself (generator and lead function), arrhythmias, or on patient physiology (heart rate, activity,
heart sounds, bio-impedance). There is strong evidence that monitoring can detect device malfunction earlier than by conventional monitoring and that it may be useful for detecting arrhythmias such as AF. However, there is little evidence that device monitoring reduces admissions for HF or mortality.368370,371
Devices that only provide a monitoring function are also available.
Implantable loop-recorders can be injected subcutaneously and used to monitor heart rate and rhythm, activity, and bio-impedance.
Monitoring devices can also be placed in the pulmonary artery to monitor pressure wirelessly, although the external reader required to detect the device signal is rather bulky and requires patient cooperation. A rise in diastolic pulmonary artery pressure may be one of the earliest signs of congestion. A preliminary, but fairly substantial,
trial showed a reduction in the risk of recurrent HF hospitalization.372
A much larger trial has completed recruitment (GUIDE-HF).373
Thus, non-invasive HTM may be considered for patients with HF
in order to reduce the risk of recurrent CV and HF hospitalizations and CV death; further evidence on management guided by implanted systems is awaited.374
10 Advanced heart failure
10.1 Epidemiology, diagnosis, and prognosis
Many patients with HF progress into a phase of advanced HF, characterized by persistent symptoms despite maximal therapy.375377 The prevalence of advanced HF is increasing due to the growing number of patients with HF, ageing of the population, and better treatment and survival of HF. Prognosis remains poor, with a 1-year mortality ranging from 25% to 75%.378380
The updated HFA-ESC 2018 criteria for the definition of advanced
HF are reported in Table 13.376 A severely reduced LVEF is common but not required for a diagnosis of advanced HF as it may develop in patients with HFpEF as well. In addition to the reported criteria,
extra-cardiac organ dysfunction due to HF (e.g. cardiac cachexia,
liver or kidney dysfunction) or type II pulmonary hypertension may be present, but are not required for the definition of advanced
HF.376
The Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) profiles, developed to classify patients with a potential indication for durable MCS devices, describes clinical parameters and characteristics consistent with a need for advanced therapies (Table 14).381 This classification has also been shown to be useful in estimating the prognosis of patients undergoing urgent heart transplantation382 or LV assist device (LVAD)
implantation,383 and for risk assessment in ambulatory advanced
HF patients.384
Prognostic stratification is important to identify the ideal time for referral to an appropriate centre (i.e. one capable of providing advanced HF therapies), to properly convey expectations to patients and families, and to plan treatment and follow-up strategies
Recommendations for telemonitoring
Recommendations
Classa
Levelb
Non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV
death.374
IIb
B
Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF
in order to improve clinical outcomes.372
IIb
B
CV = cardiovascular; HF = heart failure; HTM = home telemonitoring; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................
ESC Guidelines
3637


<!-- PAGE 40 -->

### Page 40

Table 13
Criteria for deﬁnition of advanced heart failure
All the following criteria must be present despite optimal medical treatment:
1. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV].
2. Severe cardiac dysfunction deﬁned by at least one of the following:
• LVEF <_30%
• Isolated RV failure (e.g., ARVC)
• Non-operable severe valve abnormalities
• Non-operable severe congenital abnormalities
• Persistently high (or increasing) BNP or NT-proBNP values and severe LV diastolic dysfunction or structural abnormalities (according to the deﬁnitions of HFpEF).
3. Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics (or diuretic combinations) or episodes of low output requiring inotropes or vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or hospitalization in the last 12 months.
4. Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 m) or pVO2 <12 mL/kg/min or <50% predicted value,
estimated to be of cardiac origin.
6MWT = 6-minute walk test; ARVC = arrhythmogenic right ventricular cardiomyopathy; BNP = B-type natriuretic peptide; HFpEF = heart failure with preserved ejection fraction; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart
Association; pVO2 = peak oxygen consumption; RV = right ventricular. Modiﬁed from 376.
ESC 2021
Table 14
Interagency Registry for Mechanically Assisted Circulatory Support proﬁle descriptions of patients with advanced heart failure
Profile
Time frame for intervention
Proﬁle 1. Critical cardiogenic shock
Patient with life-threatening hypotension despite rapidly escalating inotropic support,
critical organ hypoperfusion, often conﬁrmed by worsening acidosis and/or lactate levels. “Crash and burn.”
Deﬁnitive intervention needed within hours.
Proﬁle 2. Progressive decline
Patient with declining function despite i.v. inotropic support, may be manifest by worsening renal function, nutritional depletion, inability to restore volume balance. “Sliding on inotropes.” Also describes declining status in patients unable to tolerate inotropic therapy.
Deﬁnitive intervention needed within few days.
Proﬁle 3. Stable on inotrope or inotrope-dependent
Patient with stable blood pressure, organ function, nutrition, and symptoms on continuous i.v. inotropic support (or a temporary circulatory support device or both) but demonstrating repeated failure to wean from support due to recurrent symptomatic hypotension or renal dysfunction. “Dependent stability.”
Deﬁnitive intervention elective over a period of weeks to few months.
Proﬁle 4. Frequent Flyer
Patient can be stabilized close to normal volume status but experiences daily symptoms of congestion at rest or during activities of daily living. Doses of diuretics generally ﬂuctuate at very high levels. More intensive management and surveillance strategies should be considered, which may in some cases reveal poor compliance that would compromise outcomes with any therapy. Some patients may shuttle between 4 and 5.
Deﬁnitive intervention elective over a period of weeks to few months.
Proﬁle 5. Housebound
Comfortable at rest and with activities of daily living but unable to engage in any other activity, living predominantly within the house. Patients are comfortable at rest without congestive symptoms, but may have underlying refractory elevated volume status, often with renal dysfunction. If underlying nutritional status and organ function are marginal,
patients may be more at risk than INTERMACS 4, and require deﬁnitive intervention.
Variable urgency, depends upon maintenance of nutrition,
organ function, and activity.
Proﬁle 6. Exertion limited
Patient without evidence of ﬂuid overload, comfortable at rest and with activities of daily living and minor activities outside the home but fatigues after the ﬁrst few minutes of any meaningful activity. Attribution to cardiac limitation requires careful measurement of peak oxygen consumption, in some cases with haemodynamic monitoring, to conﬁrm severity of cardiac impairment. “Walking wounded.”
Variable, depends upon maintenance of nutrition, organ function, and activity level.
Continued


<!-- PAGE 41 -->

### Page 41

................................................................................................................
(Figure 4).376 Patients with contraindications to MCS or heart transplantation should be considered for palliative care (see section 10.2.4).
Despite many prognostic parameters (Supplementary Table 13),
predicting outcomes remains difficult and patients are often referred to advanced HF centres too late. Identifying warning signs in patients with non-advanced symptoms may allow early referral so that MCS
and heart transplantation may be offered before the development of end-organ failure (Figure 5; Supplementary Table 14).376,386 An organizational model between centres with different levels of care complexity, based on a ‘Hub and Spoke’ network is the key to good patient management.376
10.2 Management
In patients with advanced HF, pharmacological therapy and shortterm MCS may be needed until the implantation of long-term MCS
or heart transplantation becomes available.
10.2.1
Pharmacological therapy and renal replacement
Inotropes may improve haemodynamic parameters, reducing congestion, augmenting cardiac output, and aiding peripheral perfusion.
Although not proven, this may help to prevent worsening end-organ function. Conversely, traditional inotropes may favor myocardial ischaemia and/or tachyarrhythmias and worsen the clinical course.387,388 They can be used as palliative therapy for the relief of symptoms in patients without other treatment options. Intermittent long-term use of inotropes may be considered in outpatients to improve functional class and QOL.389,390
Kidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling of the loop diuretic dose is proposed, in the first instance, followed by concomitant administration of thiazides or metolazone (see section
11.3.3).145 In patients who fail to respond to diuretic-based strategies,
renal replacement therapies should be considered. Ultrafiltration is one of the most common approaches. It may be considered in those with diuretic resistance even if data about its effects on outcomes are unsettled.391,392
10.2.2
Mechanical circulatory support
MCS can improve survival and symptoms of patients with advanced
HF.376,393 The use of MCS should be considered for the different scenarios listed in Table 15. Indications for short- and long-term MCS
should be based on the INTERMACS profiles (Table 14, Figure 4).
Short-term mechanical circulatory support
Short-term MCS devices are indicated to reverse critical endorgan hypoperfusion and hypoxia in the setting of cardiogenic shock. They can be used for a short, limited, period of time, from a few days up to several weeks. The aim is to support the central nervous system and organ perfusion, to reverse acidosis and multi-organ failure until the patient’s outcome becomes clearer be that of cardiac recovery, transition to durable MCS or heart transplantation, or, in some cases, towards a more palliative approach. The care of patients on short-term MCS is complex and requires dedicated expertise including having specific plans for stopping support when neither cardiac nor brain injury recovers.
Short-term MCS should be used in patients with INTERMACS
profiles 1 or 2 as a bridge to decision (BTD), bridge to recovery
(BTR), bridge to bridge (BTB) for either long-term MCS or urgent heart transplantation (Figure 4).394 Further details about shortterm MCS are reported in the Supplementary text 11.4.
Long-term mechanical circulatory support
Long-term MCS is indicated in selected patients when MT is insufficient or when short-term MCS has not led to cardiac recovery or clinical improvement, to prolong life and improve QOL, or to keep the patient alive until transplantation (bridge to transplantation, BTT)
or to reverse contraindications to heart transplantation (bridge to candidacy, BTC), or as destination therapy (DT) (Table 15).
Long-term
MCS
should be considered in patients with
INTERMACS profiles 2 to 4 and also in patients with INTERMACS
Table 14
Continued
Profile
Time frame for intervention
Proﬁle 7. Advanced NYHA class III symptoms
Patient without current or recent episodes of unstable ﬂuid balance, living comfortably with meaningful activity limited to mild physical exertion.
Heart transplantation or MCS may not be currently indicated.
Modiﬁers for proﬁles
Possible proﬁles that can be modiﬁed
Temporary MCS can modify proﬁle only in hospitalized patients. They include IABP,
ECMO, TandemHeart, LVAD, Impella.
1, 2, 3
Arrhythmia can modify any proﬁle. They include recurrent ventricular tachyarrhythmias that have recently contributed substantially to clinical compromise, frequent ICD shocks or requirement for external deﬁbrillation, usually more than twice weekly.
17
Frequent episodes of HF decompensation characterize patients requiring frequent emergency visits or hospitalizations for diuretics, ultraﬁltration, or temporary i.v. vasoactive therapy. Frequent episodes may be considered as at least two emergency visits/
admissions in the past 3 months or three in the past 6 months.
3 if at home, 4, 5, 6. Rarely for proﬁle 7.
ECMO = extracorporeal membrane oxygenation; HF = heart failure; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁbrillator; INTERMACS = Interagency
Registry for Mechanically Assisted Circulatory Support; i.v. = intravenous; LVAD = left ventricular assist device; MCS = mechanical circulatory support; NYHA = New York
Heart Association. Modiﬁed from 381.
ESC 2021
ESC Guidelines
3639


<!-- PAGE 42 -->

### Page 42

Management of patients with advanced heart failurea
Weaning from
MCS support
LVAD-DT
(Class IIa)
List for HT or de-listing with very close follow-up in case of meaningful improvement
(Class I)
Withdrawal of
MCS support
Advanced HF
therapies
(HT/LVAD) can be deferred.
Very close follow-up
Contraindications for HT
N
Cardiac,
neurological and end-organ recovered
Neurological and end-organ recovered but no cardiac recovery
Persistence of severe brain damage and severe irreversible end-organ damage
Potentially reversible
High riskb
Contraindication reversed
LVAD-BTC
(Class IIa)
Short-term MCS
BTD/BTR/BTB/BTT
(Class IIa)
INTERMACS
>4 “Stable ambulatory”
INTERMACS
3–4
INTERMACS
2
INTERMACS
1
Y
N
Y
Y
Y
N
N
Figure 4 Algorithm for the treatment of patients with advanced heart failure. BTB = bridge to bridge; BTC= bridge to candidacy; BTD= bridge to decision; BTR= bridge to recovery; BTT= bridge to transplantation; CA= cardiac amyloidosis; DT= destination therapy; ESC= European Society of
Cardiology; HCM=hypertrophic cardiomyopathy; HF= heart failure; HFA= Heart Failure Association; HT =heart transplantation; INTERMACS =
Interagency Registry for Mechanically Assisted Circulatory Support; LVAD= left ventricular assist device; LVAD-BTC= left ventricular assist device 
bridge to candidacy; LVAD-DT= left ventricular assist device  destination therapy; MCS= mechanical circulatory support. aThis algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria,376 with exception of HCM, CA, arrhythmic storm, adult congenital heart disease, refractory angina. bRecurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption <12 mL/min/kg or <50% of expected value.385 Colour code for classes of recommendation: Green for Class of recommendation I and Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation).


<!-- PAGE 43 -->

### Page 43

Any of these characteristics
Very limited life expectancy and/or poor QOL conditions that may impair follow-up and/or worsened prognosis after advanced HF therapies (HT/LT-MCS)a
N
Triage of patients with advanced heart failure and appropriate timing of referral
>1 admission or unplanned visit to HF clinic within last 12 months
Prior inotropic use
Intolerant to beta-blocker or RASi/ARNI
LVEF <20%
Worsening RV function
Worsening renal function
Worsening liver function
Ventricular arrhythmias/ICD shocks
Need for escalating diuretic doses for persistent congestion
SBP <90 mmHg and/or signs of peripheral hypoperfusion
Y
N
NYHA III–IV despite optimal medical therapy
(including ICD/CRT when indicated)
NYHA class II
Manage in local HF service
Refer to or discuss with advanced HF centre
Re-evaluation every
3–6 months
Palliative care
Y
Figure 5 Triage of patients with advanced heart failure and appropriate timing of referral.376 ARNI= angiotensin receptor-neprilysin inhibitor; CRT=
cardiac resynchronization therapy; HF= heart failure; HT= heart transplantation; ICD= implantable cardioverter-defibrillator; LT-MCS= long-term mechanical circulatory support; LVEF= left ventricular ejection fraction; NYHA= New York Heart Association; RASi= renin-angiotensin system inhibitor;
RV= right ventricular; SBP= systolic blood pressure; QOL= quality of life. aLimited life expectancy may be due by major comorbidities such as cancer,
dementia, end-stage organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cognitive dysfunction, psychiatric disorder, or psychosocial issues.
ESC Guidelines
3641


<!-- PAGE 44 -->

### Page 44

.................................................................................................................
profile 56, when they have high-risk characteristics. Patients with no irreversible end-organ failure other than cardiac, recovering from
INTERMACS level 1 while on short-term MCS, may also qualify for long-term MCS (Figure 4).376,378,383,395402 The characteristics of patients potentially eligible for implantation of an LVAD are reported in Table 16.
The details of the devices and studies on long-term MCS are summarized in Supplementary Table 15.
Current 2-year survival rates in patients receiving the latest continuous-flow LVADs are comparable to those after heart transplantation, although adverse events negatively affect QOL.
Among patients with continuous flow LVADs, actuarial survival was reported of 80% at 1 year and 70% at 2 years.403,404 Two-year survival was 84.5% and survival free of disabling stroke or need of reoperation for LVAD malfunction was 76.9% with a centrifugal-flow
LVAD in MOMENTUM 3.405 The fully magnetically levitated centrifugal-flow LVAD has significantly reduced pump thrombosis. In
MOMENTUM 3, the need for reoperation to replace a malfunctioning device was 2.3% per 24 months, with only 0.6% per 24 months risk of pump replacement because of pump thrombosis. Stroke
(namely, disabling stroke), major bleeding, and gastrointestinal haemorrhage were also lower in the centrifugal-flow pump group than in the axial-flow pump group. However, the incidence of all bleeding events, thromboembolism and driveline infection remained similar to that with older devices.402
Data on fully magnetically centrifugal-flow LVAD use in real-world studies with the 2-year outcomes from the ELEVATE registry showed an overall survival of 74.5%, with gastrointestinal bleeding in
9.7%, stroke in 10.2%, and pump thrombosis in 1.5% of patients.406
According to the IMACS Registry, a new composite endpoint including QOL and adverse events beyond survival was proposed to help in guiding decision making. In this sense ‘living well at one year’
defined as freedom from death, stroke, bleeding requiring operation,
RV assist device, pump replacement, or device-related infection within the first year, was 56.8% after isolated, centrifugal flowLVAD.383
Although now outdated,
REMATCH
was the only
RCT
comparing an LVAD as DT with OMT in patients with advanced HF,
NYHA class IV and a contraindication to transplantation. REMATCH
showed lower all-cause mortality with LVAD therapy when compared with medical treatment (primary endpoint). However, there were high mortality rates at 2 years in both arms.378 Other studies were not randomized (INTrEPID, ROADMAP)396,407,408 or compared different devices (ADVANCE, ENDURANCE, MOMENTUM
3).399,402,409 The two strategies of early LVAD implantation vs. medical treatment with LVAD implantation only after serious deterioration of the patient’s condition are currently being compared in a
Table 15
Terms describing various indications for mechanical circulatory support
Bridge to decision (BTD)/
Bridge to bridge (BTB)
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic shock until haemodynamics and end-organ perfusion are stabilized, contraindications for long-term MCS are excluded (brain damage after resuscitation) and additional therapeutic options including long-term VAD therapy or heart transplant can be evaluated.
Bridge to candidacy (BTC)
Use of MCS (usually LVAD) to improve end-organ function and/or to make an ineligible patient eligible for heart transplantation.
Bridge to transplantation (BTT)
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise at high risk of death before transplantation until a donor organ becomes available.
Bridge to recovery (BTR)
Use of MCS (short-term or long-term) to keep a patient alive until cardiac function recovers sufﬁciently to remove
MCS.
Destination therapy (DT)
Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for transplantation.
BiVAD = biventricular assist device; ECMO = extracorporeal membrane oxygenation; HF = heart failure; LVAD = left ventricular assist device; MCS = mechanical circulatory support; TAH = total artiﬁcial heart; VAD = ventricular assist device.
ESC 2021
Table 16
Patients potentially eligible for implantation of a left ventricular assist device
Patients with persistence of severe symptoms despite optimal medical and device therapy, without severe right ventricular dysfunction and/or severe TR, with a stable psychosocial background and absence of major contraindications*, and who have at least one of the following:
 LVEF <25% and unable to exercise for HF or, if able to perform cardiopulmonary exercise testing, with peak VO2 <12 mL/kg/min and/or
<50% predicted value.
 >_3 HF hospitalizations in previous 12 months without an obvious precipitating cause.
 Dependence on i.v. inotropic therapy or temporary MCS.
 Progressive end-organ dysfunction (worsening renal and/or hepatic function, type II pulmonary hypertension, cardiac cachexia) due to reduced perfusion and not to inadequately low ventricular ﬁlling pressure (PCWP >_20 mmHg and SBP <_90 mmHg or cardiac index
<_2 L/min/m2).
HF = heart failure; i.v. = intravenous; LVAD = left ventricular assist device; LVEF =
left ventricular ejection fraction; MCS = mechanical circulatory support; PCWP =
pulmonary capillary wedge pressure; SBP = systolic blood pressure; TR = tricuspid regurgitation; VO2 = oxygen consumption.
*Stable psychosocial background includes demonstrated understanding of the technology and patient living in the same household with a caregiver that will help the patient (i.e. living alone and poor psychosocial background is LVAD contraindication). Major contraindications include contraindication to long-term oral anticoagulation, infection, severe renal dysfunction, ventricular arrhythmias.
ESC 2021


<!-- PAGE 45 -->

### Page 45

......................................................
prospective trial,
Early-VAD
(ClinicalTrials.gov
Identifier:
NCT02387112). Also, the Swedish evaluation of LVAD (SweVAD)
study is comparing the survival of patients with advanced HF ineligible for heart transplantation prospectively randomized to LVAD as DT
vs. MT (ClinicalTrials.gov Identifier: NCT02592499).410
10.2.3
Heart transplantation
Heart transplantation remains the gold standard for the treatment of advanced HF in the absence of contraindications. Post-transplant 1year survival is around 90% with a median survival of 12.5
years.385,411,412 Transplantation significantly improves QOL and functional status, although, for unclear reasons, the percentage of patients returning to work is lower than expected.412 Apart from primary graft dysfunction, the main challenges after heart transplantation relate to either the efficacy or side effects of immunosuppression
(e.g. rejection, infection, cardiac allograft vasculopathy, late graft dysfunction, malignancy, renal failure, hypertension, diabetes mellitus).
Organ donor shortage remains the main limitation to heart transplantation. Thus, the donor heart criteria have now been extended to allow an increased upper limit of the donor age, particularly in
Europe. Moreover, careful recipient selection is needed, based on pre-transplant and post-transplant life expectancy (both are influenced by pre-operative status and comorbidities).
The main indications and contraindications for heart transplantation are listed in Table 17.376,385
Active infection is a relative contraindication to transplant but in some cases of infected LVADs it may actually be an indication. Elderly age is not an absolute contraindication. Although patients aged <65
years might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age,
and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered.
The decision pathway to transplantation or LVAD is never straightforward and is unique to each patient. Eligibility for each option may change according to the particular conditions of each patient, which may also change over time. Other factors, not related to the patient, such as time on the heart transplant waiting list, the
Table 17
Heart transplantation: indications and contraindications
Indications
Advanced HF376
No other therapeutic option, except for LVAD as BTT
Contraindications
Active infectiona
Severe peripheral arterial or cerebrovascular disease
Pharmacologic irreversible pulmonary hypertension (LVAD should be considered to reverse elevated pulmonary vascular resistance with subsequent re-evaluation to establish candidacy)
Malignancy with poor prognosis (a collaboration with oncology specialists should occur to stratify each patient as regards their risk of tumour progression or recurrence which increases with the use of immunosuppression)
Irreversible liver dysfunction (cirrhosis) or irreversible renal dysfunction
(e.g. creatinine clearance <30 mL/min/1.73 m2). Combined heart-liver or heart-kidney transplant may be considered
Systemic disease with multiorgan involvement
Other serious comorbidity with poor prognosis
Pre-transplant BMI >35 kg/m2 (weight loss is recommended to achieve a
BMI <35 kg/m2)
Current alcohol or drug abuse
Psychological instability that jeopardizes proper follow-up and intensive therapeutic regime after heart transplantation
Insufﬁcient social supports to achieve compliant care in the outpatient setting
BMI = body mass index; BTT = bridge to transplantation; HF = heart failure;
LVAD = left ventricular assist device.
aActive infection is a relative contraindication to transplant although in some cases of infected LVADs it may actually be an indication.
Adapted from Crespo-Leiro et al.376
Recommendations for the treatment of patients with advanced heart failure
Recommendations
Classa
Levelb
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.414416
I
C
Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
C
Long-term MCS should be considered in patients with advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.378,396,397,401,402,404,417
IIa
A
Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms,
reduce the risk of HF hospitalization and the risk of premature death.398400,402,404
IIa
B
Renal replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure.
IIa
C
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.389,390
IIb
C
Ultraﬁltration may be considered in refractory volume overload unresponsive to diuretic treatment.391,392
IIb
C
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MCS =
mechanical circulatory support.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
........................................................................................................................
ESC Guidelines
3643


<!-- PAGE 46 -->

### Page 46

.......................................................................................................................................................................
centre’s surgical experience, and resources, can also influence decision making.413
10.2.4
Symptom control and end-of-life care
While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading either to sudden death or death due to progressive HF. Communication about the disease trajectory and anticipatory planning should start when a patient is diagnosed with advanced HF. Indications for and key components of a palliative care service are reported in Tables 18 and 19.312,418
A team-based approach to palliative and end-of-life care for patients with HF has been proposed.419 Specific models of palliative care for patients with advanced HF have been also reported. They reduce hospitalizations, without a clear effect on survival, and have some effects on QOL and symptom burden.420,421
Symptom assessment should be performed on a regular basis. In addition to clinical assessment, symptoms can be assessed using the Numeric Rating Scale, the Edmonton Symptom Assessment
Scale (ESAS) or ESAS-HF, or the Integrated Palliative care Outcome
Scale.
Treatment for symptoms needs to be considered and might include additional intervention on top of OMT:
• Breathlessness: repeat doses of opioids may be considered for the relief of dyspnoea; however, their effectiveness is not demonstrated.422,423 While using opioids, all patients should be guided about opioid side effects such as constipation and nausea, urinary retention, and mental status changes. Benzodiazepines may be considered as a second- or third-line treatment, when opioids and non-pharmacological measures have failed to control breathlessness. Increasing the inspired oxygen concentration may provide relief of dyspnoea.
• Pain: non-pharmacologic management can be helpful. In addition,
opioid, oxycodone, hydromorphone, and fentanyl are generally viewed as safe options and can be provided orally, intravenously,
and transdermally, especially in the hospital or in patient palliative care or hospice setting.424
• Anxiety and depression: adequate conventional treatment should be offered.
Proactive decisions and advanced planning with regard to palliative and end-of-life care discussions should be documented, regularly reviewed, and routinely communicated to all those involved in the patient’s care. Healthcare providers should make sure that patients’
and carer preferences are followed, wherever possible. They should also take into account that patients may choose not to, or may not be in a position to, express preferences (e.g. due to symptoms of depression or cognitive impairment).
11 Acute heart failure
11.1 Epidemiology, diagnosis and prognosis
AHF refers to rapid or gradual onset of symptoms and/or signs of
HF, severe enough for the patient to seek urgent medical attention, leading to an unplanned hospital admission or an emergency department visit. Patients with AHF require urgent evaluation with subsequent initiation or intensification of treatment, including i.v. therapies or procedures. AHF is a leading cause of hospitalizations in subjects aged >65 years and is associated with high mortality and rehospitalization rates. In-hospital mortality ranges from 4% to 10%.425428 Post-discharge 1-year mortality can be
2530% with up to more than 45% deaths or readmission rates.104,426,427,429,430
AHF may be the first manifestation of HF (new onset) or, more frequently, be due to an acute decompensation of chronic HF.
Compared to patients with acutely decompensated CHF, those with new onset HF may have a higher in-hospital mortality425 but have lower post-discharge mortality and rehospitalization rates.425,428,431,432 Specific extrinsic factors may precipitate, but not cause, AHF in patients with pre-existing cardiac dysfunction
(Supplementary Table 16). Clinical severity and in-hospital trajectory are determined by the complex interplay between precipitants,
the underlying cardiac substrate,
and the patient’s comorbidities.
Table 18
Patients with heart failure in whom end-of-life care should be considered
Progressive functional decline (physical and mental) and dependence in most activities of daily living.
Severe heart failure symptoms with poor QOL despite optimal pharmacological and non-pharmacological therapies.
Frequent admissions to hospital or other serious episodes of decompensation despite optimal treatment.
Heart transplantation and MCS ruled out.
Cardiac cachexia.
Clinically judged to be close to end of life.
MCS = mechanical circulatory support; QOL = quality of life.
Table 19
Key components of palliative care service in patients with advanced heart failure
Focus on improving or maintaining the QOL of a patient and his/her family as well as possible until he/she dies.
Frequent assessment of symptoms (including dyspnoea and pain) resulting from advanced heart failure and other comorbidities and focus on symptom relief.
Access for the patient and his/her family to psychological support and spiritual care according to need.
Advanced care planning, taking into account preferences for place of death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team decision).
ICD = implantable cardioverter-deﬁbrillator; MCS = mechanical circulatory support; QOL = quality of life.
ESC 2021
ESC 2021


<!-- PAGE 47 -->

### Page 47

.........................................
The diagnostic workup of AHF starts at the time of the first medical contact, and is continued throughout the initial patient pathway,
aiming to identify the clinical presentation and to diagnose and manage any potentially reversible causes/precipitants/coexisting life-threatening conditions in a timely manner (Figure 6). Diagnostic tests are outlined at Table 20. In addition to clinical signs and symptoms, diagnostic workup includes ECG and echocardiography, if possible. Additional investigations, i.e. chest X-ray and lung ultrasound may be used to confirm AHF diagnosis, especially when NP testing is not available. Plasma NP levels (BNP or NT-proBNP or MRproANP) should be measured if the diagnosis is uncertain and a point-of-care assay is available. Normal concentrations of NPs make the diagnosis of AHF unlikely. Cut-offs for acute HF are: BNP <100
pg/mL, NT-proBNP <300 pg/mL and MR-proANP <120 pg/
mL.74,433435 However, elevated NP values are associated with a wide range of cardiac and non-cardiac conditions (Table 6). Low concentrations can be detected in some patients with advanced decompensated end-stage HF, obesity, flash pulmonary oedema or rightsided AHF. Higher levels can be found in the patients with concomitant AF and/or reduced renal function.74
Among other laboratory tests, troponin is useful for the detection of acute coronary syndrome (ACS) although elevated levels are detected in the vast majority of patients with AHF.436438 Blood urea nitrogen or urea, serum creatinine, electrolytes (sodium, potassium,
chloride), and antigen carbohydrate 125 may help tailor treatment.439,440 Detection of abnormal liver function identifies patients
Diagnostic workup of new onset acute heart failure
Electrocardiogram
Pulse oximetry
Echocardiography
Initial laboratory investigationsa
Chest X-ray
Lung ultrasound
Other specific evaluationsb
Patient history, signs and/or symptoms suspected of acute HF
Natriuretic peptide testing
BNP <100 pg/mL
NT-proBNP <300 pg/mL
MR-proANP <120 pg/mL
BNP ≥ 100 pg/mL
NT-proBNP ≥300 pg/mLc
MR-proANP ≥120 pg/mL
Acute heart failure ruled out
Acute heart failure confirmed
Comprehensive echocardiography
Figure 6 Diagnostic workup of new onset acute heart failure. ACS = acute coronary syndrome; BNP= B-type natriuretic peptide; CT= computed tomography; HF= heart failure; MR-proANP= mid-regional pro-atrial natriuretic peptide; NT-proBNP= N-terminal pro-B-type natriuretic peptide; TSH
= thyroid-stimulating hormone. aInitial laboratory exams include troponin, serum creatinine, electrolytes, blood urea nitrogen or urea, TSH, liver function tests as well as D-dimer and procalcitonin when pulmonary embolism or infection are suspected, arterial blood gas analysis in case of respiratory distress,
and lactate in case of hypoperfusion. bSpecific evaluation includes coronary angiography, in case of suspected ACS, and CT in case of suspected pulmonary embolism. cRule-in values for the diagnosis of acute HF: >450 pg/mL if aged <55 years, >900 pg/mL if aged between 55 and 75 years and >1800 pg/mL if aged >75 years.433,434
ESC Guidelines
3645


<!-- PAGE 48 -->

### Page 48

.......................................
with a poor prognosis.441 Since both hypothyroidism and hyperthyroidism may precipitate AHF, thyroid-stimulating hormone (TSH)
should be assessed in those with newly diagnosed AHF. Arterial blood gas analysis should be performed when a precise measurement of O2 and CO2 partial pressure is needed (i.e. patients with respiratory distress). Lactate and pH levels should be measured in patients with cardiogenic shock. D-dimer should be measured when acute pulmonary embolism is suspected. Procalcitonin may be used for the diagnosis of pneumonia and antibiotic therapy may have an indication when plasma levels are >0.2 lg/L. However, no impact of a strategy based on routine procalcitonin measurements on outcomes was shown in a prospective, controlled, trial.442 Pulse oximetry should be measured routinely at the time of first presentation of patients with
AHF and continuous monitoring may be needed in the first hours or days.443,444
11.2 Clinical presentations
Four major clinical presentations can be described with possible overlaps between them (Table 21).1,425,445 Clinical presentations are mainly based on the presence of signs of congestion and/or peripheral hypoperfusion and require different treatments
(Table
21).1,425427,432,446,447
11.2.1
Acute decompensated heart failure
Acute decompensated heart failure (ADHF) is the most common form of AHF, accounting for 5070% of presentations.426,427,432 It
Table 20
Diagnostic tests in patients with acute heart failure
Exam
Time of measurement
Possible findings
Diagnostic value for
AHF
Indication
ECG
Admission, during hospitalization,a,b pre-discharge
Arrhythmias, myocardial ischaemia
Exclusion of ACS or arrhythmias
Recommended
Chest-X ray
Admission, during hospitalizationa
Congestion, lung infection
Conﬁrmatory
May be considered
LUS
Admission, during hospitalization,a pre-discharge
Congestion
Conﬁrmatory
May be considered
Echocardiography
Admission, during hospitalization,a pre-discharge
Congestion, cardiac dysfunction, mechanical causes
Major
Recommended
Natriuretic peptides
(BNP, NT-proBNP,
MR-proANP)
Admission, pre-discharge
Congestion
High negative predictive value
Recommended
Serum troponin
Admission
Myocardial injury
Exclusion of ACS
Recommended
Serum creatinine
Admission, during hospitalization,a pre-discharge
Renal dysfunction
None
Recommended for prognostic assessment
Serum electrolytes
(sodium, potassium,
chloride)
Admission, during hospitalization,a pre-discharge
Electrolyte disorders
None
Recommended for prognostic assessment and treatment
Iron status (transferrin,
ferritin)
Pre-discharge
Iron depletion
None
Recommended for prognostic assessment and treatment
TSH
Admission
Hypo- hyperthyroidism
None
Recommended when hypohyperthyroidism is suspected
D-dimer
Admission
Pulmonary embolism
Useful to exclude pulmonary embolism
Recommended when pulmonary embolism is suspected
Procalcitonin
Admission
Pneumonia
Useful for diagnosis of pneumonia
May be done when pneumonia is suspected
Lactate
Admission, during hospitalizationa
Lactic acidosis
Useful to assess perfusion status
Recommended when peripheral hypoperfusion is suspected
Pulse oximetry and arterial blood gas analysis
Admission, during hospitalizationa
Respiratory failure
Useful to assess respiratory function
Recommended when respiratory failure is suspected
ACS = acute coronary syndrome; AHF = acute heart failure; BNP = B-type natriuretic peptide; ECG = electrocardiogram; LUS = lung ultrasound; MR-proANP = mid-regional pro-atrial natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSH = thyroid-stimulating hormone.
aBased on clinical conditions.
bContinuous ECG monitoring can be considered based on clinical conditions.
ESC 2021


<!-- PAGE 49 -->

### Page 49

..................................................................................
usually occurs in patients with history of HF and previous cardiac dysfunction across the spectrum of LVEF and may include RV dysfunction. Distinct from the acute pulmonary oedema phenotype, it has a more gradual onset, and the main alteration is progressive fluid retention responsible for systemic congestion. Sometimes,
congestion is associated with hypoperfusion.426 The objectives of treatment are identification of precipitants, decongestion, and in rare instances, correction of hypoperfusion (Figure 7).
11.2.2
Acute pulmonary oedema
Acute pulmonary oedema is related to lung congestion. Clinical criteria for acute pulmonary oedema diagnosis include dyspnoea with orthopnoea, respiratory failure (hypoxaemia-hypercapnia), tachypnoea, >25 breaths/min, and increased work of breathing.448
Three therapies should be commenced, if indicated. First, oxygen,
given as continuous positive airway pressure, non-invasive positivepressure-ventilation and/or high-flow nasal cannula, should be started. Second, i.v. diuretics should be administered, and third, i.v.
vasodilators may be given if systolic BP (SBP) is high, to reduce LV
afterload (Figure 8). In a few cases of advanced HF, acute pulmonary oedema may be associated with low cardiac output and, in this case,
inotropes, vasopressors, and/or MCS are indicated to restore organ perfusion.
11.2.3
Isolated right ventricular failure
RV failure is associated with increased RV and atrial pressure and systemic congestion. RV failure may also impair LV filling, and ultimately reduce systemic cardiac output, through ventricular interdependence.449
Diuretics are often the first option of therapy for venous congestion. Noradrenaline and/or inotropes are indicated for low cardiac output and haemodynamic instability. Inotropes reducing cardiac filling pressures may be preferred (i.e. levosimendan, phosphodiesterase type III inhibitors). Since inotropic agents may aggravate arterial hypotension, they may be combined with norepinephrine if needed
(Figure 9).449
11.2.4
Cardiogenic shock
Cardiogenic shock is a syndrome due to primary cardiac dysfunction resulting in an inadequate cardiac output, comprising a lifethreatening state of tissue hypoperfusion, which can result in multiorgan failure and death.450452 Cardiac insult causing severe impairment of cardiac performance may be acute, as a result of the acute loss of myocardial tissue (acute MI, myocarditis) or may be progressive as seen in patients with chronic decompensated HF who may experience a decline in disease stability as a result of the natural progression of advanced HF and/or specific precipitants.426
Diagnosis of cardiogenic shock mandates the presence of clinical signs of hypoperfusion, such as cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. In addition, biochemical manifestations of hypoperfusion, elevated serum creatinine, metabolic acidosis and elevated serum lactate are present and reflect tissue hypoxia and alterations of cellular
Table 21
Clinical presentations of acute heart failure
Acute decompensated heart failure
Acute pulmonary oedema
Isolated right ventricular failure
Cardiogenic shock
Main mechanisms
LV dysfunction
Sodium and water renal retention
Increased afterload and/or predominant LV diastolic dysfunction
Valvular heart disease
RV dysfunction and/or pre-capillary pulmonary hypertension
Severe cardiac dysfunction
Main cause of symptoms
Fluid accumulation, increased intraventricular pressure
Fluid redistribution to the lungs and acute respiratory failure
Increased central venous pressure and often systemic hypoperfusion
Systemic hypoperfusion
Onset
Gradual (days)
Rapid (hours)
Gradual or rapid
Gradual or rapid
Main haemodynamic abnormalities
Increased LVEDP and PCWPa
Low or normal cardiac output
Normal to low SBP
Increased LVEDP and
PCWPa
Normal cardiac output
Normal to high SBP
Increased RVEDP
Low cardiac output
Low SBP
Increased LVEDP and
PCWPa
Low cardiac output
Low SBP
Main clinical presentations1,446
Wet and warm OR Dry and cold
Wet and warmb
Dry and cold OR Wet and cold
Wet and cold
Main treatment
Diuretics
Inotropic agents/vasopressors
(if peripheral hypoperfusion/hypotension)
Short-term MCS or RRT if needed
Diuretics
Vasodilatorsb
Diuretics for peripheral congestion
Inotropic agents/vasopressors (if peripheral hypoperfusion/hypotension)
Short-term MCS or RRT if needed
Inotropic agents/
vasopressors
Short-term MCS
RRT
LV = left ventricular; LVEDP = left ventricular end-diastolic pressure; MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge pressure; RV = right ventricular;
RVEDP = right ventricular end-diastolic pressure; RRT = renal replacement therapy; SBP = systolic blood pressure.
aMay be normal with low cardiac output.
bWet and cold proﬁle with need of inotropes and/or vasopressors may rarely occur.
ESC 2021
ESC Guidelines
3647


<!-- PAGE 50 -->

### Page 50

.................
metabolism leading to organ dysfunction.437,453 Of note, hypoperfusion is not always accompanied by hypotension, as BP may be preserved by compensatory vasoconstriction (with/without pressor agents), albeit at the cost of impaired tissue perfusion and oxygenation.426,427,450,454
Management of cardiogenic shock should start as early as possible. Early identification and treatment of the underlying cause,
concomitant with haemodynamic stabilization and management of organ dysfunction, are key components of its management (Figure
10, Supplementary text 11.1; Supplementary Figure 2).
N
Management of patients with acute decompensated heart failure
Congestion/Fluid overload
Y
Hypoperfusion
Medical therapy optimization
(Class I)
Loop diureticsa
(Class I)
Loop diureticsa (Class I)
and consider inotropes (Class IIb)
Congestion relief
Hypoperfusion and congestion relief
N
Increase diuretic doses
(Class I) and/or combine diuretics (Class IIa)   
Consider vasopressors
(Class IIb)
(i.e. norepinephrine)
Diuretic resistance or end-stage renal failure
Persistent hypoperfusion
Organ damage
N
N
Y
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
MCS
(Class IIa)
AND/OR
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
N
Y
Y
Y
N
Figure 7 Management of acute decompensated heart failure. MCS= mechanical circulatory support. aAdequate diuretic doses to relieve congestion and close monitoring of diuresis is recommended (see Figure13) regardless of perfusion status.


<!-- PAGE 51 -->

### Page 51

....................................................
11.3 Management
11.3.1
General aspects
Management can be subdivided in three stages (pre-hospital, in-hospital, and pre-discharge), having different goals and requiring different approaches (Figure 11).
Pre-hospital phase
In the pre-hospital setting, AHF patients should benefit from noninvasive monitoring, including pulse oximetry, BP, heart rate respiratory rate, and a continuous ECG, instituted within minutes of patient contact and in the ambulance if possible.305 Oxygen therapy may be given based on clinical judgment unless oxygen saturation is <90% in which case it should be administered. In patients with respiratory distress, respiratory rate >25 breaths/min, oxygen saturation <90%,
non-invasive ventilation should be initiated.444,448 Although therapeutic tools may be available in the prehospital setting, whether more effective pre-hospital care would alter the clinical outcome remains to be proven in randomized clinical trials.455 Furthermore, prehospital management should not delay the rapid transfer of AHF
patients to the most appropriate medical setting.455,456
In-hospital management
Diagnostic workup and appropriate pharmacological and nonpharmacological treatment must be started promptly and in parallel
(Figure 12). AHF patients are triaged to the appropriate level of care according to the degree of haemodynamic instability and severity of the critical illness. Disposition decisions are important components of the initial phase of management (see Supplementary text 11.2 and
Supplementary Tables 1719).
The type and intensity of in-hospital monitoring depends on clinical severity, settings of care and in-hospital course (see Supplementary text 11.3). As AHF is a heterogeneous condition, management may differ according to the main clinical presentation. Management starts with the search for specific causes of AHF.1,305,430 These include
Management of patients with pulmonary oedema
SBP ≥110 mmHg
Loop diuretics (Class I)
and/or vasodilators
(Class IIb)
N
Y
N
Y
Signs of hypoperfusion
Loop diuretics (Class I)
and inotropes/vasopressors
(Class IIb)
Loop diuretics
(Class I)
Congestion relief
N
Y
Medical therapy optimization
(Class I)
Consider RRT, MCS,
other devices (Class IIa)
OR
Consider palliative care
Oxygen (Class I) or ventilatory support
(Class IIa)
Figure 8 Management of pulmonary oedema. MCS= mechanical circulatory support; RRT= renal replacement therapy; SBP =systolic blood pressure.
ESC Guidelines
3649


<!-- PAGE 52 -->

### Page 52

Management of patients with isolated right ventricular failure
Y
Specific treatments
ACS with RV involvement or acute pulmonary embolism
N
Loop diuretics
(Class I)
Consider careful fluid administration
Marked congestion
Y
RVAD
AND/OR
Renal replacement therapy
OR
Consider palliative care
N
Y
Optimize fluid status
N
Peripheral hypoperfusion/
persistent hypotension
N
Vasopressors and/or inotropesa
(Class IIb)
Relief of signs and symptoms
Y
Follow-up
Figure 9 Management of right ventricular failure. ACS= acute coronary syndrome; RV= right ventricular; RVAD= right ventricular assist device.
aInotropes alone in case of hypoperfusion without hypotension.


<!-- PAGE 53 -->

### Page 53

.....................
ACS, a hypertensive emergency, rapid arrhythmias or severe bradycardia/conduction disturbance, acute mechanical causes such as acute valve regurgitation or acute pulmonary embolism, infection, including myocarditis, and tamponade (CHAMPIT) (Figure 12). After exclusion of these conditions, which need to be treated/corrected urgently,
management of AHF differs according to the clinical presentations
(Figures 710).
Pre-discharge phase
Details on this phase are shown in section 11.3.11.
11.3.2
Oxygen therapy and/or ventilatory support
In AHF, oxygen should not be used routinely in non-hypoxaemic patients, as it causes vasoconstriction and a reduction in cardiac output.457 Oxygen therapy is recommended in patients with AHF and
MCS
(Class IIa)
AND/OR
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
Management of patients with cardiogenic shock
Identify and treat other specific causesb
ACS and/or mechanical complications
N
Y
Emergency PCI or surgical treatmenta
Consider oxygen
(Class I) or ventilatory support (Class IIa)
Consider inotropes/
vasopressors
(Class IIb)
Consider short-term
MCS
(Class IIa)
AND
AND
Improvement of hypoperfusion and organ dysfunction
N
Y
Weaning from inotropes/vasopressors and/or MCS
Continue aetiological treatment if needed and medical therapy optimization
(Class I)
Figure 10 Management of cardiogenic shock. ACS = acute coronary syndrome; BTT =bridge to transplantation; MCS= mechanical circulatory support;
PCI= percutaneous coronary intervention. aPCI in ACS, pericardiocentesis in tamponade, mitral valve surgery in papillary muscle rupture. In case of interventricular septum rupture, MCS as BTT should be considered. bOther causes include acute valve regurgitation, pulmonary embolism, infection, acute myocarditis, arrhythmia (see Figure 12).
ESC Guidelines
3651


<!-- PAGE 54 -->

### Page 54

.......................................................
SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia. In chronic obstructive pulmonary disease (COPD), hyper-oxygenation may increase ventilationperfusion mismatch, suppress ventilation and lead to hypercapnia. During oxygen therapy, acid-base balance and
SpO2 should be monitored.
Non-invasive positive pressure ventilation, either continuous positive airway pressure and pressure support, improves respiratory failure, increases oxygenation and pH, and decreases the partial pressure of carbon dioxide (pCO2) and work of breathing. Although a large randomized trial had neutral results, meta-analyses suggest it may improve dyspnoea and reduce the need for intubation and mortality, compared with traditional oxygen therapy.1,458,459 Noninvasive positive pressure ventilation should be started as soon as possible in patients with respiratory distress (respiratory rate >25
breaths/min, SpO2 <90%) to improve gas exchange and reduce the rate of endotracheal intubation.448,459 The fraction of inspired oxygen
(FiO2) should be increased up to 100%, if necessary, according to oxygen saturation level.
Blood pressure should be monitored regularly during non-invasive positive pressure ventilation. The increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and BP and should therefore be used with caution in patients with reduced preload reserve and hypotension. The increase in pulmonary vascular resistance and RV afterload may also be detrimental in RV dysfunction.448
Intubation is recommended for progressive respiratory failure in spite of oxygen administration or non-invasive ventilation
(Supplementary Table 20).448
11.3.3
Diuretics
Intravenous diuretics are the cornerstone of AHF treatment. They increase renal excretion of salt and water and are indicated for the treatment of fluid overload and congestion in the vast majority of
AHF patients.
Determine aetiology
Alleviate symptoms
Improve congestion and organ perfusion
Restore oxygenation
Limit organ damage (cardiac,
renal, hepatic, gut)
Prevent thromboembolism
Close monitoring of vital signs and grading severity of symptoms/signs
Disposition decisions: ICU/ICCU
ward
Initial treatment to support circulatory and respiratory functions (vasodilators,
vasopressors, inotropes,
diuretics, supplemental O2)
Identify aetiology and relevant co-morbidities and start targeted treatment
Titrate therapy to control symptoms and to relieve congestion, manage hypoperfusion and optimize blood pressure
Initiate and up-titrate diseasemodifying pharmacological therapy
Consider device therapy in appropriate patients
Goals
Procedures
Phases
Determine aetiology
Improve signs and symptoms
Limit organ damage
Prevent thromboembolism
Improve symptoms and quality 
of life
Achieve full congestion relief
Prevent early readmission
Improve survival
Initiate and up-titrate diseasemodifying pharmacological and device therapy
Develop a care plan with the identification of caregivers, a schedule for up-titration and monitoring of pharmacological therapy, review of device therapy
Enrolment in a disease management programme
Immediate
Pre-discharge and long-term
Intermediate
Phases
Figure 11 Stages of management of patients with acute heart failure. ICCU= intensive coronary care unit; ICU= intensive care unit.


<!-- PAGE 55 -->

### Page 55

....................................................
Loop diuretics are commonly used due to their rapid onset of action and efficacy. Data defining their optimal dosing, timing, and method of administration are limited. No difference in the primary efficacy outcome of patients’ symptoms global assessment was shown with a high-dose regimen, compared with a low-dose regimen, in the DOSE trial. However, there was a greater relief of dyspnoea, change in weight and net fluid loss (with no prognostic role for increases in serum creatinine) in the higher-dose regimen.460462
High diuretic doses may cause greater neurohormonal activation and electrolyte abnormalities and are often associated with poorer outcomes, although a cause and effect relation cannot be proven by these retrospective analyses.463466 Based on these observations, it may be appropriate, when starting i.v. diuretic treatment, to use low doses, to assess the diuretic response and increase the dose when that is insufficient.
Diuretic treatment should be started with an initial i.v. dose of furosemide, or equivalent dose of bumetanide or torasemide,
corresponding to 12 times the daily oral dose taken by the patient before admission. If the patient was not on oral diuretics, a starting dose of 2040 mg of furosemide, or a bolus of 1020 mg i.v. torasemide, can be used.145,467 Furosemide can be given as 23 daily boluses or as a continuous infusion. Daily single bolus administrations are discouraged because of the possibility of post-dosing sodium retention.145,461 With continuous infusion, a loading dose may be used to achieve steady state earlier. Diuretic response should be evaluated shortly after start of diuretic therapy and may be assessed by performing a spot urine sodium content measurement after 2 or
6 h and/or by measuring the hourly urine output. A satisfactory diuretic response can be defined as a urine sodium content
>5070 mEq/L at 2 h and/or by a urine output >100150 mL/h during the first 6 h.145,468 If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled, with a further assessment of diuretic response.145 If the diuretic response remains inadequate, e.g.
<100 mL hourly diuresis despite doubling loop diuretic dose,
Identification of acute aetiology
Cardiogenic shock and/or respiratory failure
N
Management of patients with suspected acute heart failure
Pharmacological support
Ventilatory support
MCS
Y
acute Coronary syndrome
Hypertension emergency
Arrhythmia
Mechanical causea
Pulmonary embolism
Infections
Tamponade
C
H
A
M
P
I
T
Y
Immediate initiation of specific treatment
Further treatmentb
N
Urgent phase after first medical contact
Immediate phase
(initial 60–120 min)
Figure 12 Initial management of acute heart failure. MCS= mechanical circulatory support. aAcute mechanical cause: myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis. bSee Figures 710 for specific treatments according to different clinical presentations.
ESC Guidelines
3653


<!-- PAGE 56 -->

### Page 56

............................................................
concomitant administration of other diuretics acting at different sites,
namely thiazides or metolazone or acetazolamide, may be considered. However, this combination requires careful monitoring of serum electrolytes and renal function (Figure 13).145,469,470 This strategy, based on early and frequent assessment of diuretic response,
allows starting treatment with relatively low doses of loop diuretics,
with frequent dose adjustments that may be less likely to cause dehydration and increase in serum creatinine. The loop diuretic dose should be progressively decreased when a significant negative fluid balance has been obtained. However, it should be pointed out that this algorithm is entirely based on expert opinion, to date.145,461
Transition to oral treatment should be commenced when the patient’s clinical condition is stable. It is recommended that, after achievement of congestion relief, oral loop diuretics are continued at the lowest dose possible to avoid congestion.463,471 Care must also be taken to avoid patients being discharged from hospital with persistent congestion, as this is a major predictor of increased deaths and rehospitalizations.462,472 Hence, care should be taken to achieve adequate decongestion and establish an appropriate long-term diuretic dose before discharge.427,473
11.3.4
Vasodilators
Intravenous vasodilators, namely nitrates or nitroprusside (Supplementary Table 21), dilate venous and arterial vessels leading to a reduction in venous return to the heart, less congestion, lower afterload, increased stroke volume and consequent relief of symptoms.
Nitrates act mainly on peripheral veins whereas nitroprusside is more a balanced arterial and venous dilator.474,475 Because of their mechanisms of action, i.v. vasodilators may be more effective than diuretics in those patients whose acute pulmonary oedema is caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.427,476478 However,
two recent randomized trials comparing usual care with early intensive and sustained vasodilation failed to show a beneficial effect of i.v.
vasodilators vs. high-dose diuretics.479,480 No recommendation favouring a regimen based on vasodilator treatment vs. usual care can thus be given, to date.
Intravenous vasodilators may be considered to relieve AHF symptoms when SBP is >110 mmHg. They may be started at low doses and uptitrated to achieve clinical improvement and BP control.
Nitrates are generally administered with an initial bolus followed by
Management of diuretic therapy in patients with acute heart failure
On oral loop diuretic
1–2 times daily oral dose i.v.
≥20–40 mg i.v.
furosemide 
Urinary spot sodium     after 2 h 
≥50–70 mEq/L
Urine output                after 6 h      ≥100–150 mL/h
Double dose i.v. until maximum i.v. dosea
Repeat similar dose i.v. every 12 h
Check serum creatinine and electrolytes at least every 24 h 
Continue until complete decongestion
Combination diuretic therapiesb
N
Y
Y
N
≥
Urinary spot sodium     50–70 mEq/L at 2–6 h
≥
Urine output                100–150 mL/h
Y
N
Figure 13 Diuretic therapy (furosemide) in acute heart failure. i.v.= intravenous. aThe maximal daily dose for i.v. loop diuretics is generally considered furosemide 400600 mg though up to 1000 mg may be considered in patients with severely impaired kidney function. bCombination therapy is the addition to the loop diuretic of a diuretic with a different site of action, e.g. thiazides or metolazone or acetazolamide. Modified from 145.


<!-- PAGE 57 -->

### Page 57

.............................................................................
continuous infusion. However, they may also be given as repeated boluses. Nitroglycerine can be given as 12 mg boluses in severely hypertensive patients with acute pulmonary oedema.477 Care should be taken to avoid hypotension due to an excessive decrease in preload and afterload. For this reason, they should be used with extreme caution in patients with LVH and/or severe aortic stenosis.
However, favorable effects were described in patients with LV systolic dysfunction and aortic stenosis when vasodilators were given with careful monitoring of haemodynamic parameters.481
11.3.5
Inotropes
Inotropes are still needed for treatment of patients with low cardiac output and hypotension (Table 22). They should be reserved for patients with LV systolic dysfunction, low cardiac output and low SBP
(e.g. <90 mmHg) resulting in poor vital organ perfusion. However,
they must be used with caution starting at low doses and uptitrating them with close monitoring.387,388
Inotropes, especially those with adrenergic mechanisms, can cause sinus tachycardia, increase ventricular rate in patients with AF,
may induce myocardial ischaemia and arrhythmias, and increase mortality.387,388,430,478
Levosimendan or type-3-phosphodiesterase inhibitors may be preferred over dobutamine for patients on beta-blockers as they act through independent mechanisms.482,483
Excessive peripheral vasodilation and hypotension can be major limitations of type-3-phosphodiestaerase inhibitors or levosimendan,
especially when administered at high doses and/or when commenced with a bolus dose.482,484
11.3.6
Vasopressors
Vasopressors used for the treatment of AHF are reported in Table 22.
Among drugs with a prominent peripheral arterial vasoconstrictor action, norepinephrine may be preferred in patients with severe hypotension. The aim is to increase perfusion to the vital organs.
However, this is at the expense of an increase in LV afterload.
Therefore, a combination of norepinephrine and inotropic agents may be considered, especially in patients with advanced HF and cardiogenic shock.
Some studies, though with limitations, support the use of norepinephrine as first choice, compared with dopamine or epinephrine.
Dopamine was compared with norepinephrine as a first-line vasopressor therapy in patients with shock and was associated with more arrhythmic events and with a greater mortality in patients with cardiogenic shock but not in those with hypovolaemic or septic shock.
Although the trial included 1679 patients, significance was seen only in a subgroup analysis of the 280 patients with cardiogenic shock and
<10% of the patients had MI. As there were no data regarding revascularization, this limits the generalizability of the results.485 In another prospective randomized trial epinephrine was compared with norepinephrine in patients with cardiogenic shock due to acute MI.486 The trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Epinephrine was also associated with higher heart rate and lactic acidosis. Despite limitations related to its relatively small sample size, short time of follow-up and lack of data regarding the maximum reached dose, the study suggests superior efficacy and safety with norepinephrine. These data are consistent with a meta-analysis including 2583 patients with cardiogenic shock showing a three-fold increase in the risk of death with epinephrine,
compared with norepinephrine,
in patients with cardiogenic shock.487 However, the lack of information about dose, duration of treatment, and aetiology, makes these results partially explorative.
11.3.7
Opiates
Opiates relieve dyspnoea and anxiety. They may be used as sedative agents during non-invasive positive pressure ventilation to improve patient adaptation. Dose-dependent side effects include nausea,
hypotension, bradycardia, and respiratory depression. Retrospective
Table 22
Inotropes and/or vasopressors used to treat acute heart failure
Drug
Infusion rate
Dobutamine
220 lg/kg/min (betaþ)
Dopamine
35 lg/kg/min; inotropic (betaþ)
>5 lg/kg/min: inotropic (betaþ), vasopressor (alphaþ)
Milrinone
0.3750.75 lg/kg/min
Enoximone
520 lg/kg/min
Levosimendan
0.1 lg/kg/min, which can be decreased to 0.05
or increased to 0.2 lg/kg/min
Norepinephrine 0.21.0 lg/kg/min
Epinephrine
0.050.5 lg/kg/min
ESC 2021
Recommendations for the initial treatment of acute heart failure
Recommendations
Classa
Levelb
Oxygen and ventilatory support
Oxygen is recommended in patients with SpO2
<90% or PaO2 <60 mmHg to correct hypoxaemia.
I
C
Intubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation.448
I
C
Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2
<90%) and started as soon as possible in order to decrease respiratory distress and reduce the rate of mechanical endotracheal intubation.448
IIa
B
Diuretics
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to improve symptoms.145
I
C
Combination of a loop diuretic with thiazidetype diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.145
IIa
B
Vasodilators
In patients with AHF and SBP >110 mmHg, i.v.
vasodilators may be considered as initial therapy to improve symptoms and reduce congestion.475477,479,480
IIb
B
Continued
................................................................................................
ESC Guidelines
3655


<!-- PAGE 58 -->

### Page 58

..........................................................................................................
analyses suggest that morphine administration is associated with a greater frequency of mechanical ventilation, prolonged hospitalization,
more intensive care unit admissions, and increased mortality.488491
Thus, routine use of opiates in AHF is not recommended although they may be considered in selected patients, particularly in case of severe/intractable pain or anxiety or in the setting of palliation.
11.3.8
Digoxin
Digoxin should be considered in patients with AF with a rapid ventricular rate (>110 b.p.m.) despite beta-blockers (see also section
12.1.1).151,492,493 It can be given in boluses of 0.250.5 mg i.v., if not used previously. However, in patients with comorbidities (i.e. CKD)
or other factors affecting digoxin metabolism (including other drugs)
and/or the elderly, the maintenance dose may be difficult to estimate theoretically and measurements of serum digoxin concentrations should be performed. Digitoxin is a potential alternative to digoxin and is currently being evaluated in a randomized placebo-controlled trial (ClinicalTrials.gov Identifier: NCT03783429).158
11.3.9
Thromboembolism prophylaxis
Thromboembolism prophylaxis with heparin (e.g. low-molecularweight heparin) or another anticoagulant is recommended, unless contraindicated or unnecessary (because of existing treatment with oral anticoagulants).494,495
11.3.10
Short-term mechanical circulatory support
In patients presenting with cardiogenic shock, short-term MCS may be necessary to augment cardiac output and support end-organ perfusion. Short-term MCS can be used as a BTR, BTD or BTB.450-452
The initial improvements in cardiac output, BP and arterial lactate may be counterbalanced by significant complications. High-quality evidence regarding outcomes remains scarce. Hence, the unselected use of MCS in patients with cardiogenic shock is not supported and they require specialist multidisciplinary expertise for implantation and management, similar to that outlined for advanced HF centres
(Supplementary text 11.4; Supplementary Table 22, see also section
10.2.2).376,496 Recent studies show that a ‘standardized team-based approach’ using predefined algorithms for early MCS implant coupled with close monitoring (invasive haemodynamics, lactate, markers of end-organ damage)
may potentially translate into improved survival.497499
The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABPSHOCK-II) trial showed no difference in 30-day, as well as in longterm, mortality between intra-aortic balloon pump (IABP) and OMT
in patients with cardiogenic shock following acute MI who underwent early revascularization.500502 According to these results, IABP is not routinely recommended in cardiogenic shock post-MI. However, it may still be considered in cardiogenic shock, especially if not due to
ACS, and refractory to drug therapy, as a BTD, BTR, or BTB.
Other short-term MCS were compared with IABP in small,
randomized trials and propensity-matched analyses with inconclusive results.503507 Similarly, RCTs comparing extracorporeal membrane oxygenation (ECMO) with IABP or MT are lacking. A meta-analysis including only observational studies showed favourable outcomes in patients with cardiogenic shock or cardiac arrest treated with venoarterial (VA)-ECMO compared to controls.508 VA-ECMO may also be considered in fulminant myocarditis and other conditions causing severe cardiogenic shock.509 Depending on the severity of myocardial dysfunction and/or concomitant mitral or aortic regurgitation,
VA-ECMO may increase LV afterload with an increase in LV endInotropic agents
Inotropic agents may be considered in patients with SBP <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment,
including ﬂuid challenge, to improve peripheral perfusion and maintain end-organ function.387
IIb
C
Inotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension and evidence of hypoperfusion.387,467,478
III
C
Vasopressors
A vasopressor, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.485487
IIb
B
Other drugs
Thromboembolism prophylaxis (e.g. with
LMWH) is recommended in patients not already anticoagulated and with no contraindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.494,495
I
A
Routine use of opiates is not recommended,
unless in selected patients with severe/intractable pain or anxiety.488,489
III
C
AHF = acute heart failure; i.v. = intravenous; LMWH = low-molecular-weight heparin; PaO2 = partial pressure of oxygen; SBP = systolic blood pressure; SpO2 =
transcutaneous oxygen saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock
Recommendations
Classa
Levelb
Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD,
BTB. Further indications include treatment of the cause of cardiogenic shock or long-term
MCS or transplantation.
IIa
C
IABP may be considered in patients with cardiogenic shock as a BTR, BTD, BTB, including treatment of the cause of cardiogenic shock (i.e.
mechanical complication of acute MI) or longterm MCS or transplantation.450
IIb
C
IABP is not routinely recommended in post-MI
cardiogenic shock.500502
III
B
BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to recovery;
IABP = intra-aortic balloon pump; MCS = mechanical circulatory support; MI =
myocardial infarction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...............................................................


<!-- PAGE 59 -->

### Page 59

.............................................................................................
diastolic pressure and pulmonary congestion. In these cases, LV
unloading is mandatory and can be achieved by means of transeptal/
ventricular apex vent or adding an unloading device such as the
Impella device.510,511
11.3.11 Pre-discharge assessment and post-discharge management planning
A significant proportion of patients with AHF are discharged with minimal or no weight loss and, more importantly, persistent congestion.427,472 Persistent congestion before discharge is associated with a higher risk of readmission and mortality.426,472 Treatment, including diuretic dose, should therefore be optimized in order to keep the patient free of congestion.
In those admitted with ADHF, oral OMT should be continued,
except for possible dose reduction or withdrawal if there is haemodynamic instability (symptomatic hypotension), severely impaired renal function or hyperkalaemia. Once haemodynamic stabilization is achieved with i.v. therapy, treatment should be optimized before discharge.467 Treatment optimization has three major aims. First, to relieve congestion. Second, to treat comorbidities, such as iron deficiency, that have an impact on post-discharge outcome.512 Third, to initiate, or restart oral, OMT with beneficial effects on outcome.
Doses may be uptitrated before discharge and/or in the early postdischarge phase.
Studies have shown that such optimization of medical treatment is associated with a lower risk of 30-day readmission, although prospective randomized trials have not been performed, to date.103,467,513
Retrospective analyses show that discontinuation or dose reduction of beta-blocker therapy during an AHF hospitalization is associated with worse outcomes.514 Initiation of ARNI in recently hospitalized stable patients with HFrEF, including those who are ACE-I/ARB
naı¨ve, is safe and may be considered in this setting.106,107 Safety and better outcome have also been recently shown in a prospective randomized trial with sotagliflozin in diabetic patients hospitalized for
HF, irrespective of their LVEF.136
It is recommended to have one follow-up visit within 1 to 2 weeks after discharge.515,516 Components of this follow-up visit should include monitoring of signs and symptoms of HF, assessment of volume status, BP, heart rate, and laboratory measurements including renal function, electrolytes, and possibly NPs. Iron status and hepatic function should also be assessed when not done before discharge.
Based on clinical evaluation and laboratory exams, further optimization and/or initiation of disease-modifying treatment for HFrEF
should occur. Retrospective studies show that such an approach is associated with lower 30-day readmission rates although prospective randomized trials have not been performed, to date.513,516518
12 Cardiovascular comorbidities
12.1 Arrhythmias and conduction disturbances
12.1.1
Atrial fibrillation
AF and HF frequently coexist.519,520 They can cause or exacerbate each other through mechanisms such as structural cardiac remodelling, activation of neurohormonal systems, and rate-related LV
impairment.519523 The proportion of patients with HF who develop
AF increases with age and HF severity. When AF causes HF the clinical course seems more favourable than with other causes of HF (so called tachycardiomyopathy).524 In contrast, development of AF in patients with chronic HF is associated with worse prognosis, including stroke and increased mortality.525,526
The management of patients with concomitant HF and AF is summarized in Figure 14.7,521 It includes:
(1)
Identification and treatment of possible causes or triggers of AF
(2)
Management of HF
(3)
Prevention of embolic events
(4)
Rate control
(5)
Rhythm control
Identification of triggers and management of heart failure
Potential causes or precipitating factors such as hyperthyroidism,
electrolyte disorders, uncontrolled hypertension, mitral valve disease, and infection should be identified and corrected.
Worsening congestion due to AF should be managed with diuretics. Congestion relief may reduce sympathetic drive and ventricular rate and increase the chance of spontaneous return to SR. The presence of AF may reduce or abolish the prognostic benefits of beta-blockers and renders ivabradine ineffective.12,125 Some treatments for HF decrease the risk of developing AF, including ACE-I,
slightly, and CRT, probably.7,527
Prevention of embolic events
Unless contraindicated, an oral, long-term anticoagulant is recommended in all patients with HF and paroxysmal, persistent, or permanent AF. Direct-acting oral anticoagulants (DOACs) are preferred
Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure
Recommendations
Classa
Levelb
It is recommended that patients hospitalized for
HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.427,472
I
C
It is recommended that evidence-based oral medical treatment be administered before discharge.103,513
I
C
An early follow-up visit is recommended at 12
weeks after discharge to assess signs of congestion, drug tolerance and start and/or uptitrate evidence-based therapy.517,518
I
C
Ferric carboxymaltose should be considered for iron deﬁciency, deﬁned as serum ferritin <100
ng/mL or serum ferritin 100299 ng/mL with
TSAT <20%, to improve symptoms and reduce rehospitalizations.512
IIa
B
HR = heart failure; TSAT = transferrin saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...............................................................................
ESC Guidelines
3657


<!-- PAGE 60 -->

### Page 60

Management of atrial fibrillation in patients with HFrEF
Haemodynamic instability
Anticoagulation for preventing embolic events (Class I)
Treatment of trigger(s) (Class I)
Optimization of heart failure therapies (Class I)
OR
Beta-blockers
(Class IIa)
Digoxin/digitoxin
(Class IIa)
Amiodarone i.v.
(Class IIa)
OR
Rate control
Symptom improvement
Sinus rhythm
Amiodarone
(Class IIb)
ECV
(Class IIb)
Rhythm control
PV ablation
(Class IIa)
ECV
(Class I)
Rhythm control
OR
Amiodarone
(Class IIb)
Rhythm control
PV ablation
(Class IIa)
AVN ablation
(Class IIb)
Rate control
Sinus rhythm
Follow-up
N
N
N
Y
Y
Y
Y
N
OR
OR
Figure 14 Management of atrial fibrillation in patients with heart failure with reduced ejection fraction. AF= atrial fibrillation; AVN= atrioventricular node; ECV= electrical cardioversion; HF= heart failure; i.v.= intravenous; PV= pulmonary vein. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see
Table 1 for further details on classes of recommendation).


<!-- PAGE 61 -->

### Page 61

.............................................................................................................................................................................
for the prevention of thromboembolic events in patients with AF and without severe mitral stenosis and/or mechanical valve prosthesis, as they have similar efficacy to vitamin K antagonists (VKAs) but a lower risk of intracranial haemorrhage.528
LA appendage closure can be considered in patients with HF and
AF who have a contraindication to oral anticoagulation though data from randomized trials have not included patients with contraindications to oral anticoagulants.529,530
Rate control
Data regarding rate control are not conclusive for the patients with
AF and HF. A strategy of lenient rate control, defined by a resting heart rate <110 b.p.m., was compared to a strategy of strict rate control, defined by a heart rate <80 b.p.m. at rest and <110 b.p.m. during moderate exercise, in RACE II and in a pooled analysis of RACE and
AFFIRM.152,531 The studies showed no differences in outcome between the two strategies. However, only 10% of the patients in
RACE II and 17% of those in the pooled analysis had a history of HF
hospitalization or NYHA class IIIII, respectively.152,531 Higher heart rates are associated with worse outcomes in observational studies.532,533 Thus, a lenient rate control is an acceptable initial approach with, however, treatment targeting a lower heart rate in case of persistent symptoms or cardiac dysfunction likely related to tachycardia
(e.g. tachycardia-induced cardiomyopathy).7,534
Beta-blockers can be used for rate control in patients with HFrEF
or HFmrEF because of their established safety in these patients (see section 5.3.2).7,534,535 Digoxin or digitoxin can be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated.151,493,536 It may therefore be considered also an alternative to beta-blockers. For patients with NYHA class IV and/or haemodynamic instability, i.v.
amiodarone can be considered to reduce ventricular rate.537 For
HFpEF, there is a paucity of evidence to demonstrate efficacy of any agent. The RATE-AF trial compared digoxin with bisoprolol in patients with persistent AF and NYHA class IIIV symptoms.
Compared with bisoprolol, digoxin had the same effect on QOL at 6
months (primary endpoint) and a better effect on EHRA and NYHA
functional class.536 Only 19% of the patients had LVEF <50% so that most of the patients can be considered as having HFmrEF or
HFpEF.536
AV node ablation can be considered in patients with poor ventricular rate control despite medical treatment not eligible for rhythm control by catheter ablation or in patients with biventricular pacing.7,538540
Rhythm control
Urgent electrical cardioversion is recommended in the setting of acute worsening HF in patients presenting with rapid ventricular rates and haemodynamic instability, after consideration of the thromboembolic risk. Cardioversion should be considered also to improve symptoms in patients who have persistent and symptomatic AF, despite optimal pharmacological management. In patients who do not receive chronic therapy with oral anticoagulant and with AF onset
>48 h, at least 3 weeks of therapeutic anticoagulation or a transoesophageal echocardiography is needed before cardioversion.7 When pharmacological cardioversion is preferred, amiodarone is the drug of choice as other antiarrhythmic drugs (i.e. propafenone, flecainide,
dronedarone)
are associated with worse outcomes in
HFrEF.186,534,541544 Amiodarone can help maintain HF patients in
SR after cardioversion.545,546
Trials including patients with HF and comparing rate control and rhythm control strategies with the latter based on antiarrhythmic drugs failed to show any benefit of one strategy over the other.547550 More recently, EAST-AFNET 4, enrolling patients with early AF, 28.6% with HF, was stopped early after a median follow-up of 5.1 years for a lower occurrence of the primary outcome of death,
stroke, or hospitalization for worsening HF or ACS in the patients assigned to early rhythm control vs. those assigned to usual care.551
However, the patients assigned to the rhythm control strategy had a closer follow-up, which may have influenced their better outcome.
Catheter ablation was performed in a minority of the patients in the rhythm control arm (19.4%).551
LA catheter ablation was compared with MT, rate or rhythm control strategy, in 363 patients with persistent or paroxysmal AF, LVEF
<35% and an implanted device (ICD or CRT-D) enrolled in the
CASTLE-AF trial.552 The primary endpoint of all-cause death or HF
hospitalizations occurred in fewer patients in the ablation group vs.
the MT group, 51 patients (28.5%) vs. 82 (44.6%) [hazard ratio (HR);
95% confidence interval (CI), 0.62; 0.430.87; P =0.007]. Also, other endpoints, all-cause or CV death or worsening HF, were reduced by catheter ablation.552 This trial suggests that catheter ablation can improve the prognosis of patients with HFrEF. However, it enrolled a highly selected population, 363 of 3013 patients, was not blinded, had crossovers between the two treatment strategies and the number of events observed was low: 24 (13.4%) vs. 46 (25.0%) all-cause deaths and 37 (20.7%) vs. 66 (35.9%) HF hospitalizations in the ablation and
MT groups, respectively.552
The CABANA trial was an investigator-initiated, open-label, multicentre, randomized trial enrolling 2204 patients with symptomatic
AF. The trial failed to show a benefit of AF ablation strategy over medical care on the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest in the overall population.553
In an analysis of the 778 patients (35%) with NYHA class symptoms
>II, the primary outcome occurred in 34 patients (9.0%) in the catheter ablation group vs. 49 (12.3%) in the drug therapy group (HR; 95%
CI, 0.64; 0.410.99).554 However, also in this trial, the number of events was small and HF was defined based only on symptoms with
LVEF available in 73% of the patients and >50% and 4049% in 79%
and 11.7% of the cases, respectively.554 Both CASTLE-AF and
CABANA showed a highly significant effect of catheter ablation on patients’ symptoms.552554
Two other prospective trials enrolled patients with HFrEF and persistent AF, who were randomized to catheter ablation or MT in one trial (AMICA trial, n = 140), and to catheter ablation or amiodarone in the other one (AATAC trial, n = 203).555,556 The first trial failed to show any difference in the LVEF increase between the two groups.555 The second trial showed superiority of catheter ablation with respect of AF recurrence, the primary endpoint, with also a reduction in unplanned hospitalizations and mortality.556 In contrast with the AMICA trial,555 but in accordance with CASTLE-AF,552
AATAC also showed a benefit of catheter ablation on LVEF.556
In conclusion, there is insufficient evidence in favour of a strategy of rhythm control with antiarrhythmic drugs vs. rate control in patients with HF and AF.547551 The results of randomized trials with
ESC Guidelines
3659


<!-- PAGE 62 -->

### Page 62

.............................................................................................................................................................................
catheter ablation vs. MT showed a consistent improvement in symptoms whereas the results on mortality and hospitalization were obtained with a relatively small number of events not permitting to draw definitive conclusions.152,548550,552554,557
12.1.2
Ventricular arrhythmias
Ventricular arrhythmias may be a complication, and in some instances, a cause of HF. Frequent ventricular premature beats (VPBs) may lead to reversible systolic dysfunction. Possible factors may include dyssynchrony and abnormal calcium handling.560
Initial management of ventricular arrhythmias in HF should include correction of potential precipitants (including electrolyte abnormalities, particularly hypo/hyperkalaemia, and pro-arrhythmic drugs) as well as the optimization of HF drug therapy. Although ischaemia may be a triggering factor, revascularization has not been shown to reduce risk of ventricular arrhythmias.561
Amiodarone is effective also for suppression of ventricular arrhythmias. However, it does not reduce the incidence of sudden cardiac death or overall mortality.161 For patients with premature ventricular contraction (PVC)-induced CMP, amiodarone administration may be considered to reduce recurrent arrhythmias and improve symptoms and LV function, although its side effects should be taken into consideration. Other drugs are discussed in
Supplementary text 12.1.
Radiofrequency ablation of VPBs may improve LV function and,
possibly, outcomes in patients with tachycardiomyopathy when VPBs contribute to LV dysfunction.562 A sustained reduction in the baseline
PVC burden has been associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for HF during followup.563,564
12.1.3
Symptomatic bradycardia, pauses and atrioventricular block
Indications for pacemaker therapy do not differ in patients with HF
from those with other CV disease. There is ample evidence that RV
pacing may have an adverse effect on LV systolic function leading, in the long term, to HF.565 Patients with HFrEF requiring frequent ventricular pacing, e.g. with AV block or slow AF, and who have systolic dysfunction, should be implanted with CRT rather than a standard pacemaker to avoid adverse outcomes, as shown in the BLOCK-HF
(Biventricular versus Right Ventricular Pacing in Heart Failure
Patients with Atrioventricular Block) trial.216 In the quest for a more physiological alternative to RV pacing, physiological pacing is being increasingly adopted.566 In a non-randomized comparison of 304 consecutive patients with His bundle pacing and 433 consecutive patients with RV pacing, the former group had less HF hospitalization and a trend in reduced mortality.567 Although the technique is promising,
more data are needed to confirm its role.
12.2 Chronic coronary syndromes
CAD is the most common cause of HF in industrialized, middleincome, and increasingly in low-income, countries. It should be considered as possible cause of HF in all patients presenting with new onset HF.
The diagnostic workup of patients with HF and chronic coronary syndromes (CCS) is reported in the recent 2019 ESC Guidelines on
CCS.5 Patients with HF should be carefully evaluated to assess signs and/or symptoms of CCS. Clinical and family histories, physical examination,
ECG
and imaging tests are recommended.5
Documentation of ischaemia using non-invasive and invasive tests can be difficult in patients with HF because of the possible exercise intolerance and the effects of increased end-diastolic LV pressures.
Coronary angiography or CTCA can be performed to establish the
Recommendations for the treatment of atrial ﬁbrillation in patients with heart failure
Recommendations
Classa
Levelb
Anticoagulation
Long-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and
CHA2DS2-VASc score >_2 in men or >_3 in women.7
I
A
DOACs are recommended in preference to
VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.528,558
I
A
Long-term treatment with an oral anticoagulant should be considered for stroke prevention in
AF patients with a CHA2DS2-VASc score of 1 in men or 2 in women.7,559
IIa
B
Rate control
Beta-blockers should be considered for shortand long-term rate control in patients with HF
and AF.535
IIa
B
Digoxin should be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated.536
IIa
C
Cardioversion
Urgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability.
I
C
Cardioversion may be considered in patients in whom there is an association between AF and worsening of HF symptoms despite optimal medical treatment.7,541
IIb
B
AF catheter ablation
In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.552554,557
IIa
B
AF = atrial ﬁbrillation; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)-
Vascular disease, Age 6574, Sex category (female) (score); DOAC = directacting oral anticoagulant; ECV = electrical cardioversion; HF = heart failure; MT =
medical therapy; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 63 -->

### Page 63

...............................................................
presence and extent of CAD and evaluate the potential indication for revascularization (see section 4.3).5
12.2.1 Medical therapy
Beta-blockers are the mainstay of therapy in patients with HFrEF and
CAD because of their prognostic benefit.116120,568 Ivabradine should be considered as an alternative to beta-blockers (when contraindicated) or as additional anti-anginal therapy in patients in SR whose heart rate is >_70 b.p.m.139,569 Other anti-anginal drugs (e.g. amlodipine,
felodipine, nicorandil, ranolazine, and oral or transdermal nitrates) are effective for treating symptoms, although data about their effects on outcomes are neutral or lacking.5,570574 Trimetazidine seems to have additive effects, such as improvement of LV function and exercise capacity, in patients with HFrEF and CCS already on beta-blockers.575577 Trimetazidine and other anti-anginal drugs may be considered in patients with HF and angina despite beta-blocker and/or ivabradine. Short-acting nitrates should be used with caution in patients with HF as they cause hypotension. Diltiazem and verapamil increase
HF-related events in patients with HFrEF and are contraindicated.578
An algorithm for the use of anti-anginal medications in patients with HFrEF is reported in Figure 15.
Beta-blockers, long-acting nitrates, calcium channel blockers
(CCBs),
ivabradine,
ranolazine,
trimetazidine,
nicorandil and their combinations should be considered in HFpEF for angina relief but without a foreseen benefit on HF and coronary end points.
Low-dose of rivaroxaban [2.5 mg twice daily (b.i.d.)] did not add prognostic benefit in patients with HFrEF and CCS in the
COMMANDER-HF trial, a study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, MI or stroke in participants with HF and CAD following an episode of decompensated HF.579 This trial included patients with HFrEF and a recent episode of worsening HF occurring within 21 days from the time of enrolment. These patients are at high risk of HF-related events and these were the main cause of deaths and hospitalizations in the trial. Rivaroxaban had no effect on these events. In contrast, in a non-pre-specified subgroup analysis of the COMPASS trial, low dose of rivaroxaban, on top of aspirin, was associated with a reduction in ischaemic events in patients with HF, mainly HFmrEF or
HFpEF.580 Based on these data, low-dose rivaroxaban may be considered in patients with CAD (or peripheral artery disease) and
Use of anti-anginal medications in patients with CCS and HFrEF
Beta-blockers
(Class I)
Persistence of
CCS symptoms
In absence of improvement
Trimetazidine
(Class IIb)
Nicorandil
(Class IIb)
OR
OR
OR
Felopidine
(Class IIb)
Ranolazine
(Class IIb)
Nitrates
(Class IIb)
Amlodipine
(Class IIb)
Ivabradine
(Class IIa)
HR <70 bpm, and/or atrial fibrillation
HR ≥70 bpm, and sinus rhythm
Diltiazem (Class III)
Verapamil (Class III)
Figure 15 Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction. CCS =
chronic coronary syndrome; HFrEF= heart failure with reduced ejection fraction; HR= heart rate. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see
Table 1 for further details on classes of recommendation).
ESC Guidelines
3661


<!-- PAGE 64 -->

### Page 64

................................................................
HF, LVEF >40% and SR, when at high risk of stroke and with a low haemorrhagic risk.
12.2.2 Myocardial revascularization
Data on the benefit of myocardial revascularization in patients with
HF are limited.
STICH compared coronary artery bypass grafting (CABG) with
MT in patients with CAD, amenable by CABG, and with reduced LV
function (EF <_35%). At a median follow-up of 56 months, there was no significant difference between the CABG group and the MT group in the rate of death from any cause, primary outcome of the trial.89
The extended follow-up report showed a significant reduction of death in the CABG group vs. the control group (58.9% vs. 66.1%; HR
0.84; 95% CI, 0.730.97; P = 0.02) over 10 years.581 CV death and the combined endpoint of all-cause death or hospitalization for
CV causes were also significantly reduced after CABG at 10 years of follow-up.581 Post hoc analyses of the STICH trial suggested that neither myocardial viability, angina, nor ischaemia were related with outcomes after revascularization.92,93,582 The Heart Failure
Revascularisation Trial (HEART) was under-powered, with only 138
of the planned 800 patients to be enrolled, and failed to show differences in outcomes between HF patients receiving CABG or MT.583
There are currently no reported RCTs comparing percutaneous coronary intervention (PCI) with MT in patients with HFrEF.
However, the REVIVED-BCIS2 trial has finished recruitment
(ClinicalTrials.gov Identifier: NCT01920048).584 There are also no randomized studies comparing PCI with CABG as such randomized trials excluded patients with HFrEF. In one prospective registry,
including 4616 patients with multivessel disease and HFrEF,
propensity-score matched comparisons showed similar survival
(mean follow-up 2.9 years) in PCI vs. CABG group with PCIs associated with a higher risk of MI, particularly in patients with incomplete revascularization, and CABG associated with a higher risk of stroke.585 A propensity-matched analysis showed a significantly lower risk of death or major CV events in diabetic patients with LV
dysfunction and multivessel disease treated with CABG compared with PCI.586 CABG was associated with better outcome than PCI
also in patients with moderate or severe LV dysfunction and left main or complex coronary disease.587,588 Two meta-analyses confirmed that CABG is associated with better outcomes, including mortality,
MI,
and repeated revascularization,
compared with
PCI
and/or MT.589,590
12.3 Valvular heart disease
12.3.1
Aortic stenosis
Aortic stenosis may cause or worsen HF by increasing LV afterload and causing LV hypertrophy and remodelling.591 When HF symptoms occur in patients with severe aortic stenosis, prognosis is extremely poor. No MT for aortic stenosis can improve outcomes.
HF medical treatment should be given to all HF patients with symptomatic severe aortic stenosis. Care must be taken using vasodilators to avoid hypotension. Importantly, possible improvement of symptoms after MT should not delay intervention.
In the presence of suspected symptomatic and severe highgradient aortic stenosis (valve area <_1 cm2, mean gradient >_40
mmHg), other causes of high flow status must be excluded and corrected (i.e. anaemia, hyperthyroidism, arteriovenous shunts)
before proceeding to aortic valve intervention.592 An aortic valve intervention is recommended in patients with HF symptoms and severe,
high-gradient aortic stenosis,
regardless of
LVEF.
Management of patients with low-flow low-gradient aortic stenosis is reported in Figure 16.592
Intervention is recommended in patients with a life expectancy >1
year, avoiding futility. Transcatheter aortic valve implantation (TAVI)
has been shown to be non-inferior to surgical aortic valve replacement (SAVR) in reducing clinical events (including mortality and disabling stroke) in patients at high and intermediate risk for surgery.593600 In low-risk patients, mean age in the RCTs comparing
TAVI and SAVR was >70 years and follow-up was restricted to
2 years. Therefore, SAVR is recommended in patients aged <75 years and at low surgical risk (STS-PROM score or EuroSCORE II <4%),
whereas TAVI is recommended in those aged >75 years or at high/
prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR should be made by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient preference and other features including clinical and anatomical aspects. Aortic
Recommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction
Recommendations
Classa
Levelb
CABG should be considered as the ﬁrst-choice revascularization strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease.581,587,588,590
IIa
B
Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS,
and coronary anatomy suitable for revascularization, despite OMT including anti-anginal drugs.
IIa
C
In LVAD candidates needing coronary revascularization, CABG should be avoided, if possible.
IIa
C
Coronary revascularization may be considered to improve outcomes in patients with HFrEF,
CCS, and coronary anatomy suitable for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal LAD),
comorbidities, life expectancy, and patient’s perspectives.
IIb
C
PCI may be considered as an alternative to
CABG, based on Heart Team evaluation, considering coronary anatomy, comorbidities, and surgical risk.
IIb
C
CABG = coronary artery bypass graft; CCS = chronic coronary syndrome; HFrEF
= heart failure with reduced ejection fraction; LAD = left anterior descending artery; LVAD = left ventricular assist device; OMT = optimal medical therapy; PCI
= percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.....................................................................................................................


<!-- PAGE 65 -->

### Page 65

.........
valve interventions should be performed only in centres having both interventional cardiology and cardiac surgery services on site and a structured collaborative Heart Team approach.
Balloon aortic valvuloplasty may be considered in highly symptomatic patients with AHF (i.e. cardiogenic shock) as bridge to TAVI or
SAVR, or in advanced HF as BTR or DT.
Management of patients with heart failure and suspected severe low-flow low-gradient ASa
Dobutamine echo
LVEF < 50%
OR
TAVI
(Class I)
SAVR
(Class I)
Y
N
Flow reservec
Clinical and echo criteriab
High calcium scored by CT
Y
Severe low-flow 
low-gradient AS
N
Medical therapy optimization
(Class I)
Heart Teamg
(Class I)
Heart Teamg
(Class I)
Follow-up
Y
f
N
e
Y
f
OR
TAVI
(Class IIa)
SAVR
(Class IIa)
N
Y
Y
Figure 16 Management of patients with severe low-flow low-gradient aortic stenosis and heart failure. AS= aortic stenosis; CT = computed tomography; EuroSCORE II= European System for Cardiac Operative Risk Evaluation II; LVEF= left ventricular ejection fraction; OMT = optimal medical therapy;
SAVR= surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI= transcatheter aortic valve implantation. aValve area <_1 cm2, peak velocity <4.0 m/s, mean gradient <40; stroke volume index <_35 mL/m2. bAge >70 years, typical symptoms without other explanations, left ventricular hypertrophy or reduced left ventricular longitudinal function, mean gradient 3040 mmHg, valve area <_0.8 cm2, stroke volume index <_35 mL/m2 assessed by techniques other than standard Doppler. cFlow reserve is defined as stroke volume index increase >20%. dAS is very likely if calcium score is >_3000 in men and >_1600 in women. AS is likely if calcium score is >_2000 in men and >_1200 in women. AS is unlikely if calcium score is <1600 in men and <800 in women. eIncrease in valve area to >1.0 cm2 in response to flow increase (flow reserve) during dobutamine echo.
fIncrease in mean gradient to at least 40 mmHg without significant change in valve area in response to flow increase (flow reserve) during dobutamine echo. gSAVR is recommended in patients aged <75 years and low surgical risk (STS-PROM score or EuroSCORE II <4%), whereas TAVI in those aged
>75 years or at high/prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR is recommended to be decided by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient preference and features including clinical and anatomical aspects. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for
Class of recommendation IIa (see Table 1 for further details on classes of recommendation).
ESC Guidelines
3663


<!-- PAGE 66 -->

### Page 66

...........................
12.3.2
Aortic regurgitation
Severe aortic regurgitation can lead to progressive LV dilation with subsequent dysfunction, HF, and poor prognosis.
MT can improve HF symptoms in patients with severe aortic regurgitation. In particular, inhibitors of the RAAS can be useful.601
Beta-blockers should be cautiously used as they prolong diastole and may worsen aortic regurgitation.
Aortic valve surgery is recommended in patients with severe aortic regurgitation and HF symptoms regardless of LVEF.592,602,603 In case of high or prohibitive surgical risk, TAVI has been used to treat also aortic regurgitation.604
12.3.3
Mitral regurgitation
Primary (organic) mitral regurgitation
Primary mitral regurgitation (MR) is caused by abnormalities of the valve apparatus and can cause HF.
Surgery, preferably repair, is recommended in patients with severe primary MR and HF symptoms. If surgery is contraindicated
Management of secondary mitral regurgitation in patients with HFrEF
PCI
(Class IIb)
CABG and mitral valve surgery
(Class IIa)
Heart Team
(Class I)
Need for coronary revascularization
OMT including CRT
if indicated
Y
N
Y
High surgical risk
Persistence of HF symptomsa and significant SMRb
N
MT optimization and implant CRT if indicated
(Class I)
Y
N
N
Y
Consider surgery if low-risk
(Class IIb)
Percutaneous EE
mitral valve repair
(Class IIa)
Consider percutaneous
EE mitral valve repair to improve symptoms or as BTT or to LVAD
(Class IIb)
Maintain ongoing therapy.
Consider palliative care and/or MCS or HT,
if possible
HeartTeam
(Class I)
Follow-up
Echocardiographic and clinical criteria for outcome improvement after percutaneous EE mitral valve repairc
N
Y
Figure 17 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. BTT= bridge to transplantation;
CABG= coronary artery bypass graft; CRT = cardiac resynchronization therapy; EE= edge-to-edge; EROA= effective regurgitant orifice area; HF= heart failure; LVAD= left ventricular assist device; LVEF= left ventricular ejection fraction; LVESD=left ventricular end-systolic diameter; MCS= mechanical circulatory support; MT =medical therapy; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI= percutaneous coronary intervention; SMR= secondary mitral regurgitation; TR= tricuspid regurgitation. aNYHA class IIIV. bModerate-to-severe or severe (EROA >_30 mm2). cAll of the following criteria must be fulfilled: LVEF 2050%, LVESD <70 mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability.612 Colour code for classes of recommendation: Green for Class of recommendation I;
Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb (see Table 1 for further details on classes of recommendation).


<!-- PAGE 67 -->

### Page 67

......................................
or considered at high risk, then percutaneous repair may be considered.592,605
Secondary (functional) mitral regurgitation
Secondary mitral regurgitation (SMR) is mostly a disease of the left ventricle. It can also be caused by mitral annulus enlargement due to LA dilation.606 Moderate or severe SMR is associated with an extremely poor prognosis in patients with HF.607,608 The assessment of MR aetiology and severity should be performed by an experienced echocardiographer applying a
multi-parametric approach, and ideally in stable patient conditions, after optimization of medical and resynchronization therapies. Being SMR a dynamic condition, echocardiographic quantification during exercise may be helpful in patients with moderate SMR at rest and symptoms during physical activity.609 Early referral of patients with HF and moderate or severe MR to a multidisciplinary Heart Team, including HF specialists, is recommended for assessment and treatment planning.
The Heart Team has to verify, first of all, that the patient is on optimal therapy, including CRT, when indicated (Figure 17).
In patients with severe SMR and HFrEF requiring revascularization,
mitral valve surgery and CABG should be considered. Isolated mitral valve surgery may be considered in symptomatic patients with severe
SMR despite optimal therapy and low surgical risk.592
Two randomized trials, MITRA-FR and COAPT, evaluated the effectiveness of percutaneous edge-to-edge mitral valve repair plus
OMT compared to OMT alone, in symptomatic patients with reduced LVEF (1540% in MITRA-FR and 2050% in COAPT) and moderate-to-severe or severe SMR [effective regurgitant orifice area
(EROA) >_ 20 mm2 in MITRA-FR and EROA >_ 30 mm2 in
COAPT].610612 MITRA-FR failed to show any benefit from the intervention on all-cause mortality or HF hospitalization at 12
months (primary endpoint; HR 1.16, 95% CI 0.731.84) and at 24
months.610,611 In contrast, COAPT showed a significant reduction in hospitalization for HF at 24 months (primary endpoint; HR 0.53, 95%
CI 0.400.70) and mortality (secondary endpoint; HR 0.62, 95% CI
0.460.82).612 Differences in patient selection, concomitant MT,
echocardiographic assessment, procedural issues and severity of
SMR in relation to the degree of LV dilatation may be responsible for the diverging results of the MITRA-FR and COAPT trials.613615
Thus, percutaneous edge-to-edge mitral valve repair should be considered for outcome improvement only in carefully selected patients who remain symptomatic (NYHA class IIIV) despite OMT, with moderate-to-severe or severe SMR (EROA >_30 mm2), favourable anatomical conditions, and fulfilling the inclusion criteria of the
COAPT study (i.e. LVEF 2050%, LV end-systolic diameter <70
mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe RV dysfunction, absence of severe TR, absence of haemodynamic instability) (Figure 17).615,616
Percutaneous edge-to-to edge mitral valve repair may also be considered to improve symptoms in patients with advanced HF,
severe SMR and severe symptoms despite OMT. In these patients,
cardiac transplantation or LVAD implantation must also be considered.376,617
Other percutaneous mitral valve repair systems, such as indirect annuloplasty, are available for treatment of SMR. This approach has a shorter learning curve and lesser technical requirements than percutaneous edge-to-to edge mitral valve repair and does not preclude different procedures once it is performed. A sham-controlled randomized trial testing a transcatheter indirect mitral annuloplasty device met its primary endpoint of mitral regurgitant volume reduction with reverse LV and LA remodelling at 12 months.618 Further studies confirmed favourable results on LA volumes and LV remodelling with trends towards improvement in mean 6MWT distance and symptoms and a reduction in HF hospitalizations in an IPD meta-analysis.619622 Transcatheter mitral valve replacement is also emerging as a possible alternative option, but randomized trials are still lacking.623
Mitral valve interventions are not recommended in patients with a life expectancy of <1 year due to extra-cardiac conditions.592
Recommendations for the management of valvular heart disease in patients with heart failure
Recommendations
Classa
Levelb
Aortic stenosis
Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe highgradient aortic stenosis to reduce mortality and improve symptoms.594
I
B
It is recommended that the choice between
TAVI and SAVR be made by the Heart Team,
according to individual patient preference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.592
I
C
Secondary mitral regurgitation
Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomaticc despite
OMT and who fulﬁl criteriad for achieving a reduction in HF hospitalizations.612
IIa
B
In patients with HF, severe secondary mitral regurgitation and CAD who need revascularization, CABG and mitral valve surgery should be considered.
IIa
C
Percutaneous edge-to-edge mitral valve repair may be considered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.617
IIb
C
CABG = coronary artery bypass graft; CAD = coronary artery disease; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter;
NYHA = New York Heart Association; OMT = optimal medical therapy; SAVR =
surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation;
TR = tricuspid regurgitation.
aClass of recommendation.
bLevel of evidence.
cNYHA class IIIV.
dAll of the following criteria must be fulﬁlled: LVEF 2050%, LVESD <70 mm,
systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability.612
ESC 2021
.......................................................................................................................................
ESC Guidelines
3665


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
12.3.4
Tricuspid regurgitation
Tricuspid regurgitation (TR) can be caused by or be a consequence of RV dysfunction and HF. The management of HF with TR includes
MT (i.e. diuretics, neurohormonal antagonists). Transcatheter therapy and surgery may be considered in selected cases.592 A multidisciplinary Heart Team, including HF specialists, should be considered for assessment and treatment planning.
Tricuspid valve surgery is recommended in patients with severe
TR requiring left-sided cardiac surgery. It should be also considered in patients with moderate TR and tricuspid annulus dilatation requiring left-sided cardiac surgery and in symptomatic patients with isolated severe TR.592 However, surgery in isolated TR is burdened by high in-hospital mortality (8.8%) although the advanced stage of HF
may have influenced these data.624 Transcatheter techniques have recently emerged as potential treatment options of TR. Preliminary results show improvement in TR severity and symptoms with low complication rates.625 Further prospective studies are needed to show the prognostic impact of these treatments in HF patients.
12.4 Hypertension
Arterial hypertension is a leading risk factor for the development of
HF. Almost two-thirds of HF patients have a past history of hypertension.104,626 Clinical trials evaluating antihypertensive strategies and BP
targets in patients with HF and hypertension have not been performed.
Treatment of HFrEF is similar in hypertensive and normotensive patients. Recommended medications, including neurohormonal antagonists and diuretics, lower also BP. Lifestyle modifications, such as weight loss, reduced sodium intake, and increased physical activity,
are useful adjunctive measures.4 Uncontrolled hypertension in patients with HFrEF is rare, provided the patient is receiving OMT at recommended doses for HF. If further BP lowering is required, in absence of signs of fluid overload, amlodipine and felodipine have been shown to be safe in HFrEF and may be considered.570,571 Nondihydropyridine CCBs (diltiazem and verapamil) and centrally acting agents, such as moxonidine, are contraindicated as they are associated with worse outcomes.627 Alpha-blockers have no effects on survival and are therefore not indicated.143 They can be used for the treatment of concomitant prostatic hyperplasia but should be withdrawn in cases of hypotension.
Hypertension is the most important cause of HFpEF, with a prevalence of 60% to 89%.39 Patients with HFpEF also frequently have an exaggerated hypertensive response to exercise and may present with hypertensive acute pulmonary oedema.628,629 Antihypertensive agents, including ACE-I, ARBs, beta-blockers, CCB, and diuretics reduce the incidence of HF.630,631 Reducing BP leads also to LVH
regression, the degree of which depends on the class of drug used.4
ARBs, ACE-I, and CCBs cause more effective LVH regression than beta-blockers or diuretics.632 Poorly controlled hypertension may precipitate episodes of decompensation. Causes of secondary hypertension, such as renal vascular or parenchymal disease, primary aldosteronism and obstructive sleep apnoea (OSA), should be ruled out or, if confirmed, considered for treatment. Treatment of hypertension is an important issue in patients with HFpEF, but the optimal treatment strategy is uncertain. The treatment strategy used in
HFrEF should also be considered in HFpEF.4
BP targets are uncertain in both HFrEF and HFpEF. However, evaluation of patient’s age and comorbidities (i.e. diabetes, CKD, CAD,
valvular heart disease and stroke) can be helpful to personalize the
BP target.4 Every effort should be made to reach target doses of evidence-based medications in HFrEF patients, despite slight hypotension.4,633 Conversely, in HFpEF patients with LVH and limited preload reserve, hypotension should be avoided.
12.5 Stroke
HF and stroke frequently coexist because of an overlap of shared risk factors and subsequent mechanisms.519,634 A higher risk of stroke is present also in HF patients in SR.39,426,635637 AF confers an additional risk and patients with HF and AF have a five-fold increased risk compared to the control population.519,634,638
As a temporal trend, the incidence of stroke is higher in the first
30 days after HF diagnosis or an episode of HF decompensation and decreases in the first 6 months following the acute event.637,639
Patients with stroke and HF have higher mortality, more severe neurological deficits and longer hospital stays than those without
HF.637,640 Similarly, patients with HF and stroke have a higher mortality than patients without stroke.640 In COMMANDER-HF, 47.5% of strokes were either disabling, 16.5%, or fatal, 31%.637
Patients with HF and concomitant AF, including paroxysmal AF,
have a CHA2DS2-VASc score of at least 1 and have therefore an indication to anticoagulation. The indication to antithrombotic strategies in patients with HF and SR is controversial. In the Warfarin and
Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, warfarin reduced ischaemic stroke as compared with aspirin, but increased major haemorrhages and did not influence the primary endpoint of ischaemic stroke, intracerebral haemorrhage, or death.641 Meta-analyses confirm an increased risk of bleeding outweighing ischaemic stroke prevention in placebo-controlled trials in patients with HFrEF and SR.642 In COMMANDER-HF, rivaroxaban
2.5 mg b.i.d. did not improve the composite outcome of all-cause mortality, MI or stroke, nor did it favourably influence HF-related deaths or HF hospitalizations.579 There are no data to support a routine strategy of anticoagulation in patients with HFrEF in SR who do not have history of paroxysmal AF. However, low-dose rivaroxaban may be considered in patients with concomitant CCS or peripheral artery disease, a high risk of stroke and no major haemorrhagic risk
(see section 12.2).
Patients with visible intraventricular thrombus or at high thrombotic risk, such as those with history of peripheral embolism or some patients with PPCM or LV non-compaction (LVNC), should be considered for anticoagulation.3,643645
13 Non-cardiovascular comorbidities
13.1 Diabetes
Treatment of HF is similar in patients with and without diabetes.6,646
Conversely, antidiabetic drugs differ in their effects in patients with
HF and preference must be given to drugs that are both safe and reduce HF-related events.6,646,647


<!-- PAGE 69 -->

### Page 69

.............................................................................................
The SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin,
ertugliflozin and sotagliflozin were studied in patients with established
CV disease in the EMPA-REG OUTCOME and VERTIS-CV trials,
with established CV disease or CV risk factors in the CANVAS and
DECLARE-TIMI 58 trials, and with CKD and CV risk in the SCORED
trial, respectively.293297 A small proportion of patients had a history of HF. Empagliflozin and canagliflozin reduced the primary composite endpoint of major CV adverse events, including CV death or nonfatal MI or non-fatal stroke, and HF hospitalizations in EMPA-REG
OUTCOME and CANVAS, respectively.293,294 Empagliflozin also reduced all-cause death or CV death alone.293 The effects on the primary endpoint were driven by the reduction in HF-related events.293,294 In DECLARE-TIMI 58, dapagliflozin did not reduce major CV events but reduced the co-primary efficacy endpoint of CV
death or HF hospitalization and HF hospitalization alone.295 In
VERTIS-CV, neither the primary major CV event endpoint nor the key secondary outcome of CV death or HF hospitalization were reduced significantly by ertugliflozin, although there was a statistically significant reduction in HF hospitalization and repeated hospitalizations.297,648 In SCORED, sotagliflozin reduced CV deaths and HF
hospitalizations.296 In a meta-analysis of these trials and one further trial in patients with CKD (CREDENCE), overall SGLT2 inhibitors reduced HF and CV hospitalization by 22%.649 SGLT2 inhibitors were well tolerated, although they may cause genital fungal skin infections and, rarely, diabetic ketoacidosis.293295 Trial results with dapagliflozin and empagliflozin in patients with HFrEF, with or without diabetes, and with the SGLT1/2 inhibitor sotagliflozin in patients with type 2 diabetes stabilized after hospitalization for acute HF or within
3 days after discharge, further support the administration of these agents (see section 5.3.5 and section 11.3.11).108,109,136
EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and
VERTIS-CV also showed a reduction in worsening renal function,
end-stage renal disease or death from renal causes, with SGLT2
inhibitors.
Based on these results, the SGLT inhibitors canagliflozin, dapagliflozin, empagliflozin, ertugliflozin or sotagliflozin are recommended to prevent HF and CV death and worsening kidney function in patients with type 2 diabetes and CV disease and/or CV risk factors,
or CKD. Dapagliflozin and empagliflozin are also indicated for the treatment of patients with type 2 diabetes and HFrEF (see section 5.3.5 and section 11.2.4) and sotagliflozin was shown to reduce CV deaths and HF rehospitalizations in patients recently hospitalized for HF.6,296,646,647,650
Metformin is thought to be safe in patients with HF, compared with insulin and sulfonylureas, based on observational studies.651,652
However, it is not recommended in patients with an eGFR <30 mL/
min/1.73 m2 or hepatic impairment because of the risk of lactic acidosis. It has not been studied in controlled outcome trials, to date.6,646
Regarding dipeptidyl peptidase-4 (DPP-4) inhibitors, HF hospitalizations were increased by 27% in one trial with saxagliptin in patients with diabetes.653 However, no difference over placebo for HF events was found with alogliptin, sitagliptin, and linagliptin.654656 Vidagliptin was associated with an increase in LV volumes and a numerically greater number of deaths and CV events in a small trial in patients with diabetes and HF.657 Overall, the effects on mortality or CV
events were neutral in the DPP-4 inhibitor trials and metaanalyses.658,659 These drugs are therefore not recommended to reduce CV events in diabetic patients with HF.
Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of MI, stroke, and CV death in patients with diabetes, although probably do not reduce incident HF.6,660 Liraglutide had no effect on
LVEF, increased heart rate, and increased serious cardiac events in a randomized placebo-controlled trial in 241 patients with HFrEF with and without diabetes.661 Neutral results on the primary endpoint were found in another trial in 300 patients with a numerical increase in deaths and HF hospitalizations, compared with placebo.662 GLP-1
receptor agonists are therefore not recommended for the prevention of HF events.
Insulin is needed in patients with type 1 diabetes and to control hyperglycaemia in some patients with type 2 diabetes, especially when beta-cell function is exhausted. It is a sodium-retaining hormone and concern has been raised that it may exacerbate fluid retention in patients with HF. However, in a RCT that included patients with type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose, insulin did not increase the risk of incident HF.663 Use of insulin was associated with poorer outcomes in retrospective analyses of randomized trials and administrative databases.664,665 If insulin is needed in a patient with HF, the patient should be monitored for evidence of worsening of HF after treatment initiation.
Sulfonylureas were associated with a higher risk of HF events in some analyses.666,667 Therefore, they are not a preferred treatment in patients with HF and, if needed, patients should be monitored for evidence of worsening of HF after treatment initiation.6,646
Thiazolidinediones (glitazones) cause sodium and water retention and an increased risk of worsening HF and hospitalization.668 They are contraindicated in patients with HF.
13.2 Thyroid disorders
Assessment of thyroid function is recommended in all patients with HF
as both hypo- and hyperthyroidism may cause or precipitate HF.669
Subclinical hypothyroidism and isolated low triiodothyronine levels
Recommendations for the treatment of diabetes in heart failure
Recommendation
Classa
Levelb
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,
empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV
events to reduce hospitalizations for HF, major
CV events, end-stage renal dysfunction, and CV
death.293297
I
A
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin,
and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.108,109,136
I
A
CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.............................................................................
ESC Guidelines
3667


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
were associated with poorer outcomes in observational studies in patients with HF.670,671 Treatment of thyroid disorders should be guided by general endocrine guidelines. There are no randomized trials evaluating the efficacy of thyroid replacement therapy in subclinical hypothyroidism, but there is a general agreement to correct it when the TSH is >10 mIU/L, particularly in patients <70 years. Correction may also be considered at lower TSH levels (710 mIU/L).672674
13.3 Obesity
Obesity is a risk factor for hypertension and CAD and is also associated with an increased risk of HF. There is possibly a stronger association with HFpEF.258,675677 Once obese patients have HF, an obesity paradox has been described such that overweight or mildly/moderately obese patients have a better prognosis than leaner patients, particularly compared with those who are underweight.678,679 However,
other variables may influence this relationship and the obesity paradox is not observed in patients with diabetes.680,681 Second, BMI
does not take into account body composition, e.g. the relation between lean skeletal muscle mass and fat mass. Obese patients who are fit and have a preserved skeletal muscle mass have better prognosis than obese sarcopenic patients.682 Waist circumference or the waist-to-hip ratio, measuring visceral obesity, is less influenced by muscle mass and may have a stronger relationship with outcomes than BMI, especially in female patients.683,684
Body fat has a major impact on the diagnostic and prognostic value of multiple parameters. Obese patients with HF have lower NP concentrations due to increased expression of clearance receptors and augmented peptide degradation by the adipose tissue.74 Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients and an adjustment for lean body mass should be used for risk stratification.96
Obesity may be a major cause of HFpEF and obese HFpEF patients display several pathophysiologic mechanisms that differ from nonobese patients with HFpEF.258,675677,685 Caloric restriction and exercise training had additive beneficial effects on exercise capacity and QOL of patients with obesity and HFpEF in a randomized trial.337
13.4 Frailty, cachexia, sarcopenia
Frailty is a multidimensional dynamic state, independent of age, that makes the individual more vulnerable to the effect of stressors.686 HF
and frailty are two distinct yet commonly associated conditions. The assessment of frailty in patients with HF is crucial as it is associated with both unfavourable outcomes and reduced access to, and tolerance of, treatments. Several tools have been proposed for frailty screening and assessment in different chronic conditions, including HF.
The HFA of ESC has developed a HF-specific tool based on four major domains, clinical, psycho-cognitive, functional, and social.686
Frailty is more prevalent in patients with HF than in the general population and may occur in up to 45% of the patients, according to a recent meta-analysis.687,688 Patients with HF are up to six times more likely to be frail, and frail people have a significantly increased risk of developing HF.689,690 Frailty is associated with a higher risk of death,
hospitalizations, and functional decline as well as with a longer duration of hospital stay.691693 The treatment of frailty in HF should be multifactorial and targeted to its main components and may include physical rehabilitation with exercise training, nutritional supplementation as well as an individualized approach to treating comorbidities.686
Cachexia is defined as a ‘complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass’.694 Its major clinical feature is a >5%
oedema-free body weight loss during the previous 12 months or less.694,695 Cachexia is a generalized wasting process that may coexist with frailty and may occur in 515% of patients with HF, especially those with HFrEF and more advanced disease status. It is associated with reduced functional capacity and decreased survival.695698 As it is associated with other chronic diseases, such as cancer, alternative,
non-cardiac causes for cachexia should always be investigated.699
Sarcopenia is defined by the presence of low muscle mass together with low muscle function, strength, or performance.698 It is usually identified by an appendicular skeletal muscle mass, defined as the sum of the muscle mass of the four limbs, 2 standard deviation below the mean of a healthy reference group aged 1840years with a cut-off value of 7.26 kg/m2 for men.688,700,701 It occurs physiologically with aging. However, it is accelerated by chronic diseases, such as cancer and HF. Sarcopenia can be found in 2050% of patients with HFrEF
and is often associated with frailty and increased morbidity and mortality. It is a major determinant of outcomes outweighing the effect of body weight and BMI.684,698,701,702 So far, the most effective strategy for sarcopenia treatment is resistance exercise training, possibly combined with a protein intake of 11.5 g/kg/day.698,703 Drug treatments,
including anabolic compounds like testosterone, growth hormone,
ghrelin receptor agonists, were tested in small studies, showing favourable results mostly in terms of exercise capacity and muscle strength.697,703705 There are no data showing a favourable impact of sarcopenia treatment on outcomes. However, exercise training has favourable effects in patients with HF (see section 9.4).95,323329
13.5 Iron deficiency and anaemia
Iron deficiency and anaemia are common in patients with HF, being independently associated with reduced exercise capacity, recurrent
HF hospitalizations, and high CV and all-cause mortality.706,707
According to the World Health Organization criteria, anaemia is defined as a haemoglobin concentration <12 g/dL in women and
<13 g/dL in men. In patients with HF, iron deficiency is defined as either a serum ferritin concentration <100 ng/mL or 100299 ng/
mL with transferrin saturation (TSAT) <20%.708710 Ferritin tissue expression and concentration in the peripheral blood is increased by inflammation and several disorders such as infection, cancer, liver disease, and HF itself. Hence, higher cut-off values have been applied for the definition of iron deficiency in patients with HF.709711 Another marker reflecting depleted intracellular iron can be high serum soluble transferrin receptors, which derives from proteolysis of the membrane transferrin receptor. Its synthesis is increased in case of iron deficiency and is not affected by inflammation. High serum soluble transferrin receptors identify patients at high risk of death beyond standard prognostic variables.711,712 However, its applicability for iron supplementation therapy has not been demonstrated yet.
Iron deficiency, which can be present independently of anaemia, is present in up to 55% of chronic HF patients and in up to 80% of those with AHF.713716 It may be caused by increased loss, reduced intake or absorption (i.e. malnutrition, gut congestion) and/or impaired iron metabolism caused by the chronic inflammatory activation of HF,
although the exact cause of iron deficiency in HF remains unknown.
Iron deficiency may impair functional capacity, precipitate circulatory


<!-- PAGE 71 -->

### Page 71

..........................................................................................................................................................................
decompensation, promote skeletal muscle dysfunction, and is associated with frailty, irrespective of anaemia.716718
It is recommended that all patients with HF are regularly screened for anaemia and iron deficiency with full blood count, serum ferritin concentration, and TSAT. The detection of anaemia and/or iron deficiency should prompt appropriate investigation to define their cause.
Darbepoetin-alpha failed to reduce all-cause death or HF hospitalization and increased the risk of thromboembolic events in the only large-scale randomized trial in patients with HFrEF and mild to moderate anaemia.719 As a result, erythropoietin stimulating agents are not indicated for the treatment of anaemia in HF.
RCTs have shown that iron supplementation with i.v. ferric carboxymaltose is safe and improves symptoms, exercise capacity, and
QOL of patients with HFrEF and iron deficiency.720723 Metaanalyses of RCTs showed also a reduction in the risk of the combined endpoints of all-cause death or CV hospitalization, CV death or HF
hospitalization, CV death or recurrent CV or HF hospitalizations.724,725 The favourable effects of iron supplementation were independent from anaemia coexistence.726 In AFFIRM-AHF, patients hospitalized for HF with LVEF <50% and concomitant iron deficiency were randomized to i.v. ferric carboxymaltose or placebo, repeated at 6- and then 12-week intervals if indicated according to repeat iron studies.512 Administration of ferric carboxymaltose did not significantly reduce the primary composite outcome of total HF hospitalizations and CV death at 52 weeks (rate ratio 0.79, 95% CI
0.621.01, P = 0.059). However, it reduced the composite endpoint of first HF hospitalization or CV death (HR 0.80, 95% CI 0.660.98,
P = 0.030) and total HF hospitalizations (rate ratio 0.74, 95% CI
0.580.94, P = 0.013).512 Therefore, iron supplementation with i.v.
ferric carboxymaltose should be considered for the improvement of symptoms, exercise capacity, and QOL in patients with HF and LVEF
<45%. It should also be considered for the reduction of HF rehospitalizations in patients with LVEF <50% recently hospitalized for worsening HF. Ongoing trials are expected to provide more evidence on the effects of ferric carboxymaltose in patients with HFpEF. In addition, large outcomes trials with other iron formulations are ongoing in HFrEF, HFpEF, and AHF.727 Oral iron therapy is not effective in iron repletion and did not improve exercise capacity in patients with
HFrEF and iron deficiency.728 It is therefore not recommended for the treatment of iron deficiency in the patients with HF.
13.6 Kidney dysfunction
CKD and HF frequently coexist.471,707,729 They share common risk factors, such as diabetes or hypertension. CKD may worsen CV function causing hypertension and vascular calcification. HF may worsen renal function, through the effects of neurohormonal and inflammatory activation, increased venous pressure and hypoperfusion.
Oxidative stress and fibrosis likely play a major role as pathogenic mechanisms in HF with CKD.730,731
While CKD and worsening renal function both appear more common in HFpEF as compared to in HFmrEF and HFrEF, perhaps due to shared pathophysiological mechanisms, they appear to be less associated with worse outcomes in HFpEF than in HFmrEF and
HFrEF.732,733
CKD is a major independent determinant of increased mortality and morbidity in HF.471,734736 However, there are settings in which changes in serum creatinine are not associated with worse outcomes.
When RAAS inhibitors, ARNI or SGLT2 inhibitors are started, the initial decrease in the glomerular filtration pressure may decrease GFR
and increase serum creatinine. However, these changes are generally transient and occur despite improvement in patient outcomes and slower worsening of renal function in the long term. For instance, in
EMPEROR-Reduced, the placebo-corrected eGFR dip induced by empagliflozin at week 4 was of 2.4 mL/min/1.73 m2 for patients with
CKD and 2.7 mL/min/1.73 m2 for those without CKD, corresponding to a decrease from baseline of 5.2% and 3.8%, respectively. This was followed by a slower slope of eGFR decline and by a reduced rate of the composite kidney outcome with empagliflozin vs. placebo, with no difference between patients with or without CKD at baseline.109,737
Thus, with respect to the initiation of RAAS inhibitors, ARNI or
SGLT2 inhibitors, a transient decrease in renal function should not prompt their interruption. An increase in serum creatinine of <50%
above baseline, as long as it is <266 lmol/L (3 mg/dL), or a decrease in eGFR of <10% from baseline, as long as eGFR is >25 mL/min/1.73 m2,
can be considered as acceptable (see section 5.3 and Supplementary
Table 8). Also, with respect to diuretic therapy, small and transient rises in serum creatinine during treatment of acute HF are not associated with poorer outcomes when the patient is free of congestion.108,109,460462,471,729,737740
Randomized trials have shown that patients with HF and concomitant CKD are at higher risk of events but the beneficial effects of MT
Recommendations for the management of anaemia and iron deﬁciency in patients with heart failure
Recommendations
Classa
Levelb
It is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count, serum ferritin concentration, and TSAT.
I
C
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL with TSAT
<20%, to alleviate HF symptoms, improve exercise capacity and QOL.720,722,724
IIa
A
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic HF patients recently hospitalized for HF
and with LVEF <50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin
100299 ng/mL with TSAT <20%, to reduce the risk of HF hospitalization.512
IIa
B
HF = heart failure; LVEF = left ventricular ejection fraction; QOL = quality of life;
TSAT = transferrin saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3669


<!-- PAGE 72 -->

### Page 72

.......................................................................................................................................................................
are similar, if not greater, than in the patients with normal renal function.206,471,741,742 Beta-blockers reduce mortality in HFrEF patients with moderate (eGFR 4559 mL/min/1.73 m2) and moderately severe (eGFR 3044 mL/min/1.73 m2) renal dysfunction, whereas limited evidence is available regarding patients with severe renal impairment (eGFR <30 mL/min/1.73 m2).743 Sacubitril/valsartan,
compared with enalapril, led to a slower decline in renal function,
despite a slight increase in the urinary albumin/creatinine ratio, and improved CV outcomes to a similar extent in patients with CKD vs.
the others in PARADIGM-HF.127 SGLT2 inhibitors lead to a slower decline in renal function, compared with placebo, both in patients with HFrEF and in those with CKD.108,109,737,738,744 The improvement in cardiac output after CRT or LVAD implantation may be associated with, at least, a transient improvement in renal function.471,745,746 The benefits of ICDs may be reduced in patients with severe renal dysfunction because of the competing risk of nonarrhythmic causes of death.747749
There is little direct evidence to support any recommendations for treatment of HF patients with severe CKD as to date, RCTs excluded patients with advanced stages of CKD, i.e. eGFR <30 mL/
min/1.73 m2 (Supplementary Table 23). Cut-off values for inclusion were lower in recent trials: 25 mL/min/1.73 m2 in DAPA-CKD,
20 mL/min/1.73 m2 in EMPEROR-Reduced and GALACTIC-HF, and
15 mL/min/1.73 m2 in VICTORIA, respectively.109,141,737,738,750
Despite differences in baseline characteristics between patients with severely impaired renal function and the others, no interaction between drug effects and renal function was noted in subgroup analysis of these trials.109,141,738,750
13.7 Electrolyte disorders:
hypokalaemia, hyperkalaemia,
hyponatraemia, hypochloraemia
Electrolyte disturbances are frequent in patients with HF and may often be iatrogenic.751 Serum potassium levels have a U-shaped relation with mortality with the lowest risk of death within a relatively narrow range of 4 to 5 mmol/L.752758
Hypokalaemia is defined as serum potassium <3.5 mmol/L and may occur in up to 50% of patients with HF.759 Hypokalaemia is often induced by loop and thiazide diuretic administration. It may cause lethal ventricular arrhythmias and increase CV mortality. Its treatment includes the use of RAAS inhibitors, potassium-sparing diuretics, and prescription of oral potassium supplements (i.e. potassium chloride tablets). When oral administration is not possible, potassium supplementation by infusion may be necessary (20 to 40 mmol of potassium in 2501000 mL of normal saline). Potassium-rich solution should be infused at slow rate through a large vein using a venous catheter.
Hyperkalaemia is defined as serum potassium >5 mmol/L and can be classified as mild (>5.0 to <5.5 mmol/L), moderate (5.5 to 6.0
mmol/L), or severe (>6.0 mmol/L).760 It is associated with an increased risk of hospitalization and death.752,753,755,756,761,762
Hyperkalaemia can be associated with the administration of RAAS
inhibitors, CKD and increased absorption.760 Among patients with
HF, the prevalence of hyperkalaemia at any given time among patients with HF appears to be less than 5%,757 but the incidence is much higher, at up to 40% in chronic HF and 73% in CKD over follow-up durations of approximately 1 year.753,756,757,763765 In PARADIGMHF, treatment with sacubitril/valsartan was associated with lower risk of severe hyperkalaemia, compared with enalapril.128 Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium carbonate and/or sodium bicarbonate, insulin, with or without glucose, and beta adrenoceptor agonists [e.g. salbutamol, offlabel use in some European Union (EU) countries]. These agents favour potassium entry into the cells and do not increase potassium excretion. Thus, they only provide temporary benefit and rebound hyperkalaemia can occur after few hours. Loop diuretics can be administered to facilitate potassium loss.
Potassium binders bind to potassium in the gastrointestinal tract reducing its absorption. They can be used for acute and chronic potassium lowering. They include sodium polystyrene sulfonate, calcium polystyrene sulfonate, and the much better tolerated patiromer sorbitex calcium and sodium zirconium cyclosilicate (SZC). Sodium polystyrene sulfonate is still indicated in anuric or severely oliguric patients, but it should not be used in the medium or long term as it may cause severe gastrointestinal side effects, including bowel necrosis.760 Patiromer or SZC increase faecal potassium excretion and act mainly in the colon. Both compounds are effective in normalizing elevated potassium levels, maintaining normokalaemia over time and preventing the recurrence of hyperkalaemia and can be considered for treatment of hyperkalaemia766768 (see Supplementary Table
24).
Renal dysfunction and hyperkalaemia are the major causes of underuse of
RAAS
inhibitors,
particularly
MRA,
in clinical practice.342,753,758,769771 Administration of the potassium-lowering agents, patiromer or SZC, may allow their initiation or uptitration in a larger proportion of patients. This hypothesis was tested in doubleblind, placebo-controlled, randomized trials with patiromer or placebo administration to patients with CKD and hyperkalaemia, or discontinuation of RAAS inhibitors for hyperkalaemia, and with an indication for spironolactone for HF and/or resistant hypertension.
Patiromer was more likely to lower serum potassium and decreased episodes of hyperkalaemia than spironolactone initiation and uptitration.772775 The ongoing RCT DIAMOND (NCT03888066)
is testing the impact on clinical outcomes of a strategy based on patiromer administration, compared with placebo, in patients with
HFrEF who are hyperkalaemic while on RAAS inhibitors or with a history of hyperkalaemia with subsequent reduction or discontinuation of a RAAS inhibitor776,777 (see Supplementary text 13.1).
Hyponatraemia is defined as a serum sodium concentration lower than 136 mmol/L. It is common in HF and may be present in up to
30% of patients admitted to hospital with HF. It reflects neurohormonal activation and is a powerful independent marker of poor outcomes in patients with acute or chronic HF.778,779
Severe hyponatraemia may cause neurologic symptoms (seizures,
obtundation, delirium) due to cerebral oedema and may require immediate treatment with hypertonic saline with serum sodium increases by 12 mmol/L per hour, though less than 8 mmol/L in
24 h as a more rapid correction increases the risk of myelinolysis.
Intravenous treatment is not required when hyponatraemia is less


<!-- PAGE 73 -->

### Page 73

....................................................................................................................................................................
severe, e.g. >124 mmol/L, and in the absence of symptoms. As the pathogenesis of hyponatraemia in HF is dilutional, e.g. caused by water retention induced by increased vasopressin secretion, treatment is based on water restriction or vasopressin antagonists. Fluid restrictions to less than 8001000 mL/day may be indicated to achieve a negative water balance and treat hyponatraemia. Water restriction was associated with improved QOL in a small, randomized study but with only slight increases in serum sodium in an observational registry.780,781 Tolvaptan, an orally active selective arginine vasopressin V2 receptor antagonist, can be considered to increase serum sodium and diuresis in patients with persistent hyponatraemia and congestion. However, no effects on outcomes have been shown in RCTs782785 (see Supplementary text 13.1). The infusion of hypertonic saline combined with loop diuretics was associated with an increase in serum sodium levels and greater diuretic efficacy in small trials and observational studies.786788
Hypochloraemia (<96 mmol/L) is a powerful independent predictor of mortality in patients with acute and chronic HF.439,789792
Serum chloride may have a direct role in the control of renin secretion and the response to loop or thiazide diuretics.439,793 The carbonic anhydrase inhibitor acetazolamide increases chloride reabsorption causing a greater bicarbonate and sodium excretion in the proximal tubule of the nephron. It can increase serum chloride levels and diuresis in patients with severe HF at risk of diuretic resistance.145,794 It is currently being tested in a multicentre randomized study in decompensated HF.469
13.8 Lung disease, sleep-disordered breathing
Overall, COPD affects about 20% of patients with HF and has a major impact on symptoms and outcomes.795797 Due to the overlap in symptoms and signs, the differentiation between HF and COPD may be difficult. Pulmonary function testing with spirometry is recommended as the first diagnostic tool and should be considered in patients with suspected COPD. For adequate interpretation, it should be performed in stable and euvolaemic patients to avoid congestion related to obstructive pulmonary function patterns. If there is uncertainty about the reversibility of airflow obstruction, pneumology referral for more sophisticated tests (bronchodilatatory test,
bronchial provocation tests, diffusion capacity) is warranted.798,799
Treatment of HF is generally well tolerated in COPD.800 Betablockers can worsen pulmonary function in individual patients but are not contraindicated in either COPD or asthma, as stated in the
Global initiative for chronic Obstructive Lung Disease (GOLD) and the Global INitiative for Asthma (GINA), respectively.801,802 GINA
states that asthma should not be regarded as an absolute contraindication to the use of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or nebivolol) with consideration of relative risks and benefits. In clinical practice, starting with low doses of cardioselective beta-blockers combined with close monitoring for signs of airway obstruction (wheezing, shortness of breath with lengthening of the expiration) should be encouraged. Although not tested in HF
patients, inhaled corticosteroids and beta-adrenergic agonists do not seem to increase CV events, including HF, in patients at high risk.803,804 Moreover, optimal COPD management can improve cardiac function.805
Sleep-disordered breathing occurs in more than one third of patients with HF and is even more prevalent in patients with AHF.
The most common types are: central sleep apnoea (CSA, similar to
Cheyne-Stokes respiration), OSA, and a mixed pattern of the two.
CSA and OSA have been shown to be associated with a worse prognosis in HF. OSA is associated with an increased risk of incident HF in men. CSA is the most common form of sleep-disordered breathing in HFrEF and HFmrEF is the most common cause of CSA.806,807
Patients with HF can be investigated for sleep-disordered breathing. History taking should involve partners. Questionnaires are instrumental in identifying patients at risk. Home monitoring can usually identify and distinguish the type of sleep apnoea. However, overnight polysomnography remains the definitive investigation.807 The use of adaptive servo-ventilation in patients with HFrEF and predominantly
CSA is not recommended, based on the results of SERVE-HF, which was neutral regarding the composite primary endpoint of death from any cause or lifesaving CV intervention, but showed an increase in both all-cause mortality and CV mortality with adaptive servo-ventilation.808 Transvenous phrenic nerve stimulation was tested in a prospective, multicentre, randomized trial involving 151 patients with
CSA.809 The primary efficacy endpoint was the reduction of the apnoea-hypopnoea index from baseline to 6 months and was achieved by a larger percentage of patients with the active treatment.
Other measurements of sleep quality and QOL were improved and no difference in any safety endpoint was found between active treatment and control.809 Similar results were observed in the 96 patients with HF.810
Patients with HFrEF being considered for a sleep-disordered breathing treatment with positive pressure airway mask must undergo formal sleep study to document the predominant type of sleep apnoea (central vs. obstructive). When sleep-disordered breathing is caused by OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure, bi-level positive airway pressure, and adaptive servoventilation. However, none of these interventions has been shown to have beneficial effects on outcomes in HF.807 When sleepdisordered breathing is caused by CSA, positive pressure airway masks are contraindicated in HFrEF patients.808 In these patients,
implantable phrenic nerve stimulation can be considered for symptomatic relief.
13.9 Hyperlipidaemia and lipid-modifying therapy
Two large RCTs, including mainly patients with HFrEF, as well as a meta-analysis of 24 RCTs, showed no benefit of statin treatment on
CV mortality or stroke in patients with HFrEF.811,812 A reduction in
HF hospitalizations as well as a small reduction in MI was observed in a meta-analysis of the CORONA and GISSI-HF trials.813815 Based on current evidence, routine administration of statins in patients with
HF without other indications for their use (e.g. CAD) is not
ESC Guidelines
3671


<!-- PAGE 74 -->

### Page 74

.......................................................................................................................................................................
recommended. Because there is no evidence of harm in patients on statin treatment after the occurrence of HF, there is no need for statin discontinuation for patients already treated.
13.10 Gout and arthritis
Hyperuricemia is a common finding in patients with CHF with a prevalence up to 50%.816,817 Hyperuricemia may be caused or aggravated by diuretic treatment and it is related to symptoms, exercise capacity,
severity of diastolic dysfunction and long-term prognosis.817,818 For every 1 mg/dL increase in serum uric acid levels the risk of all-cause mortality and of HF hospitalization increases by 4% and 28%, respectively.819 Both febuxostat and allopurinol reduce uric acid levels.
However, allopurinol was associated with a lower rate of all-cause death and CV death, compared with febuxostat, in a prospective,
multicentre, double-blind, non-inferiority trial enrolling 6190 patients with gout and CV disease, 20% with HF, with a median follow-up of
32 months.820 Allopurinol is therefore recommended as the firstchoice urate-lowering drug in HF patients with no contraindication.
There is no evidence that uric acid-lowering treatment has beneficial effects on LV function, symptoms or outcomes of patients with
HF.821823
With respect to treatment of acute gout attacks, non-steroidal anti-inflammatory drugs (NSAIDs) can worsen renal function and precipitate acute HF decompensation. Colchicine should be preferred as it is associated with less side effects.824 However, it, too,
should be used with caution in patients with severe renal dysfunction and is contraindicated in patients on dialysis. An increase in ventricular vulnerability was shown in experimental models.825
Arthritis is a common comorbidity and is a common cause of both self-taken and prescribed NSAIDs. These agents are relatively contraindicated as they may precipitate acute decompensation in patients with HF.826 Rheumatoid arthritis is associated with a two- to threefold increase in the risk of HF and this increased risk is independent of ischaemic heart disease, suggesting a direct role in HF pathophysiology.827,828 The safety of disease-modifying drugs used for the treatment of rheumatoid arthritis has not been established in HF. High doses of anti-tumour necrosis factor alpha agents were associated with worsening HF in initial trials and should be used with caution.
No adverse effects were noted with lower doses.829831
13.11 Erectile dysfunction
Erectile dysfunction is a serious problem in HF patients due to its association with CV risk factors, comorbidities (e.g. diabetes), lifestyle (e.g. inactivity), and treatment (e.g. drugs).832 In the general population, the prevalence of erectile dysfunction is estimated to be 50%
in men aged >_60, but erectile dysfunction can be present in up to
81% of cardiac patients across different cultures and ethnic groups.833
Optimal assessment should include both questions assessing the presence of erectile dysfunction and factors that can be related to erectile dysfunction. Numerous classes of CV drugs, particularly diuretics and beta-blockers, have been implicated causing erectile dysfunction. However, the relationships between many contemporary
CV drugs and erectile dysfunction is not clear.834 For the treatment of erectile dysfunction, phosphodiesterase type 5 inhibitors are generally safe and effective in patients with compensated HF.834,835 No studies have shown one agent to be more effective or safer than the others. However, phosphodiesterase type 5 inhibitors should not be used in patients receiving nitrates and nitrates should not be administered to patients within 24 h of sildenafil or vardenafil administration or within 48 h of tadalafil administration.834
13.12 Depression
Depression affects 20% of patients with HF and is severe in half of them. Its occurrence is higher in women and it is associated with worse clinical status and a poor prognosis.836838 Screening using a validated questionnaire is recommended when there is a clinical suspicion of depression. The Beck Depression Inventory and Cardiac
Depression Scale are the tools formally validated for the assessment of depression in patients with HF. Other questionnaires (e.g.
Geriatric Depression Scale, Hamilton Depression Scale, Hospital
Anxiety and Depression Scale) can also be used.837,838
There is still no consensus on the best therapy for HF patients with depression. Psychosocial intervention may improve depressive symptoms but has no effect on prognosis of depressed patients with
HF.839 Depressive symptoms may improve with selective serotonin reuptake inhibitors but trials specifically designed to assess the effect of these drugs in patients with HF and depression have failed to show any significant benefit over placebo on both symptoms and outcomes.840,841 Interestingly, patients improved also in the placebo arm showing the importance of better care in these patients. Both trials showed the safety of sertraline and escitalopram, respectively.840,841
Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, worsening HF, and arrhythmias.837,838
13.13 Cancer
HF occurs in patients with cancer as a result of the interaction among anticancer therapy, cancer itself, and patients’ CV background (risk factors and coexisting CV disease).842846 Several anticancer therapies may cause HF directly, thorough their cardiotoxic effects (Table
23), or, indirectly, through other mechanisms, such as myocarditis,
ischaemia, systemic or pulmonary hypertension, arrhythmias or valve disease.844,845,847852 HF, in turn, may affect cancer outcomes by depriving patients of effective anticancer therapies.699 Some epidemiological and experimental evidence suggests a further reciprocal interaction between cancer and HF with some, though not all, studies showing a higher incidence rate of cancer in patients with HF.853858
The prevention of HF in patients with cancer undergoing potential cardiotoxic therapies requires careful patient’s assessment and management before, during, and after cancer therapy, preferably in the context of an integrated
Cardio-Oncology service
(Figure 18).845,859,860 A CV baseline risk assessment for all patients scheduled to receive potentially cardiotoxic cancer therapies using the HFA-ICOS risk assessment is advisable.846 Baseline CV risk assessment forms have been developed for different potentially cardiotoxic cancer therapies. History of HF or CMP characterizes patients as being at very high risk or at high risk for all cancer therapies, except anti-androgen treatments for prostate cancer. An LVEF
<50% is an additional factor for high-risk patients and elevated levels


<!-- PAGE 75 -->

### Page 75

...................................................
of NPs or troponin at baseline are additional criteria of medium risk for most of the cancer treatments.846
During cancer treatment with potential cardiotoxic therapies, LV
systolic function can be monitored through echocardiography.
Chemotherapy should be reconsidered and treatment with an ACE-I
and a beta-blocker (preferably carvedilol) should be started in patients who develop LV systolic dysfunction, defined as 10% or more absolute reduction in LVEF to a value below 50%.844,861864
Global longitudinal strain can detect cardiac dysfunction at an earlier stage.865,866 A >_12% relative reduction in global longitudinal strain was compared with an LVEF decline in a prospective randomized trial in high-risk patients undergoing potentially cardiotoxic chemotherapy. Compared to treatment based on LVEF, treatment based on changes in global longitudinal strain led to the same decrease in LVEF
(primary endpoint) but with fewer patients who developed cardiac dysfunction at the end of the study, thus suggesting usefulness of global longitudinal strain for the early detection of cardiotoxicity.867
Promising results for the early detection of cardiac dysfunction have also been obtained through monitoring of biomarkers, such as NPs and troponin.868,869 Patients on immunotherapy with immune checkpoint inhibitors are at increased risk of myocarditis and should be monitored for related symptoms and signs and by weekly assessment of cardiac troponin during at least the first 6 weeks of therapy and managed accordingly.870
Timing of the imaging procedures and biomarkers assessment depend on the anticancer treatment and patient’s risk profile
(Figure 18).865 In general, all patients scheduled for potential cardiotoxic therapies must undergo a baseline evaluation that would define the level of risk for cardiotoxicity (low, medium, or high)
and the intensity of monitoring and follow-up during and after cancer treatment.865 Cancer survivors exposed to potentially cardiotoxic therapies should be periodically monitored in the long term as HF may develop several years after cancer therapy.865,871
Table 23
Cancer drugs causing heart failure
Cancer therapy
Indication
Anthracycline chemotherapy
(doxorubicin, epirubicin, daunorubicin, idarubicin)
Breast cancer, lymphoma, acute leukaemia, sarcoma
HER2-targeted therapies
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib, neratinib,
tucatinib)
HER2þ breast cancer
HER2þ gastric cancer
VEGF inhibitors
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib, cabozantinib, regorafenib,
lenvatinib, vandetinib) and antibodies (bevacizumab, ramucirumab)
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon cancer, sarcoma, GIST
Antibodies: breast cancer, ovarian cancer, gastric cancer, gastro-oesophageal cancer, colon cancer
Multi-targeted kinase inhibitors:
second and third generation BCR-ABL TKIs (ponatinib, nilotinib, dasatinib,
bosutinib)
Chronic myeloid leukaemia
Proteasome inhibitors
(carﬁlzomib, bortezomib, ixazomib)
Immunomodulatory drugs
(lenalidomide, pomalidomide)
Multiple myeloma
Combination RAF and MEK inhibitors
(dabrafenibþtrametinib, vemurafenibþcobimetinib, encorafenibþ
binimetinib)
RAF mutant melanoma
Androgen deprivation therapies
GnRH agonists (goserelin, leuprorelin)
Antiandrogrens (abiraterone)
Prostate cancer, breast cancer
Immune checkpoint inhibitors:
anti-programmed cell death 1 inhibitors
(nivolumab, pembrolizumab)
anti-cytotoxic T-lymphocyte-associated protein 4 inhibitor (ipilimumab)
anti-programmed death-ligand 1 inhibitors
(avelumab, atezolizumab, durvalumab)
Melanoma (metastatic and adjuvant)
Metastatic renal cancer, non-small cell lung cancer, small cell lung cancer,
refractory Hodgkin’s lymphoma, metastatic triple negative breast cancer,
metastatic urothelial cancer, liver cancer, MMR-deﬁcient cancer
GIST = gastrointestinal stromal tumour; GnRH = gonadotropin-releasing hormone; HER2 = human epidermal growth factor receptor 2; MEK = mitogen-activated protein kinase;
MMR = mismatch repair; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.
ESC 2021
ESC Guidelines
3673


<!-- PAGE 76 -->

### Page 76

Management of patients receiving potential cardiotoxic treatments
Baseline risk assessment including clinical assessment, ECG, resting echocardiogram and cardiac biomarkers (NP, troponin)
Pre-existing heart failure or high-risk cardiovascular disease
Medium- and high-risk patientb
Increasedc surveillance with ECG
and cardiac biomarkers during treatment
Reassessment at
3 months and 12 months after completion of cancer therapy
Low-risk patientb
Standard surveillanced
Before cardiotoxic 
cancer treatmenta
After cardiotoxic 
cancer treatmenta
During cardiotoxic 
cancer treatmenta
Reassessment at
12 months after completion of cancer therapy
Surveillance every 5 years following therapies with established cardiotoxicity
(e.g. high-dose anthracycline chemotherapy)e
Follow-up by heart failure or cardio-oncology team for new heart failure or left ventricular systolic dysfunction
Figure 18 Management of patients with cancer and heart failure. ECG= electrocardiogram; HER2= human epidermal growth factor receptor 2; HF=
heart failure; HFA= Heart Failure Association; ICOS= International Cardio-Oncology Society; MEK= mitogen-activated protein kinase; NP=natriuretic peptide; VEGF= vascular endothelial growth factor. aAnthracycline chemotherapy, trastuzumab and HER2 targeted therapies, VEGF inhibitors,
proteasome inhibitors, combination RAFþMEK inhibitors. bLow, medium and high risk may be calculated using the HFA-ICOS baseline cardiovascular risk proformas.846 cIncreased surveillance is intended between 1 and 4 weeks. dStandard surveillance is intended every 3 months. e5 yearly surveillance at follow-up= clinical review every 5 years with history, examination, NP and troponin levels, and echocardiogram.865


<!-- PAGE 77 -->

### Page 77

..................................................................................................
13.14 Infection
Infective disorders may worsen HF symptoms and be a precipitant factor for AHF.872,873 Severe sepsis and pneumonia can cause myocardial injury and depress cardiac function leading to cardiac dysfunction and HF and this risk is greater in patients with a history of
HF.873875 More recently, the coronavirus disease 2019 (COVID19) pandemic has emerged as a major cause of morbidity and mortality as well as of HF decompensation.873,876878 Specific guidance is available.879 General recommendations related to infections are given in Table 24.
Influenza vaccination is associated with a reduced risk of all-cause death in patients with HF in observational studies and retrospective analyses.880882 Influenza and pneumococcal vaccination, as well as
COVID-19 vaccination, when available, should be considered in patients with HF.879,883
14 Special conditions
14.1 Pregnancy
14.1.1
Pregnancy in pre-existing heart failure
Women with pre-existing HF have a higher risk of pregnancy-related
CV complications including HF decompensation. Moderate- and high-risk patients according to the modified
World
Health
Organization (mWHO) class IIIIV should be referred to a specialist centre with a multidisciplinary Pregnancy Heart Team.884 An algorithm for the management of HF patients before and during pregnancy is reported in Figure 19.
Pre-pregnancy management includes the modification of existing
HF medications to avoid foetal harm. ACE-Is, ARBs, ARNI, MRAs,
ivabradine, and SGLT2 inhibitors are contraindicated and should be stopped prior to conception with close clinical and echocardiographic monitoring. Beta-blockers should be continued and switched to beta-1-selective blockers (bisoprolol, metoprolol succinate).
Hydralazine, oral nitrates and methyldopa can be started if required.
Therapeutic anticoagulation with low-molecular-weight heparin
(LMWH), in the first and last trimesters, and VKAs, with the usual target international normalized ratios (INRs) or LMWH for the second trimester, is recommended for patients with HF and AF. DOACs should be avoided.884
Assessment of patients with HF in pre-pregnancy or at presentation with a new pregnancy should include a clinical assessment
(symptoms, clinical examination, BP, SaO2), ECG and resting echocardiography. The modalities of delivery should be planned by cardiologists, obstetricians, and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy Heart Team. Bimonthly assessments for women in mWHO IIIII, and monthly assessments for women with pre-existing HF in mWHO III, must be performed. Women with advanced HF (LVEF <30%, NYHA class IIIIV) in mWHO IV who are pregnant can be referred to a specialist centre for counselling regarding any consideration of termination of pregnancy. The decision regarding modalities of delivery can be planned by cardiologists,
obstetricians, and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy Heart Team and discussed with the patient.884
14.1.2
New heart failure presenting during pregnancy
The increased demands on ventricular function due to the increased circulating volume and cardiac output of pregnancy can unmask preRecommendations for the management of patients with cancer and heart failure
Recommendation
Classa
Levelb
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease, previous cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in CardioOncology.
I
C
Treatment with an ACE-I and a beta-blocker
(preferably carvedilol) should be considered in cancer patients developing LV systolic dysfunction, deﬁned as a 10% or more decrease in LVEF and to a value lower than 50%, during anthracycline chemotherapy.861,862
IIa
B
A baseline CV risk assessment should be considered in all cancer patients scheduled to receive a cancer treatment with the potential to cause heart failure.846,865
IIa
C
ACE-I = angiotensin-converting enzyme inhibitor; CV = cardiovascular; LV = left ventricular; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
Table 24
Infections in patients with heart failure
Patients with HF are at increased risk of infections and have poorer outcomes once infected.
Telemonitoring avoids the risks of infections caused by close contact. It is useful during pandemic conditions.
Telemonitoring may be implemented for patients’ follow-up in pandemic conditions.
During pandemics, HF patients should be screened for infection at the time of hospitalization, in case of urgent admissions, or before elective hospitalizations.
Careful assessment of ﬂuid status, in addition to clinical signs of HF, is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by echocardiography may be used to assess ﬂuid status.
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and haemodynamic conditions permit and considering drug interaction with infection related therapies and side effect proﬁle.
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BP = blood pressure;
HF = heart failure; MRA = mineralocorticoid receptor antagonist; OMT = optimal medical therapy; SGLT2 = sodium-glucose co-transporter 2.
ESC 2021
ESC 2021
..........................................................................
ESC Guidelines
3675


<!-- PAGE 78 -->

### Page 78

................
existing, but previously undiagnosed, causes of HF such as CMPs and valve diseases.885 Symptoms are more likely to occur in the second trimester when the demand for an increased cardiac output is the highest. Severe emotionally stressful episodes during pregnancy and delivery can also cause Takotsubo syndrome.884,885
PPCM presents as HF secondary to LV systolic dysfunction, usually shown by an LVEF <45%, occurring towards the end of pregnancy
(third trimester) or in the months following delivery without any other identifiable cause. The majority of PPCM cases are diagnosed in post-partum. The prevalence ranges from 1:100 in Nigeria to 1:1000
Management of patients with heart failure before and during pregnancy
Bi-monthly or 
monthly review
(mWHO II)
Counselling including risk assessment and educationa
Cardiac assessment including clinical assessment, ECG, echocardiogram
Review HF therapy and switch to non-teratogenic HF medication
Moderate and high-risk HF patients 
(mWHO II, II–III and IV)
Referral  to a specialist centre for high-risk pregnancies with multidisciplinary Pregnancy Heart Team
Reassessment at the beginning of the second trimester i.e. 20 weeks
Reassessment at 20 weeks
Low-risk HF patients
(mWHO I)
Discuss with a specialist centre for high-risk pregnancies
Reassessment at the beginning of the second trimester i.e. 20 weeks
Monthly review 
(mWHO III)
Urgent counselling for consideration of pregnancy termination
(mWHO IV)
Pre-pregnancy
At pregnancy diagnosis or planning
During pregnancy
Figure 19 Management of patients with heart failure before and during pregnancy. ECG= electrocardiogram; HF= heart failure; mWHO= modified
World Health Organization. aAdvice regarding contraception, HF medication, to contact HF specialist when planning pregnancy.


<!-- PAGE 79 -->

### Page 79

.......................................................................................................................................................................
in South Africa and 1:1500 in Germany.643 Prospective large cohort studies report a 6-month mortality ranging from 2.0% in Germany to
12.6% in a 206 PPCM patient cohort from South Africa.643
PPCM frequently presents with acute HF but may also present with ventricular arrhythmias and/or cardiac arrest. An LVEF <30%,
marked LV dilatation, LV end-diastolic diameter >6.0 cm, and RV
involvement are associated with adverse outcomes.643 Cardiac recovery may occur in the first 36 months though it may be delayed to up to 2 years. Recovery rates vary among regions, from
75% to less than 50%.886888
Assessment and management of pregnant patients presenting with
HF depends upon the clinical setting and severity of presentation.
Detailed cardiac assessment with echocardiography, NP levels, foetal ultrasound and foetal monitoring is recommended. In cases of new
HF or if there is diagnostic uncertainty non-contrast CMR may be considered.
Milder cases can be treated with oral diuretics, beta-blockers,
hydralazine and oral nitrates. Pregnant women presenting with signs of acute HF require urgent hospital admission. In case of PPCM presenting with severe HF and cardiogenic shock requiring inotropic or vasopressor support, transfer to an advanced HF centre, where
ECMO, LVAD and/or cardiac transplantation can be performed, is recommended. Urgent delivery by caesarean section (irrespective of gestation) should be considered with MCS immediately available.
Adrenergic agents (dobutamine, adrenaline) may have detrimental effects.889 When a PPCM patient is haemodynamically unstable, levosimendan or MCS may be considered. LVAD implantation as a BTT
or BTR should be considered in refractory cases of cardiogenic shock.643 Bromocriptine has been proposed for patients with acute
PPCM to reduce the production of a cleaved 16 kDa prolactin fragment, which may contribute to the pathophysiology of PPCM.
Bromocriptine was tested in a randomized trial in 63 patients comparing its long-term, 8 weeks, with its short-term, 1-week, treatment.
It was associated with recovery of LV function, with no difference between the two regimens and in line with the results of a previous international PPCM registry.890,891 Bromocriptine may be considered for treatment of PPCM. Untoward effects of treatment, including deep venous thrombosis and cessation of lactation, must be considered if it is initiated. It should therefore be accompanied by prophylactic (or therapeutic) anticoagulation.
14.2 Cardiomyopathies
14.2.1
Epidemiology and diagnosis
CMPs can be either inherited (genetic/familial) and/or acquired. They can also be accelerated by disease modifiers.892894 They are a heterogeneous group of diseases and are major causes of HF.895 DCM has an estimated prevalence of 1 in 250 to 1 in 500 of the general population, HCM ranges between 1 in 500 to 1 in 5000, and AC is estimated to be present in around 1 in 1000 to 1 in 5000 persons.895,896
Direct causes of CMPs include pathogenic gene variants (mutations), toxins, auto-immunity, storage diseases, infections, and tachyarrhythmias. Disease modifiers, conditions that may aggravate or trigger a CMP, include epigenetic factors and acquired modifiers,
such as pregnancy and most CV comorbidities. It is important to consider this key interaction between genetic and acquired causes during the diagnostic workup.897 Identification of an acquired cause of the CMP does not exclude an underlying pathogenic gene variant,
whereas the latter may require an additional acquired cause and/or disease modifier to become manifest clinically. The commonest causes and disease modifiers are shown in Table 25.
The key elements of the diagnostic workup for all patients with HF
and CMP are reported in Table 26.892,894,895,898,899 Specifics aspects of diagnosis and treatment are summarized in Tables 2729. Clinical history, laboratory tests, and imaging are the first-line investigations.
Echocardiography is central for the diagnosis and monitoring of
HCM, DCM, and AC. CMR imaging provides more detailed morphological and prognostic information and should be performed at baseline. The prevalence of gene mutations may vary according to the morphological phenotype or the underlying acquired cause. Gene mutations occur in up to 40% of DCM, 60% of
HCM, and 15% in chemotherapy-induced, alcoholic or peripartum
CMPs.895,898,900905 The prevalence of genetic mutations is over
10% also in non-familial DCM.898,906 Finding a pathogenic gene variant in a patient with CMP allows better prediction of the disease outcome and progression, may contribute to the indications for device implantation and inform genetic counselling for families.
Endomyocardial biopsy (EMB) with immunohistochemical quantification of inflammatory cells remains the gold standard investigation for the identification of cardiac inflammation. It may confirm the diagnosis of auto-immune disease in patients with DCM and suspected giant cell myocarditis, eosinophilic myocarditis, vasculitis and sarcoidosis.893,907 It may also help for the diagnosis of storage diseases,
including amyloid or Fabry disease, if imaging or genetic testing does not provide a definitive diagnosis (see also section 14.6). EMB might be considered also in HCM if genetic or acquired causes cannot be identified. The risks and benefits of EBM should be evaluated and this procedure should be reserved for specific situations where its results may affect treatment.
14.2.2
Treatment
The current pharmacological treatment of HF in DCM, HCM, or AC
patients does not differ from general HF management, except for peculiar aspects reported in Tables 2729. A pilot randomized study,
TRED-HF, investigated the possibility of withdrawing medical treatment in those patients with non-ischaemic DCM who had had partial to complete recovery of LVEF (>40%). However, relapse of DCM
within 6 months was observed in 44% of patients, and rapid LV
remodelling with early tissue and functional changes, even amongst patients who did not relapse, was found.271,908
In a phase 3, randomized, double-blind, placebo-controlled trial
(EXPLORER-HCM), treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive HCM. This offers the possibility of disease-specific treatment for inherited CMPs. 909
ICD implantation should be considered for patients with DCM,
HCM, or AC (see section 6).895,910912 The strength of the indication varies according to the clinical risk factors for sudden cardiac death with higher priority being given to those patients with significant LGE
ESC Guidelines
3677


<!-- PAGE 80 -->

### Page 80

Table 25
Possible causes and disease modiﬁers of most frequent cardiomyopathies
Cause
Disease modifier
Phenotype
Genetic mutations
LMNA
x
DCM
TTN
x x
DCM, (HCM)
RBM20
x
DCM
MYH7
x
DCM, HCM
MYPC
x
DCM, HCM
TNNT
x
DCM, HCM
PLN
x
DCM, HCM, AC
DSP
x x
AC, DCM, myocarditis
SCN5a x
x
AC, (DCM)
Tropomyosin-1
x
DCM
Haemochromatosis (HFE gene, C282Y)
x
HCM, DCM
Galactosidase-A (Fabry disease)
x
HCM
Neuromuscular disorders
Duchenne muscular dystrophy, Becker muscular dystrophy,
myotonic dystrophy x
DCM
Syndromic disorders
Mitochondrial X-linked mutations x
DCM
Acquired diseases
Infection (viruses)
x x
Myocarditis, DCM
Immuno-mediated diseases (rheumathoid arthritis, systemic lupus erythematosus, dermatomyositis)
x x
Myocarditis, DCM
Toxic (alcohol, amphetamines, cocaine)
x x
DCM, myocarditis
Drugs (anthracyclines, trastuzumab, immune checkpoint inhibitors)
x x
DCM, myocarditis
Overload (haemochromoatosis)
x x
HCM, DCM
Peripartum (pregnancy)
x x
DCM
Comorbidities with possible interactions with the gene mutations and an effect on phenotype and outcome
Tachy-arrhythmias x
x
DCM
Diabetes mellitus x
x
DCM, HCM
Hypertension x
x
DCM, HCM
Hypo- and hyperthyroidism x
DCM, HCM, myocarditis
AC = arrhythmogenic cardiomyopathy; DCM = dilated cardiomyopathy; DSP = desmoplakin; HCM = hypertrophic cardiomyopathy; LMNA = lamin A/C; MYH7 (gene) = myosin heavy chain 7; MYPC = myosin-binding protein C; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; SCN5a = sodium channel alpha unit 5; TTN = titin; TNNT
= troponin-T.
Table 26
Initial diagnostic assessment in patients with suspected cardiomyopathy
History including detailed questions on any systemic disease, toxic agents (chemotherapy, alcohol, drugs), and familial history of cardiac or neuromuscular disease, or sudden cardiac death in family members at young age (<50 years).
Laboratory exams including cardiac and muscular enzymes, liver and renal function, haemoglobin, white blood cell count (including differential white blood cell count to detect eosinophilia), natriuretic peptides, thyroid function tests, iron status, and markers of systemic auto-immune disease (hsCRP, antinuclear antibodies, soluble IL-2 receptor).
Standard 12-lead ECG and echocardiography to detect arrhythmias and assess cardiac structure and function and concomitant abnormalities.
Invasive coronary angiography or CTCA to rule out signiﬁcant CAD in patients with cardiac dysfunction.
CMR imaging with T1 and T2 sequencing and LGE to visualize structural changes, storage, inﬁltration, inﬂammation, ﬁbrosis and scarring.
Genetic counselling and genetic testing should be performed depending on age, family history, cardiac phenotype.
24 or 48-hour ambulatory ECG monitoring to detect atrial and ventricular arrhythmias.
CAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; hsCRP = high-sensitivity
C-reactive protein; IL-2 = interleukin-2; LGE = late gadolinium enhancement.
ESC 2021
ESC 2021


<!-- PAGE 81 -->

### Page 81

Table 27
Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: speciﬁc aspects of diagnosis and treatment
Diagnostic criteria and deﬁnitions894,895
DCM: LV dilatation and systolic dysfunction in the absence of known abnormal loading conditions or signiﬁcant CAD.
HNDC: LV or biventricular global systolic dysfunction (LVEF <45%) without dilatation in the absence of known abnormal loading conditions or signiﬁcant
CAD.
DCM and HNDC can be considered “familial” if two or more ﬁrst- or second-degree relatives have DCM or HNDC, or a ﬁrst-degree relative has autopsy proven DCM and sudden death at <50 years of age.
Genetic counselling and testing892,894,898,916
Indication. All patients with a diagnosis of DCM or HNDC and all ﬁrst-degree adult relatives of these patients and a deﬁnite disease-causing mutation,
regardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.
First-degree adult relatives should have their evaluation repeated every 5 years or less when aged <50 years or non-diagnostic abnormalities are found.
Clinical evaluation, ECG, echocardiography and possibly CMR, must be performed in ﬁrst-degree relatives of patients.
Results can identify patients with DCM or HNDC at highest risk of arrhythmia and/or deserving other speciﬁc treatments.
Early identiﬁcation of asymptomatic relatives may lead to early treatment and prevention of progression to HF and proper genetic counseling.
Minimal set of genesa: TTN, LMNA, MHC, TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3, actin alpha cardiac muscle,
nexilin, tropomyosin-1, vinculin.
The use of additional sequencing for the analysis of very large panel of genes may be considered when there is a clear familial history or structural phenotype, by preference combined with family segregation.
Endomyocardial biopsy97,907,917919
Indication. In suspected phenotypes requiring speciﬁc treatments (i.e. giant cell myocarditis, eosinophilic myocarditis, sarcoidosis, vasculitis, SLE, other systemic, auto-immune inﬂammatory conditions, or storage diseases).
Number of samples. A minimum of 5 but possibly at least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for RNA viruses/viral replication.918,919
Aetiology. Search for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for active viral replication should be assessed, if possible.
Further assessment if indicated: CMV, HIV, Borrelia burgdorferi (Lyme disease), Coxiella burnetii (Q-fever), Trypanosoma cruzi (Chagas disease) and
SARS-CoV-2.
Immunohistochemistry. Quantiﬁcation of CD3-, CD4-, CD8- or CD45- staining lymphocytes and CD68 macrophages per mm2; anti-HLA-DR.
Histology. Haematoxylin and eosin staining, ﬁbrosis assessment with Masson’s Trichrome and Picrosirius Red, amyloid ﬁbrils detection with Congo Red.
Therapeutic options895,917
HF treatment for HFrEF (see sections 5 and 6)
LMNA, RBM20, PLN and FLN mutation. Higher risk of sudden cardiac death: early indication for primary prevention by ICD implantation should be considered (guided by risk factors as detailed).920
TTN mutation. Higher rate of LV reverse remodeling (in up to 70%), but a higher risk of atrial and ventricular tachyarrhythmias.
Lyme disease (Borrelia). Treatment with doxycycline.
Chagas disease (Trypanosoma cruzi). Speciﬁc treatment according to current recommendations.921,922
Auto-immune/inﬂammatory. Consider immunosuppressive therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis or vasculitis, and in highly selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling (cardiology and immunology).
BAG3 = Bcl2-associated athanogene 3; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DCM = dilated cardiomyopathy; DNA =
deoxyribonucleic acid; ECG = electrocardiogram; FLN = ﬁlamin; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HHV = human herpes virus; HIV =
human immunodeﬁciency virus; HLA-DR = human leukocyte antigen-DR isotype; HNDC = hypokinetic non-dilated cardiomyopathy; ICD = implantable cardioverter-deﬁbrillator; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection fraction; MHC = myosin heavy chain; MYPC = myosin-binding protein C; mRNA = messenger ribonucleic acid; NSVT = non-sustained ventricular tachycardia; PCR = polymerase chain reaction; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; RNA =
ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SLE = systemic lupus erythematosus; TNNT = troponin-T; TTN = titin.
aThis list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using.
bRisk factors in patients with a conﬁrmed LMNA mutation: NSVT during ambulatory ECG monitoring, LVEF <45% at ﬁrst evaluation, male sex and non-missense mutations
(insertion, deletion, truncations, or mutations affecting splicing).
ESC 2021
ESC Guidelines
3679


<!-- PAGE 82 -->

### Page 82

Table 28
Hypertrophic cardiomyopathy: speciﬁc aspects of diagnosis and treatment
Deﬁnition895,896,923
Wall thickness >14 mm in one or more LV myocardial segments not sufﬁciently explained solely by abnormal loading conditions.
LVOTO >_30 mmHg at rest or exercise, asymmetric hypertrophy, or increased LGE in a patchy mid-wall pattern in the most hypertrophied segment,
further suggest the presence of HCM.
It can be considered familial when two or more ﬁrst- or second-degree relatives with HCM or a ﬁrst-degree relative with autopsy proven HCM and sudden death at <50 years of age are detected.
Differential diagnosis
It might be difﬁcult with physiological hypertrophy induced by intense athletic training, severe hypertension or aortic stenosis and with isolated septal hypertrophy. Consider a genetic HCM if the degree of LV hypertrophy is disproportionate with respect to the acquired trigger.
Consider amyloidosis as a cause when increased thickness of the interatrial septum, AV valve and/or RV free wall are detected (see section 14.6).
Genetic counselling and testing
Indication. Must be offered to all patients with a diagnosis of HCM to identify a possible underlying genetic cause and to all ﬁrst-degree adult relatives of patients with HCM and a deﬁnite disease-causing mutation, regardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.
Clinical evaluation, ECG and echocardiography, must be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing mutation as the index patient.
When no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in ﬁrst-degree adult relatives and repeated every 25 years or less if non-diagnostic abnormalities are present.
Minimal set of genesa (sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT, Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.898,924926
The use of additional sequencing for the analysis of very large panel of genes may be considered if there is a clear familial history or structural phenotype,
by preference combined with family segregation.
Speciﬁc conditions.
Muscular weakness: consider mitochondrial X-linked mutations, glycogen storage disorders, FHLI mutations, Friedreich’s ataxia.
Syndromic conditions (cognitive, visual impairment, drooping eyelid): consider mitochondrial X-linked mutations, Noonan syndrome, Danon disease.
Cafe´ au lait spots (lentigines): consider Leopard/Noonan syndrome
Endomyocardial biopsy
Indication. It may be considered when the baseline clinical assessment suggests cardiac inﬂammation or storage disease which cannot be diagnosed by other means896 (see also Section 14.6).
Therapeutic options895,896,923
With LVOTO
Avoid hypovolaemia (dehydration), arterial and venous dilators (nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
Use non-vasodilating beta-blockers or use verapamil if beta-blockers non-tolerated or ineffective.
Low-dose loop or thiazide diuretics must be used with caution to improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
Invasive treatment (septal reduction therapy by alcohol ablation or myomectomy), in experienced centres, may be considered in those patients with a resting or maximum provoked LVOT >_50 mmHg and/or who remain symptomatic (NYHA class III or IV, syncope) despite OMT.
Novel drugs or devices may be considered once available.909,927
Symptomatic without LVOTO
Cautious use of low-dose loop or thiazide diuretics avoiding hypovolaemia.
Verapamil/diltiazem if LVEF >50% and beta-blockers are not tolerated or ineffective.
Indication to ICD
Based on sudden cardiac death risk models.928930
Consider ICD implantation if:
-
family history of sudden cardiac death in one or more ﬁrst degree relatives under 40 years of age or sudden cardiac death in a ﬁrst degree relative with conﬁrmed HCM at any age;
-
NSVT;
-
unexplained syncope.931
Fabry disease
Enzyme replacement therapy (alpha-galactosidase A deﬁciency).895
Amyloidosis. See section 14.6 and Figure 21.
AV= atrio-ventricular; BAG3= Bcl2-associated athanogene 3; ECG= electrocardiogram; HCM= hypertrophic cardiomyopathy; ICD= implantable cardioverter-deﬁbrillator; LGE=
late gadolinium enhancement; LMNA =lamin A/C; LV= left ventricular; LVEF= left ventricular ejection fraction; LVOT= left ventricular outﬂow tract; LVOTO= left ventricular outﬂow tract obstruction; MHC= myosin heavy chain; MYPC= myosin-binding protein C; NSVT= non-sustained ventricular tachycardia; NYHA= New York Heart Association; OMT
= optimal medical therapy; PLN= phospholamban; RMB20= ribonucleic acid binding motif 20; RV= right ventricular; TNNT =troponin-T; TTN= titin.
aThe list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using.
ESC 2021


<!-- PAGE 83 -->

### Page 83

...................
on CMR, younger age, or with a specific familial/genetic phenotype
(Tables 2729). Risk models for the prediction of ICD benefits were applied to the patients enrolled in DANISH and may help for the indication to ICD implantation in DCM.166,913 Treatment of HCM and
AC,
including indications for
ICD,
are detailed in previous documents.895,896,899,912,914,915
14.3 Left ventricular non-compaction
LVNC is a very rare congenital CMP characterized by endomyocardial trabeculations that increase in number and prominence. In most cases, including when the condition is caused by mutations in the MYH7 or MYBPC3 gene, LVNC is inherited in an autosomal dominant pattern.644,937,938 A clear overlap exists in families with
Table 29
Arrhythmogenic cardiomyopathy: speciﬁc aspects of diagnosis and treatment912,915,932
Deﬁnition
Inherited heart muscle disease characterized by progressive ﬁbrofatty replacement of the RV myocardium which may act as a substrate for ventricular arrhythmias, unexplained syncope and/or sudden cardiac death.
LV involvement and systolic dysfunction occurs in >30% of AC patients, therefore its phenotype may overlap with DCM.
Diagnosis933
Based upon the evaluation of a combination of the genetic factors (most cases autosomal dominant desmosomal mutations), documentation of ventricular arrhythmias and imaging criteria (echocardiography and MRI) of RV dysplasia with the ﬁbrofatty replacement either or not conﬁrmed by EMB. Speciﬁc ECG
abnormalities can be present or absent.
Genetic counselling/testing898,912
Indication. Must be offered to all patients with a suspected AC and has to be offered to all ﬁrst-degree adult relatives of patients with AC and a deﬁnite disease-causing mutation, regardless of their phenotype in order to identify genetically affected individuals at a preclinical phase.
Genetic family screening can be also indicated for arrhythmic risk stratiﬁcation purposes.
Clinical evaluation, ECG, echocardiography and possibly CMR have to be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing mutation as the index patient.
When no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in ﬁrst-degree adult relatives and repeated every 25 years or less if non-diagnostic abnormalities are present.
Minimal set of genes:
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2, DSG2 and DSC2a
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3, desmin, a-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2,
TRPM4 or PLN variants in particular.
If mild LV hypertrophy: consider TNNT variants.
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider rare recessive mutations leading to Carvajal syndrome and Naxos disease. Plakoglobin
(JUP).
With CMR presentation of myocarditis along AC: consider DSP gene variants.934,935
Endomyocardial biopsy
It should be reserved to highly selected cases after all non-invasive studies have been assessed. Fibrofatty replacement with or without replacement type ﬁbrosis at RV septal biopsies are the characteristic ﬁndings. EMB has low sensitivity for the diagnosis of AC in cases of focal distribution.
Therapeutic options
HF treatment for HFrEF (see sections 5 and 6).
Competitive sports should be avoided, limit activities to leisure-time activities.936
In patients with ventricular arrhythmias: beta-blockers must be titrated to the maximally tolerated dose as ﬁrst-line therapy. Amiodarone can be considered in addition to beta-blockers or if beta-blockers contraindicated or not tolerated; ICD implantation is indicated if history of aborted sudden cardiac death or sustained and/or haemodynamically poorly tolerated ventricular tachycardia.910912
In patients with no ventricular arrhythmias: ICD can be considered (see section 6.1) even in patients with LMNA or FLNC gene mutations and LVEF
<45%.912
AC = arrhythmogenic cardiomyopathy; BAG3 = Bcl2-associated athanogene 3; CMR = cardiac magnetic resonance; DCM = dilated cardiomyopathy; DSC2 = desmocollin 2;
DSG2 = desmoglein 2; DSP = desmoplakin; ECG = electrocardiogram; EMB = endomyocardial biopsy; FLN = ﬁlamin; FLNC = ﬁlamin C; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; JUP = junction plakoglobin; KCNH2 = potassium voltage-gated channel subfamily H member 2;
KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM domain binding 3; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NKX2-5 = NK2 transcription factor related, locus 5; PLN = phospholamban; PKP2 = plakophilin 2; RMB20 = ribonucleic acid binding motif 20; RV = right ventricular; SCN5A = sodium channel alpha subunit 5; TMEM43 = transmembrane protein 43; TNNT = troponin-T; TRPM4 = transient receptor potential cation channel subfamily M member 4.
ESC 2021
ESC Guidelines
3681


<!-- PAGE 84 -->

### Page 84

...............................................................................................................................................................
DCM and HCM phenotypes. Quite commonly individuals with features of LVNC are found in families where other affected relatives have typical HCM or DCM. Therefore, LVNC is not treated as a separate disease entity, but as a separate rare presentation of a genetic susceptibility to either HCM or DCM.939
14.4 Atrial disease
14.4.1
Definition
Atrial disease, also termed atrial failure or myopathy, can be defined as a complex of subclinical structural, electrophysiological, and functional changes that affect the atria with the potential to produce clinical consequences.606,940,941 It has been suggested that atrial disease links the pathophysiology of HF, especially HFpEF, with AF, as they often coexist, are closely inter-related and share common risk factors.606,685,942,943
14.4.2
Diagnosis
Atrial size and function can be evaluated by multimodality imaging including two- and three-dimensional echocardiography, myocardial deformation, computed tomography (CT) and CMR.944
Cardiac biomarkers, including high-sensitivity cardiac troponins and NPs, may assess pathophysiological aspects of atrial disease.945947 The increased levels of NPs in AF may also be an indicator of an underlying atrial disease.942,948 A comprehensive characterization of atrial disease combining clinical, imaging, biochemical and molecular features is, however, still lacking.
14.4.3
Management
Atrial disease is an emerging therapeutic target in the prevention of
AF, systemic thromboembolism, and perhaps HFpEF.949 As atrial disease appears to result from the intersection of shared risk factors and comorbidities predisposing to both AF and HF, diabetes mellitus,
hypertension, obesity, smoking, and physical inactivity may be of paramount importance for its development.7,950 Effective management of
HF and AF (see section 12.1.1), as well as treatment of mitral regurgitation (see section 12.3.3), may also be important to counteract atrial disease progression.
14.5 Myocarditis
14.5.1
Epidemiology and diagnosis
The incidence of acute myocarditis is estimated to be 1.5 million cases per year globally.951 The contribution of myocarditis as a cause of HF
varies by age and region from approximately 0.5% to 4.0%.918,952
Chronic, EMB proven, inflammation can be found in 9% to 30% of adult patients with a DCM.918,953 The most frequent potential aetiologies triggering acute myocarditis in Europe are reported in Table 30.
The clinical presentation of acute myocarditis may vary from mild symptoms to cardiogenic shock. Workup for the diagnosis of acute myocarditis in patients with HF is reported in Table 31 and Figure 20.
Specific criteria about biopsies and CMR are reported in Tables 32
and 33.
14.5.2
Treatment
Hospitalization for at least 48 h may be useful for patients with acute myocarditis and HF, especially when troponins are elevated and when cardiac dysfunction, and/or arrhythmias are present at initial presentation.
Despite the lack of evidence in the specific setting of acute myocarditis, treatment of HFrEF is recommended in the presence of systolic
LV dysfunction. Immunosuppression is only indicated in selected cases of acute myocarditis (Table 34). Once cardiac enzymes decrease, arrhythmias are absent, and cardiac systolic dysfunction is stabilized, standard HF therapy should be continued for at least
6 months (see also Figure 20).
Immunosuppression has been considered for treatment of patients with chronic cardiac inflammation at EMB and no evidence of active viral infection.918,919 This was associated with an improvement in cardiac function in small studies and with better outcomes in a retrospective observational study.953,963,964 Prospective trials with old or newer immunosuppressive/immunomodulatory drugs are needed. A
placebo-controlled trial testing the effects of immunoadsorption with i.v. immunoglobulins on LV function is ongoing and other treatment options are being tested.919
14.6 Amyloidosis
14.6.1
Epidemiology and diagnosis
CA or amyloid cardiomyopathy is still an underdiagnosed cause of
HF.895,965,966 The two most prevalent forms of CA are light chain immunoglobulin (AL) and transthyretin (ATTR) amyloidosis. ATTR
includes the wild-type (>90% of cases), and the hereditary or variant type (<10% of cases). It is estimated that 6% to 16% of all patients
Table 30
Aetiologies to be considered triggering acute myocarditis917
Infectious
Viral
Parvovirus B19, human herpes virus-6, EpsteinBarr virus, enteroviruses, (coxsackievirus,
adenovirus), CMV, HIV, SARS-CoV-2
Others
Borrelia, Coxiella burnetii (Q-fever)
Systemic disease
Auto-immune and others
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE, ANCA-positive vasculitis,
rheumatoid arthritis, any other auto-immune disease
Toxic
Medications
Immune check point inhibitors, anthracyclines,
clozapine, adrenergic drugs, 5-ﬂuorouracil
Other agents
Alcohol, amphetamines, cocaine
ANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus; HIV =
human immunodeﬁciency virus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SLE = systemic lupus erythematosus.
ESC 2021


<!-- PAGE 85 -->

### Page 85

...........................
with unexplained LVH or HFpEF at hospitalization or severe aortic stenosis undergoing aortic valve replacement, aged above 65 years,
may have wtTTR-CA.967972
Diagnosis and treatment of CA were recently reviewed.973 Age
>65 years and HF along with a LV wall thickness >12 mm at echocardiography are major criteria for the suspicion of CA.973 Criteria for a suspicion of CA and to confirm diagnosis are reported in Table 35,
Supplementary Table 25, and Figure 21.973,974 Cardiac imaging and
EMB or extra-cardiac biopsy are needed for the diagnosis of AL-CA
in patients with abnormal haematological tests
(Figure
21).
Technetium-labelled 99mTc-PYP or DPD or HMDP scintigraphy with planar and SPECT imaging has a specificity and positive predictive value for TTR-CA of up to 100%.975 In contrast, CMR has a sensitivity and specificity of 85% and 92%, respectively.966,976 The hereditary form should be excluded by genetic testing. EMB is the gold standard for the diagnosis of TTR-CA with nearly 100% sensitivity and specificity if specimens are collected from >4 multiple sites and tested for amyloid deposits by Congo red staining.966 However, a biopsy is not
Table 31
Diagnostic workup in suspected acute myocarditis
Deﬁnition of suspected acute myocarditis
Clinical presentation þ >_1 mandatory diagnostic test being positive (by preference CMR) in the absence of signiﬁcant coronary artery,
valvular or congenital heart disease, or other causes.
Sensitivity
Speciﬁcity
Clinical presentation
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF, and/or unexplained arrhythmias or aborted sudden death.
Low
Low
Mandatory diagnostic tests
ECG
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities.
High
Low
Laboratory tests
Elevated troponins with dynamic changes consistent with myocardial necrosis.
Standard tests including white blood cells count to exclude eosinophilia.919,954
Intermediate
Low
Echocardiography
New structural or function abnormalities, regional wall motion abnormalities or global ventricular dysfunction without ventricular dilatation or with, generally mild, dilatation, increased wall thickness due to myocardial oedema, pericardial effusion, intracardiac thrombi, not explained by other conditions (e.g., CAD, ACS or valvular heart disease).
High
Low
CMR
Oedema, inﬂammation and ﬁbrosis detection, quantiﬁcation and localization through T1 and T2 mapping, extracellular volume assessment and
LGE (see Table 33).955,956
High
Intermediate
Additional diagnostic tests
Coronary angiography or CTCA
Excludes signiﬁcant CAD or ACS in clinically suspected myocarditis.
High
High
Endomyocardial biopsy
For diagnosis and indication to speciﬁc treatment (see Table 32).
Intermediate
High
Cardiac PET
May be useful in patients who cannot undergo CMR or with suspected systemic autoimmune disease or cardiac sarcoidosis.919,957
Low
Low
Additional laboratory test
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune disease.
Low
Low
CRP elevated in 8090% patients.919,954
Intermediate
Low
PCR testing of common cardiotropic viruses. It can detect systemic infection but does not prove cardiac infection and cannot substitute viral genome analysis on EMB samples.917
Circulating IgG antibodies to cardiotropic viruses are common in the absence of viral myocarditis. Very limited diagnostic usefulness.917,918
Speciﬁc test for SARS-CoV-2, Borrelia, HIV or CMV if clinical suspicion.
Low
Low
ACS = acute coronary syndrome; AV = atrio-ventricular; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; CRP = C-reactive protein; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; EMB = endomyocardial biopsy; HF = heart failure; HIV = human immunodeﬁciency virus;
IgG = immunoglobulin G; LGE = late gadolinium enhancement; PCR = polymerase chain reaction; PET = positron emission tomography; QRS = Q, R and S waves (combination of three of the graphical deﬂections); SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; ST = ST segment of the electrocardiogram; ST-T = ST segment and T
wave of the electrocardiogram.
ESC 2021
ESC Guidelines
3683


<!-- PAGE 86 -->

### Page 86

Management of patients with heart failure and suspected myocarditis
Clinical history, signs and symptoms, ECG, laboratory,
echocardiography, CMR imaging, coronary CT/CAGa
Treatment of CAD if present and indicated
Suspected auto-immunity,
infectious, toxic
HF treatment
Clinical stabilization 
EMB if any doubt about diagnosis
Maintain HF treatment
Consider immunosuppressive therapy or anti-infection
Y
N
Consider MCS
Figure 20 Management of patients with heart failure and acute myocarditis. ACS= acute coronary syndrome; CAD= coronary artery disease; CAG=
coronary artery angiogram; CMR= cardiac magnetic resonance; CT= computed tomography; ECG =electrocardiogram; EMB= endomyocardial biopsy;
HF= heart failure; MCS= mechanical circulatory support. aTo exclude CAD/ACS.
Table 32
Endomyocardial biopsy in patients with suspected myocarditis
Indication (see also section 4.3).
Progressive or persistent severe cardiac dysfunction and/or life-threatening ventricular arrhythmias and/or Mobitz type 2 second-degree or higher AV block with lack of short-term (<1-2 weeks) expected response to usual medical treatment.
The aim is to identify aetiology and to indicate speciﬁc treatment (e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic inﬂammatory disorders).97,98,917,918,958
Number and sites of the samples
A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left and/or right ventricle. CMR or PET guided sampling may be considered.919
Aetiology
Quantitative PCR viral genome analysis for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackievirus) by rtPCR.
Viral mRNA for active viral replication may be assessed although it has low sensitivity.
On indication, search for CMV, HIV, Borrelia, Coxiella burnetii (Q-fever) and SARS-CoV-2.
Diagnosis of inﬂammation
Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45 antibodies for lymphocytes and anti-CD68 antibodies for macrophages and antiHLA-DR antibodies.907,917,918,959
Therapeutic implications
Immunosuppressive therapy may be indicated based on the results of EMB as in giant cell myocarditis or eosinophilic myocarditis and, possibly, also in sarcoidosis, vasculitis or selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling.98,917919,954
Antibiotics: Borrelia (Lyme disease).
Antiviral therapy: HIV, CMV, HHV6 pending on load and viral replication (mRNA).
CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DNA = deoxyribonucleic acid; EMB = endomyocardial biopsy; HHV = human herpes virus; HIV = human immunodeﬁciency virus; HLA-DR = human leucocyte antigen-DR isotype; mRNA = messenger ribonucleic acid; PCR = polymerase chain reaction; PET = positron emission tomography;
RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
ESC 2021


<!-- PAGE 87 -->

### Page 87

.......................................................................................
needed with a grade 23 positivity of scintigraphy with SPECT
(Figure 21).973
14.6.2
Therapy of amyloidosis and heart failure
Maintenance of euvolaemia is central to management but is challenging due to the markedly reduced ventricular capacitance.977 If
HF symptoms are present, a loop diuretic, possibly with an MRA,
may be given, but orthostatic hypotension may cause intolerance.
Beta-blockers, digitalis, ACE-I, ARBs, or ARNI may not be well tolerated because of hypotension, and their place in CA treatment is unsettled. Their withdrawal must be often considered due to hypotension and/or bradycardia.973,974 CCB should be avoided as they may cause severe hypotension and fatigue, or form complexes with amyloid.966
Amyloid infiltration of the atrial wall leads to atrial myopathy and electromechanical dissociation with high embolic risk.
Patients with CA and history of AF should receive anticoagulation.
There is no evidence to support anticoagulation for patients in SR, yet.7,978 Amiodarone is the preferred antiarrhythmic agent.973
Therapy of AL-CA is based on treatment of the underlying haematological problem with chemotherapy or autologous stem-cell transplant.
TTR stabilization and reduction of its production are the basis of TTR-CA treatment. Liver and/or cardiac transplantation can be considered only in end-stage disease of familial TTR-CA.
Tafamidis reduced all-cause mortality and CV hospitalizations in cardiac or non-cardiac biopsy-proven hereditary and wtTTR-CA,
mainly in those patients with NYHA class I and II at baseline.
Functional improvement occurred within 6 months, whereas the decrease in mortality took nearly 2 years to occur.979,980
Intravenous patisiran, a small RNA interfering molecule, or subcutaneous inotersen, antisense oligonucleotide against TTR, may be considered in those patients with combined hTTRpolyneuropathy and CA (Figure 21).981,982 Off-label use of diflunisal may be considered in wtTTR-CA in combination with a proton pump inhibitor.983
14.7 Iron overload cardiomyopathy
Iron overload results either from genetically determined increased intestinal iron absorption in the context of hereditary haemochromatosis (primary iron overload) or from multiple blood transfusions required for the management of haematological conditions such as beta-thalassaemia (secondary iron overload).984 In iron overload, the iron binding capacity of transferrin is saturated and non-transferrin-bound iron enters cardiomyocytes through Ltype calcium channels, causing oxidative myocardial damage.985
Table 33
Cardiac magnetic resonance in patients with suspected myocarditis955,956
Indication
Indicated at baseline, in all patients with clinical history þ ECG, elevated troponin or echocardiographic abnormalities, and signiﬁcant CAD
excluded or unlikely.
Advised at follow-up in patients with persistent dysfunction at echocardiography, arrhythmias or ECG abnormalities.a
Main ﬁndings
At baseline: T1-weighted (inﬂammation, injury) and T2-weighted (oedema)
sequences, extracellular volume and LGE within 2 weeks after symptom onset.956,960
At follow up: LGE to evaluate the degree of scarring, T1 and T2 to identify persistent inﬂammation.a
Diagnostic signiﬁcance
At least one T2-based criterion (global or regional increase of myocardial
T2 relaxation time or an increased signal intensity in T2-weighted images),
with at least one T1-based criterion (increased myocardial T1, extracellular volume, or LGE) in the acute phase.
Only one (i.e., T2-based or T1-based) marker may still support a diagnosis of acute myocardial inﬂammation in an appropriate clinical scenario, albeit with less speciﬁcity in the acute phase.
A negative T1/T2 scan does not exclude a still ongoing inﬂammatory process in the chronic phase.a
CAD = coronary artery disease; CMR = cardiac magnetic resonance; ECG = electrocardiogram; LGE = late gadolinium enhancement.
aIt takes at least 3 months before CMR signs of oedema (secondary to inﬂammation in the acute phase/baseline) disappear. At 6 months, T1 or T2 signs of oedema should have disappeared if inﬂammation would be completely absent.
Still, the absence of T1 or T2 oedema does not exclude chronic low-grade inﬂammation.
Table 34
Treatment and follow-up of acute myocarditis
HF therapy should be started if LV systolic dysfunction is present at presentation and should be continued for at least 6 months upon complete functional recovery (EF >50%).918,919
Immunosuppression for at least 612 months is required in acute myocarditis with clinical or EMB evidence of auto-immune disease, including giant cell myocarditis, vasculitis or sarcoidosis.98,917919,953,954,961
Immunosuppression is not advised on a routine basis in acute myocarditis without clinical or EMB-based evidence of auto-immune disease.917 Initial empirical administration of i.v. corticosteroids may be taken into consideration in cases of high suspicion of immune-mediated myocarditis especially if complicated by acute HF, malignant arrhythmias and/or high degree AV block.954,962
Intense sporting activities should be avoided as long as symptoms, cardiac enzymes elevated or ECG/imaging abnormalities are present and last for at least 6 months since complete recovery.936
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases.
AV = atrio-ventricular;
DCM = dilated cardiomyopathy;
ECG = electrocardiogram; EF = ejection fraction; EMB = endomyocardial biopsy; HF = heart failure; i.v.
= intravenous; LV = left ventricular.
ESC 2021
ESC 2021
........................................................................
ESC Guidelines
3685


<!-- PAGE 88 -->

### Page 88

.....................................................................................................
Additional iron-induced complications, such as liver disease and endocrine abnormalities, further contribute to cardiac deterioration.986,987 The end result is the development of iron overload cardiomyopathy (IOCM), which may have either a restrictive or a dilated phenotype, the former potentially evolving to the latter as the disease advances. Myocardial iron deposition can be accurately estimated by the CMRT2* technique; T2* values are correlated with left and right ventricular systolic function and predict the development of iron-induced
HF
or arrhythmias.984
Prevention of IOCM is successfully accomplished with iron chelators, including deferoxamine, deferiprone, and deferasirox, while established IOCM may be completely reversed by intensified and combined iron chelation therapy.985
14.8 Adult congenital heart disease
The management of ACHD has been reviewed in detail in a recent
ESC guideline.988 HF is a common problem affecting 2050% of the ACHD population, and an important cause of death.989 The pathophysiology of cardiac dysfunction in ACHD is often different from non-congenital (acquired) heart disease, in particular in those with: a systemic right ventricle (RV), a failing subpulmonary ventricle, a single ventricle,988 surgery-related injury, chronic pressure/volume overload in systemic and sub-pulmonary ventricles, and those with hypertrophy or non-compaction induced by gene mutations.
Therefore,
extrapolation of current HF treatment guidelines to ACHD patients is not always appropriate. In addition, the few available data on HF treatments in ACHD patients are often inconclusive and are derived from small patient cohorts. As a consequence, ACHD specific recommendations are mostly based on clinical experience or position statements.990
Importantly, ACHD patients with HF should be referred to expert centres. The general principles of management, while awaiting transfer to specialist centres, is summarized in Table 36.
Table 35
“Red ﬂags” for most common forms of cardiac amyloidosis
Type
Red Flag
TTR
AL
Extracardiac
Polyneuropathy
X
X
Dysautonomia
X
X
Skin bruising
X
Macroglossia
X
Deafness
X
Bilateral carpal tunnel syndrome
X
Ruptured biceps tendon
X
Lumbar spinal stenosis
X
Vitreous deposits
Xa
Family history
Xa
Renal insufﬁciency
X
Proteinuria
X
Cardiac
Clinical
Hypotension or normotensive if previously hypertensive
X
X
ECG
Pseudo-infarct ECG pattern
Low/decreased QRS voltage to degree of LV thickness
AV conduction disease
X
X
X
X
X
X
Laboratory
Disproportionally elevated NTproBNP to degree of HF
Persisting elevated troponin levels
X
X
X
X
Echocardiography
Granular sparkling of myocardium
Increased right ventricular wall thickness
Increased AV valve thickness
Pericardial effusion
Reduced longitudinal strain with apical sparing pattern
X
X
X
X
X
X
X
X
X
X
CMR
Subendocardial LGE
Elevated native T1 values
Increased extracellular volume
Abnormal gadolinium kinetics
X
X
X
X
X
X
X
X
AL = light chain immunoglobulin; AV = atrio-ventricular; CA = cardiac amyloidosis; CMR = cardiac magnetic resonance; ECG = electrocardiogram; HF = heart failure; LGE = late gadolinium enhancement; LV = left ventricular; NT-proBNP = Nterminal pro-B-type natriuretic peptide; QRS = Q, R and S waves (combination of three of the graphical deﬂections); TTR = transthyretin.
Modiﬁed from973.
aHereditary TTR-CA.
Recommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis
Recommendations
Classa
Levelb
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA
class I or II symptoms to reduce symptoms, CV
hospitalization and mortality.979
I
B
Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.979
I
B
CA = cardiac amyloidosis; CV = cardiovascular; hTTR = hereditary transthyretin;
NYHA = New York Heart Association; wtTTR = wild-type transthyretin.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
..........................................................


<!-- PAGE 89 -->

### Page 89

Diagnosis and treatment of cardiac amyloidosis in heart failure patients
Cardiac amyloidosis suspected
HF and LV wall thickness ≥12 mm
AND age ≥65 or at least 1 red flaga 
Serum free light-chain assay
Serum and urine protein electrophoresis with immunofixation
99mTc-PYP, DPD or HMDP
scintigraphy with SPECT
Histological 
confirmation to subtype
(usually cardiac)b
Amyloidosis unlikely
Histological confirmation of diagnosis
(cardiac/
extracardiac)c
Tafamidis
(Class I)
Amyloidosis unlikely
Both abnormal
Abnormal haematology
No myocardial uptake
Normal haematology
Grade 1 uptake
Normal haematology
Grade 2–3 uptake
All normal
ATTR
Genetic counselling
Cardiac amyloidosis on CMR imaging
Positive or inconclusive
Negative
Consider patisiran or inotersen if hereditaryATTR
and polyneuropathy
Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart failure patients. Based on.973 ATTR = transthyretin amyloidosis; CMR = cardiac magnetic resonance; DPD = 3,3-diphosphono1,2-propanodicarboxylic acid; HF = heart failure; HMDP = hydroxymethylene diphosphonate;
LV = left ventricular; SPECT = single-photon emission computed tomography; 99mTc-PYP = technetium-labelled 99mTc-pyrophosphate. aRed flags are listed in Table 35. bGenerally requires endomyocardial biopsy for a diagnosis of the cardiac subtype. cRequires biopsy that may be cardiac or abdominal.
ESC Guidelines
3687


<!-- PAGE 90 -->

### Page 90

...........................................................................................................................................................
15 Key messages
(1)
Patients with HF are classified based on their LVEF. Those with a
LVEF between 41% and 49% are defined as ‘mildly reduced LVEF’
(HFmrEF).
(2)
Measurement of NPs and echocardiography have key roles in the diagnosis of HF.
(3)
ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are recommended as cornerstone therapies for patients with HFrEF.
(4)
ICDs are recommended in selected patients with HFrEF of an ischaemic aetiology and should be considered in those with a nonischaemic aetiology.
(5)
CRT-P/D is recommended in those patients with HFrEF, in sinus rhythm, with a LBBB >_150 ms and should be considered in those with a LBBB >_130149 ms or non-LBBB >_150 ms.
(6)
Advanced HF strategies (heart transplantation/MCS) may be appropriate in selected patients.
(7)
ACE-I/ARNI, beta-blockers, and MRA may be considered in patients with HFmrEF.
(8)
The diagnosis of HFpEF requires objective evidence of cardiac structural, or functional abnormalities as well as elevated plasma
NP concentrations consistent with the presence of LV diastolic dysfunction and raised LV filling pressures. A diastolic stress test is recommended when these markers are equivocal.
(9)
To date, no treatment has been shown to reduce mortality and morbidity in patients with HFpEF.
(10)
It is recommended that all patients with HF be enrolled in a multidisciplinary HF-MP.
(11)
Exercise is recommended for all patients who are able, to improve exercise capacity and QOL, and reduce HF hospitalization.
(12)
Patients with advanced HF refractory to medical/device therapy and who do not have absolute contraindications should be referred for consideration of heart transplantation. MCS should also be considered as BTT or DT in selected patients.
(13)
Four major clinical presentations of acute HF may occur: ADHF,
acute pulmonary oedema, RV failure, and cardiogenic shock.
(14)
Treatment of acute HF is based on diuretics for congestion, inotropes, and short- term MCS for peripheral hypoperfusion.
(15)
Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. Oral treatment should be optimized before discharge.
(16)
In addition to oral anticoagulation, a strategy of rhythm control including catheter ablation should be considered in patients whose symptoms and/or cardiac dysfunction are associated with AF.
(17)
SAVR or TAVI, as advised by the Heart Team, are recommended in patients with symptomatic severe aortic valve stenosis.
(18)
Patients with isolated significant SMR and COAPT criteria should be considered for percutaneous edge-to-edge repair, whereas those with SMR and CAD, who need revascularization, should be considered for surgery.
(19)
It is recommended that patients with type II diabetes are treated with SGLT2 inhibitors.
(20)
Patients should be periodically screened for anaemia and iron deficiency and i.v. iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45%
and iron deficiency, and in patients recently hospitalized for HF
and with LVEF <_50% and iron deficiency.
Table 36
Treatment of adult congenital heart disease and heart failure in specialized centres
ACHD patients with chronic HF should be referred to specialized centres.
Speciﬁc guidelines for medical treatment of chronic HF in ACHD are lacking, and practitioners should follow the current guidelines for medical treatment of HF. It remains unknown whether the long-term use of neurohormonal modulators affects clinical outcomes and prognosis in
ACHD.
Sacubitril/valsartan may decrease morbidity,991993 however, no recommendation can be made at this moment based on the retrospective or anecdotical nature of these observations.
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron deﬁciency,
and cachexia should be treated according to speciﬁc recommendations reported in this document.
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be considered in symptomatic patients with a failing systemic right ventricle.
Diuretics are recommended to control symptoms of ﬂuid retention.
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt, should always be carefully initiated, taking the labile balance of ventricular preload and systemic afterload into account.
CRT may be a therapeutic option in ACHD patients with HF, but evidence in this speciﬁc setting is still lacking. Efﬁcacy of CRT will depend on the underlying structural and functional substrate, such as anatomy of the systemic ventricle (left, right, or functionally single), presence and degree of structural systemic AV valve regurgitation, primary myocardial disease or scarring, and type of electrical conduction delay.988
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal membrane oxygenation, and advanced bridging techniques.988,994
Timely evaluation for transplantation by ACHD HF specialists in a transplant centre with ACHD expertise is recommended.
Ventricular assist devices can bridge patients to transplantation, or in a subgroup of patients, may be an option as destination therapy.
ACHD = adult congenital heart disease; AF = atrial ﬁbrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; CSA = central sleep apnoea; HF =
heart failure; LV = left ventricular.
ESC 2021


<!-- PAGE 91 -->

### Page 91

.............................................................................................................................................................................
16 Gaps in evidence
Major advances in the diagnosis and treatment of patients with HF
have occurred over recent years. Strong evidence for new treatment options have been given by recent RCTs and HF management may undergo major changes in the next years. New discoveries, however,
pose new challenges and many areas with lack of evidence still remain. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.
(1)
Definition and epidemiology i. Further research into the underlying characteristics, pathophysiology, and diagnosis of HFmrEF and HFpEF
ii. Consensus about normal values/ranges of EF
iii. Better phenotyping of HFpEF
iv. More information on the incidence and prevalence of
‘recovered LV’ systolic function
(2)
Diagnosis i. Definitive studies on the role of biomarkers, focusing on their additive value in the diagnosis of HF
ii. More randomized studies on screening for HF in asymptomatic subjects that may translate into improved outcomes iii. Studies on biomarkers showing the impact on outcome of their measurements for the identification of subjects at risk of developing HF as well as to guide treatment in patients with HF
iv. Validated diagnostic protocols for the diagnosis of HFmrEF
and HFpEF
(3)
Pharmacotherapy of CHF
i. Pragmatic studies on the order of adding disease-modifying drugs for HFrEF
ii. Specific therapies for HFmrEF and HFpEF and, likely, their different phenotypes iii. More data and prospective clinical trials of HFrEF therapies in patients with eGFR <30 mL/min/1.73 m2
iv. Further evidence from prospective RCTs for the treatment of specific HF phenotypes: myocarditis, cardiotoxicity, inherited
CMPs, PPCM, amyloidosis v. Management strategies and therapies for ‘recovered LV’ systolic function vi. More evidence on the effects of fluid restriction, dietary salt restriction, and nutrition
(4)
Devices and interventions i. Indications for ICDs in specific subgroups of HFmrEF/HFpEF
and optimal selection of ICD candidates in HFrEF, including patients with ischaemic and non-ischaemic cardiomyopathy ii. More research on CRT efficacy in AF
iii. Further prospective randomized studies showing the impact on outcomes of AF ablation strategies compared to OMT in
HF patients iv. Further research on the percutaneous treatment of valve heart disease and its impact on patients’ outcomes and QOL
v. Larger RCTs on CCM and baroreceptor stimulation in HFrEF
(5)
Disease management i.
The role of remote monitoring strategies in HF in the post
COVID-19 era ii.
Studies on optimal models for follow-up of stable HF patients iii.
Studies to determine specific options for palliative care
(6)
Advanced HF
i.
Better definition of risk profiles according to INTERMACS and other classifications ii.
RCTs to establish the effects on outcomes of long-term MCS
in hospitalized patients as well as in ambulatory outpatients
(for instance INTERMACS 46 profiles)
iii.
Advances in long-term MCS, including strategies to reduce the risk of bleeding, thromboembolic events, and infection iv.
Advances in medical treatment for the many patients who cannot undergo MCS or heart transplantation including development of treatment strategies, novel inotropes or myotropes for patients with advanced HF
(7)
AHF
i.
Better definition and classification of patient phenotypes to facilitate improved treatment ii.
Evidence-based use of imaging techniques and biomarkers that have an impact on patients’ clinical course iii.
Development of better strategies for congestion relief, including monitoring of diuretic administration, and/or to improve organ perfusion iv.
Identification of treatments with an impact on post-discharge outcomes v.
New devices for short-term MCS
vi.
Definition of evidence-based treatment options and therapeutic algorithms for patients with cardiogenic shock
(8)
CV comorbidities i. RCTs showing best strategies for the treatment of ventricular arrhythmias ii. RCTs to establish the role of coronary revascularization procedures in different patient subsets iii. RCTs to establish the impact on patients’ outcomes and/or
QOL of percutaneous treatment of mitral or tricuspid valve disease in patients with HF
(9)
Non-CV comorbidities i.
RCTs addressing cachexia and/or sarcopenia and/or frailty and showing the impact of treatment on QOL and/or outcome ii.
RCTs of medical therapies or devices in patients with severe
CKD and HF
iii.
RCTs showing the effects on outcomes of medical treatment of electrolyte abnormalities iv.
RCTs showing the effects on outcomes of treatment of
CSA
v.
Prospective studies showing the impact on outcomes and/or
QOL of early diagnosis, better prevention and treatment of cardiotoxicity of cancer therapies vi.
Better treatment of infections and prevention of cardiac injury with infection
(10)
Special conditions i.
RCTs of treatment for PPCM
ii.
Better phenotyping of CMPs through genetic testing, biomarkers and imaging modalities, and tailoring of therapy iii.
RCTs of treatment of different types of myocarditis, including immunosuppressive therapies iv.
RCTs of new treatments of different forms of cardiac amyloid v.
Better definition and treatment of LA myopathy.
ESC Guidelines
3689


<!-- PAGE 92 -->

### Page 92

17 ‘What to do’ and ‘what not to do’ messages from the guidelines
Recommendations
Classa
Levelb
Recommendations for the diagnosis of chronic HF
BNP/NT-proBNP.c
I
B
12-lead ECG.
I
C
Transthoracic echocardiography.
I
C
Chest radiography (X-ray).
I
C
Routine blood tests for comorbidities (including full blood count, urea and electrolytes, thyroid function, fasting glucose and
HbA1c, lipids. Iron studies (TSAT and ferritin).
I
C
CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic windows.
I
C
CMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂammatory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis.
I
C
Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.
I
B
Cardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS.
I
C
Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS.
I
C
Recommendations for the treatment of HFrEF
ACE-I is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Beta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death.
I
A
MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF hospitalization and death.
I
B
Diuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms,
improve exercise capacity and reduce HF hospitalizations.
I
C
An ARBc is recommended to reduce the risk of HF hospitalization and CV death in symptomatic patients unable to tolerate an ACE-I or ARNI (patients should also receive a beta-blocker and an MRA).
I
B
The addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with
HF, because of the increased risk of renal dysfunction and hyperkalaemia.
III
C
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA
class IIIII) of an ischaemic aetiology (unless they have had an MI in the prior 40 days—see below), and an LVEF <_35% despite
>_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.
I
A
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis.
III
A
ICD therapy is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation.
III
C
CRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.
I
A
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF.
I
A
CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to highdegree AV block.
III
A
Recommendations for the treatment of HFmrEF and HFpEF
Diuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs.
I
C
Continued


<!-- PAGE 93 -->

### Page 93

Screening for, and treatment of, aetiologies, and CV and non-CV comorbidities is recommended in patients with HFpEF (see relevant sections of this document).
I
C
Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.
I
C
Recommendations for the prevention of chronic HF
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.
I
A
Treatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay the onset of HF, and to prevent HF hospitalizations.
I
A
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.
I
A
Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of HF.
I
C
Other recommendations for the management of chronic HF
It is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF
hospitalization and mortality.
I
A
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.
I
A
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospitalization and mortality.
I
A
Exercise is recommended for all patients who are able in order to improve exercise capacity and QOL, and reduce HF
hospitalization.d
I
A
Recommendations for treatment of patients with advanced HF
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.
I
C
Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
C
Recommendations for treatment of patients with acute HF
Oxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.
I
C
Intubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation.
I
C
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to improve symptoms.
I
C
Thromboembolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contraindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.
I
A
Inotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension and evidence of hypoperfusion.
III
C
Routine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety.
III
C
IABP is not routinely recommended in post-MI cardiogenic shock.
III
B
Recommendations for management of patients after HF hospitalization
It is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.
I
C
It is recommended that evidence-based oral medical treatment be administered before discharge.
I
C
An early follow-up visit is recommended at 12 weeks after discharge to assess signs of congestion, drug tolerance, and start and/or uptitrate evidence-based therapy.
I
C
Recommendations for treatment of patients with HF and AF
Long-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and CHA2DS2-VASc score >2 in men or >3 in women.
I
A
DOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.
I
A
Urgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability.
I
C
Treatment with the anti-arrhythmic agents ﬂecainide, encainide, disopyramide, dronedarone, and D-sotalol is not recommended due to safety concerns.
III
A
Continued
ESC Guidelines
3691


<!-- PAGE 94 -->

### Page 94

Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF
hospitalization.
III
C
Recommendations for treatment of patients with HF and aortic stenosis
Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.
I
B
It is recommended that the choice between TAVI and SAVR be made by the Heart Team, according to individual patient preference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.
I
C
Recommendations for treatment of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with
T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.
I
A
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.
I
A
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF
hospitalization.
III
A
The DPP-4 inhibitor saxagliptin is not recommended in patients with HF.
III
B
Recommendations for treatment of patients with HF and iron deﬁciency
It is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count,
serum ferritin concentration, and TSAT.
I
C
Treatment of anaemia in HF with erythropoietin-stimulating agents is not recommended in the absence of other indications for this therapy.
III
B
Recommendation for treatment of patients with HF and sleep apnoea
Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant CSA because of an increased allcause and CV mortality.
III
A
Recommendation for treatment of patients with HF and arthritis
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF
hospitalization.
III
B
Recommendation for treatment of patients with HF and cancer
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease,
previous cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in Cardio-Oncology.
I
C
Recommendations for treatment of patients with HF and amyloidosis
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
B
Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
B
ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial ﬁbrillation; AHF = acute heart failure; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; AV = atrio-ventricular; BNP = B-type natriuretic peptide; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled),
Diabetes, Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CRT = cardiac resynchronization therapy; CSA = central sleep apnoea; CV = cardiovascular; DOAC = direct-acting oral anticoagulant; DPP-4 = dipeptidyl peptidase-4; ECG = electrocardiogram; ECV =
electrical cardioversion; HbA1c = glycated haemoglobin; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; hTTR = hereditary transthyretin; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LMWH = low-molecular-weight heparin; LV = left ventricular/ventricle; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist; NSAID = non-steroidal anti-inﬂammatory drug; NT-proBNP = N-terminal pro-Btype natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; PaO2 = partial pressure of oxygen; QOL = quality of life; QRS = Q, R, and S
waves (on an ECG); RV = right ventricular; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; SpO2 = transcutaneous oxygen saturation; SR
= sinus rhythm; T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT = transferrin saturation; VAD = ventricular assist device; VKA = vitamin K
antagonist; wtTTR-CA = wild-type transthyretin cardiac amyloidosis.
aClass of recommendation.
bLevel of evidence.
cReferences are listed in section 4.2 for this item.
dIn those who are able to adhere to the exercise programme.
ESC 2021


<!-- PAGE 95 -->

### Page 95

....................................
18 Quality indicators
QIs are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes.995 They may also serve as a mechanism for enhancing adherence to guideline recommendations, through quality assurance endeavours and benchmarking of care providers.996 As such, the role of QIs in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations, payers, and the public.997
The ESC recognizes the need for measuring and reporting quality and outcomes of CV care. The methodology by which the ESC QIs are developed has been published997 and, to date, a suite of QIs for an initial tranche of CV conditions has been produced.998,999 To facilitate quality improvement initiatives, the disease-specific ESC QIs are included in corresponding ESC Clinical Practice Guidelines.7,1000 This is further enhanced by way of their integration in the ESC registries,
such as the EURObservational Research Programme (EORP) and the
European Unified Registries On Heart Care Evaluation and
Randomized Trials (EuroHeart) project.1001
For patients with HF, QIs may help healthcare providers to simultaneously operationalize discrete guideline recommendations and enable the discrimination between missed opportunities and appropriate care. Furthermore, QIs allow the capture of patients’
Table 37
Main European Society of Cardiology quality indicators for the evaluation of care and outcomes for patients with heart failure (a full list is published in a separate article)
Domain 1. Structural QIsa
Main (1): Centre should have a dedicated multidisciplinary team to manage patients with HF
Numerator: Availability of a dedicated multidisciplinary team to manage patients with HF.
Domain 2. Patient assessmentb
Main (1): Proportion of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)
Numerator: Number of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
Denominator: Number of patients with HF.
Main (2): Proportion of patients with HF who have a documentation of their ECG ﬁndings
Numerator: Number of patients with HF who have a documentation of their ECG ﬁndings.
Denominator: Number of patients with HF.
Main (3): Proportion of patients with HF who have their NPs measured
Numerator: Number of patients with HF who have a documentation of their NPs levels.
Denominator: Number of patients with HF.
Domain 3. Initial treatment
Main (1). Proportion of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol.
Denominator: Number of patients with HFrEF without any contraindications for the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, and nebivolol.
Main (2). Proportion of patients with HFrEF who are prescribed ACE inhibitor, ARB or ARNI in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed an ACE inhibitor, ARB or ARNI.
Denominator: Number of patients with HFrEF without any contraindications for ACE inhibitors, ARBs and ARNI.
Main (3). Proportion of patients with HF who are prescribed diuretic therapy if they have evidence of ﬂuid retention
Numerator: Number of patients with HF, with evidence of ﬂuid retention who are prescribed diuretic therapy.
Denominator: Number of patients with HF who have evidence of ﬂuid retention and no contraindications for diuretic therapy.
Main (4): Proportion of patients with HFrEF who are prescribed an MRA in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed an MRA.
Denominator: Number of patients with HFrEF without any contraindications for MRA.
Main (5): Proportion of patients with HFrEF who are prescribed a SGLT2 inhibitor in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed a SGLT2 inhibitor.
Denominator: Number of patients with HFrEF without any contraindications for SGLT2 inhibitor.
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverterdeﬁbrillator; IHD = ischaemic heart disease; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NP = natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; QI = quality indicator; SGLT2 = sodium-glucose co-transporter 2.
aStructural QIs are binary measurements (Yes/No), and thus, have only numerator deﬁnitions.
bBlood tests include urea, creatinine, electrolytes, full blood count, glucose, glycated haemoglobin, thyroid-stimulating hormone, liver function test, lipids, and iron proﬁle.
ESC 2021
ESC Guidelines
3693


<!-- PAGE 96 -->

### Page 96

.............................................................................................................................................................................
experience. As such, and in parallel with the writing of these guidelines, a suite of QIs for the evaluation of care and outcomes for patients with HF was developed. These QIs, alongside their specifications and development process are published separately with a short summary shown in Table 37.
19 Supplementary data
Supplementary data with additional Supplementary Figures, Tables, and text complementing the full text are available on the European Heart
Journal website and via the ESC website at www.escardio.org/guidelines.
20 Author information
Author/Task Force Member Affiliations: Marianna Adamo,
Medical and Surgical Specialties, Radiological Sciences and Public,
ASST Spedali Civili di Brescia, Brescia, Italy; Andreas Baumbach,
Barts Heart Centre, Queen Mary University of London, London,
United Kingdom; Michael Bo¨hm, Klinik fu¨r Innere Medizin III,
Saarland University, Homburg/Saar, Saarland, Germany; Haran
Burri,
Cardiology,
University
Hospital of
Geneva,
Geneva,
Switzerland; Jelena Celutkien_e, Clinic of Cardiac and Vascular
Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania;
Ovidiu Chioncel, Emergency Institute for Cardiovascular Diseases
‘Prof. Dr.C.C.Iliescu’, University of Medicine Carol Davila, Bucuresti,
Romania; John G.F. Cleland, Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Wellbeing, Glasgow,
Lanarkshire, United Kingdom; Andrew J.S. Coats, University of
Warwick, Coventry, United Kingdom; Maria G. Crespo-Leiro,
Cardiology,
Complexo
Hospitalario
Universitario
A
Coru~na
(CHUAC), CIBERCV, Universidade da Coru~na (UDC), Instituto de
Investigacion Biomedica de A Coru~na (INIBIC), La Coru~na, Spain;
Dimitrios Farmakis, University of Cyprus Medical School,
Nicosia, Cyprus; Roy S. Gardner, Scottish National Advanced
Heart Failure Service, Golden Jubilee National Hospital, Clyderbank,
Glasgow, Scotland, United Kingdom; Martine Gilard, Cardiology,
Brest University, Brest, France; Stephane Heymans, Department of
Cardiology,
Maastricht
University,
CARIM
School for
Cardiovascular Diseases, Maastricht, Netherlands; Arno W. Hoes,
University Medical Center Utrecht, Utrecht, Netherlands; Tiny
Jaarsma, Department of Health, Medicine and Caring Science,
Linko¨ping University, Linko¨ping, Sweden; Ewa A. Jankowska,
Department of Heart Diseases, Wroclaw Medical University,
Wroclaw, Poland; Mitja Lainscak, Division of Cardiology, General
Hospital Murska Sobota, Murska Sobota, Slovenia; Carolyn S.P.
Lam,
National
Heart
Centre
Singapore and
Duke-National
University of
Singapore,
Singapore;
Alexander
R.
Lyon,
Department of Cardiology, Royal Brompton Hospital, London,
United Kingdom; John J.V. McMurray, British Heart Foundation
Cardiovascular Research Centre, University of Glasgow, Glasgow,
Scotland, United Kingdom; Alexandre Mebazaa, Anesthesiology and Critical Care, Universite´ de Paris - Hoˆpital Lariboisie`re, Paris,
France; Richard Mindham, United Kingdom, ESC Patient Forum,
Sophia Antipolis, France; Claudio Muneretto, Cardiothoracic
Surgery, Asst Spedali Civili University of Brescia, Brescia, Italy;
Massimo Francesco Piepoli, Cardiology, Guglielmo da Saliceto
Hospital, AUSL Piacenza, Piacenza, Italy; Susanna Price, Cardiology
& Adult Intensive Care Unit, Royal Brompton Hospital, London,
United Kingdom; Giuseppe M.C. Rosano, IRCCS San Raffaele,
Roma, Italy; Frank Ruschitzka, Department of Cardiology,
University Hospital Zurich, Zurich, Switzerland; Anne Kathrine
Skibelund, Denmark, ESC Patient Forum, Sophia Antipolis, France.
21 Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Rudolf A. de Boer (CPG Review
Coordinator) (Netherlands), P. Christian Schulze (CPG Review
Coordinator)
(Germany),
Magdy
Abdelhamid
(Egypt),
Victor
Aboyans (France), Stamatis Adamopoulos (Greece), Stefan D. Anker
(Germany), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Johann
Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A.
Borger (Germany), Werner Budts (Belgium), Maja Cikes (Croatia),
Kevin Damman (Netherlands), Victoria Delgado (Netherlands), Paul
Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel
(Austria), Justin Ezekowitz (Canada), Volkmar Falk (Germany),
Laurent Fauchier (France), Gerasimos Filippatos (Greece), Alan
Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale
(United Kingdom), Finn Gustafsson (Denmark), Julie Harris (United
Kingdom), Bernard Iung (France), Stefan Janssens (Belgium), Mariell
Jessup (United States of America), Aleksandra Konradi (Russia),
Dipak Kotecha (United Kingdom), Ekatirini Lambrinou (Cyprus),
Patrizio
Lancellotti
(Belgium),
Ulf
Landmesser
(Germany),
Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva
(United Kingdom), Ales Linhart (Czech Republic), Maja-Lisa Løchen
(Norway), Lars H. Lund (Sweden), Donna Mancini (United States of
America), Josep Masip (Spain), Davor Milicic (Croatia), Christian
Mueller (Switzerland), Holger Nef (Germany), Jens-Cosedis Nielsen
(Denmark), Lis Neubeck (United Kingdom), Michel Noutsias
(Germany), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio (Italy), Piotr Ponikowski (Poland), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Dimitrios Richter (Greece), Evgeny
Schlyakhto (Russia), Petar Seferovic (Serbia), Michele Senni (Italy),
Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Carlo Gabriele
Tocchetti (Italy), Rhian Touyz (United Kingdom), Carsten Tschoepe
(Germany), Johannes Waltenberger (Germany).
ESC National Cardiac Societies actively involved in the review process of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:
Algeria: Algerian Society of Cardiology, Messaad Krim; Armenia:
Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria:
Austrian Society of Cardiology, Deddo Moertl; Azerbaijan:
Azerbaijan Society of Cardiology, Isakh Mustafayev; Belarus:
Belorussian Scientific Society of Cardiologists, Alena Kurlianskaya;
Belgium: Belgian Society of Cardiology, Michel Depauw; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of


<!-- PAGE 97 -->

### Page 97

.............................................................................................................................................................................
Cardiology, Plamen Gatzov; Croatia: Croatian Cardiac Society,
Davor Milicic; Cyprus: Cyprus Society of Cardiology, Petros
Agathangelou; Czech Republic: Czech Society of Cardiology,
Vojtech Melenovsky; Denmark: Danish Society of Cardiology,
Brian Bridal Løgstrup; Egypt: Egyptian Society of Cardiology, Ahmed
Magdy Mostafa; Estonia: Estonian Society of Cardiology, Tiina
Uuetoa; Finland: Finnish Cardiac Society, Johan Lassus; France:
French Society of Cardiology, Damien Logeart; Georgia: Georgian
Society of Cardiology, Zviad Kipiani; Germany: German Cardiac
Society, Johann Bauersachs; Greece: Hellenic Society of Cardiology,
Christina Chrysohoou; Hungary: Hungarian Society of Cardiology,
Robert Sepp; Iceland: Icelandic Society of Cardiology, Inga Jona
Ingimarsdottir; Ireland: Irish Cardiac Society, Jim O’Neill; Israel:
Israel Heart Society, Israel Gotsman; Italy: Italian Federation of
Cardiology,
Massimo
Iacoviello;
Kazakhstan:
Association of
Cardiologists of Kazakhstan, Amina Rakisheva; Kosovo (Republic of): Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan:
Kyrgyz Society of Cardiology, Olga Lunegova, Latvia: Latvian
Society of Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, Tony Abdel Massih; Libya: Libyan Cardiac Society,
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology,
DianaZaliaduonyt_e;
Luxembourg:
Luxembourg
Society of
Cardiology, Stephanie Noppe; Malta: Maltese Cardiac Society, Alice
Moore; Moldova (Republic of): Moldavian Society of Cardiology,
Eleonora
Vataman;
Montenegro:
Montenegro
Society of
Cardiology, Aneta Boskovic; Morocco: Moroccan Society of
Cardiology, Ahmed Bennis; Netherlands: Netherlands Society of
Cardiology, Olivier C. Manintveld; North Macedonia: North
Macedonian Society of Cardiology, Elizabeta Srbinovska Kostovska;
Norway: Norwegian Society of Cardiology, Geeta Gulati; Poland:
Polish
Cardiac
Society,
Ewa
Straburzynska-Migaj;
Portugal:
Portuguese Society of Cardiology, Jose´ Silva-Cardoso; Romania:
Romanian Society of Cardiology, Roxana Cristina Rimbas¸; Russian
Federation: Russian Society of Cardiology, Yury Lopatin; San
Marino: San Marino Society of Cardiology, Marina Foscoli; Serbia:
Cardiology Society of Serbia, Sinisa Stojkovic; Slovakia: Slovak
Society of Cardiology, Eva Goncalvesova; Slovenia: Slovenian
Society of Cardiology, Zlatko Fras; Spain: Spanish Society of
Cardiology, Javier Segovia; Sweden: Swedish Society of Cardiology,
Krister Lindmark; Switzerland: Swiss Society of Cardiology, Micha
T.
Maeder;
Syrian
Arab
Republic:
Syrian
Cardiovascular
Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Leila Abid; Turkey: Turkish Society of
Cardiology, Hakan Altay; Ukraine: Ukrainian Association of
Cardiology, Leonid Voronkov; United Kingdom of Great
Britain and Northern Ireland: British Cardiovascular Society,
Ceri
Davies,
Uzbekistan:
Association of
Cardiologists of
Uzbekistan, Timur Abdullaev.
ESC Clinical Practice Guidelines Committee (CPG): Colin
N. Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Celutkien_e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Jens-Cosedis
Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva
Prescott (Denmark), Lis Neubeck (United Kingdom), Amina
Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United
Kingdom).
